

company, and emerging growth company. In Rule 12b-2 of the Exchange Act, Large accelerated filer, Accelerated filer, Non-accelerated filer, and Smaller reporting company. Emerging growth company. An emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. An oil and gas company, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No. On October 31, 2024, the registrant had 74,594,154 shares of common stock, 0.000001 par value per share, outstanding. Table of Contents FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of the Federal securities laws. These may include statements about the Company's expected revenues, earnings/losses per share, net income (loss), expenses, cash flow or other financial performance, or developments, clinical trial or development activities, expected regulatory filings and approvals, planned business transactions, views of future industry, competitive or market conditions, and other factors that could affect the Company's future operations, results of operations or financial position. These statements often include words, such as believes, expects, anticipates, intends, plans, estimates, may, will, could, or similar expressions. Forward-looking statements are not guarantees of future performance or results. Known and unknown factors that could cause actual performance or results to be materially different from those expressed or implied in these statements include, but are not limited to: Market acceptance of, and the Company's ability to market and sell, its products and services, whether through its internal, direct sales force or third parties; Failure of distributors or other customers to meet purchase forecasts, historic purchase levels or minimum purchase requirements for the Company's products; Significant customer concentrations that exist or may develop in the future; The Company's ability to manufacture products in accordance with applicable specifications, performance standards and quality requirements; The Company's ability to achieve the anticipated cost savings as a result of its business restructuring, including from in-sourcing third party manufacturing; exiting microbiome services and exiting its risk assessment business; The Company's ability to obtain, and timing and cost of obtaining, necessary regulatory approvals for new products or new indications or applications for existing products; ability to comply with applicable regulatory requirements; The Company's ability to effectively resolve warning letters, audit observations and other findings or comments from the U.S. Food and Drug Administration or other regulators; Changes in relationships, including disputes or disagreements, with strategic partners or other parties and reliance on strategic partners for the performance of critical activities under collaborative arrangements; The Company's ability to meet increased demand for its products; The impact of replacing distributors on the Company's business; Inventory levels at distributors and other customers; The Company's ability to achieve its financial and strategic objectives and continue to increase its revenues, including the ability to expand international sales; The impact of competitors, competing products and technology changes on the Company's business; Reduction or deferral of public funding available to customers; Competition from new or better technology or lower cost products; The Company's ability to develop, commercialize and market new products; The Company's ability to fulfill its commitments under its contract with the U.S. government for Inteliswab® COVID-19 Rapid Tests; Table of Contents Changes in market acceptance of products based on product performance or other factors, including changes in testing guidelines, algorithms or other recommendations by the Centers for Disease Control and Prevention (the "CDC") or other agencies; The Company's ability to fund research and development and other products and operations; The Company's ability to obtain and maintain new or existing product distribution channels; Reliance on sole supply sources for critical products and components; Availability of related products produced by third parties or products required for use of the Company's products; The impact of contracting with the U.S. government on the Company's business; The impact of negative economic conditions on the Company's business; The Company's ability to achieve and maintain sustained profitability; The Company's ability to increase its gross margins; The Company's ability to utilize net operating loss carry forwards or other deferred tax assets; Volatility of the Company's stock price; Uncertainty relating to patent protection and potential patent infringement claims; Uncertainty and costs of litigation relating to patents and other intellectual property; Availability of licenses to patents or other technology; Ability to enter into international manufacturing agreements; Obstacles to international marketing and manufacturing of products; The impact of changes in international funding sources and testing algorithms on international sales; Adverse movements in foreign currency exchange rates; Loss or impairment of sources of capital; The Company's ability to attract and retain qualified personnel; The Company's exposure to product liability and other types of litigation; Changes in international, federal or state laws and regulations; Customer consolidations and inventory practices; Equipment failures and ability to obtain needed raw materials and components; The impact of terrorist attacks and civil unrest, hostilities and war; The impact of cybersecurity incidents and other disruptions involving our computer systems or those of our third-party IT service providers, suppliers and customers; and General political, business and economic conditions, including interest rates and inflationary pressures. Table of Contents These and other factors that could affect the Company's results are discussed more fully under the section titled Risk Factors, set forth in Part II, Item 1A of this Quarterly Report on Form 10-Q, if any, in Part I, Item 1A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (the SEC) on March 11, 2024, and in subsequent SEC filings. Although forward-looking statements help to provide information about future prospects, readers should keep in mind that forward-looking statements may not be reliable. Readers are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are made as of the date of this report and the Company undertakes no duty to update these statements, unless it is required to do so by law. If the Company does update one or more forward-looking statements, no inference should be drawn that it will make updates with respect to other forward-looking statements or that it will make any further updates to those forward-looking statements at any future time. Investors should also be aware that while the Company does, from time to time, communicate with securities analysts, it is against the Company's policy to disclose any material non-public information or other confidential commercial information. Accordingly, stockholders should not assume that the Company agrees with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, the Company has a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts contain any projections, forecasts or opinions, such reports are not the responsibility of OraSure. Table of Contents PART I. FINANCIAL INFORMATION Page No. Item 1. Financial Statements (Unaudited) Consolidated Balance Sheets at September 30, 2024 and December 31, 2023 Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2024 and 2023 Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 Notes to the Consolidated Financial Statements Item 2. Management Discussion and Analysis of Financial Condition and Results of Operations 20A Item 3. Quantitative and Qualitative Disclosures About Market Risk 26 Item 4. Controls and Procedures 26 PART II. OTHER INFORMATION Item 1. Legal Proceedings 27 Item 1A. Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 29 Signatures 30 Table of Contents Item 1. A FINANCIAL STATEMENTS ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited) (in thousands, except per share amounts) September 30, 2024 December 31, 2023 ASSETS Current Assets: Cash and cash equivalents \$278,571A \$290,407A Accounts receivable, net of allowance of \$1,237 and \$1,216 26,954A 40,171A Inventories 38,870A 47,614A Prepaid expenses and other 3,038A 6,041A Other current assets 2,718A 2,226A Total current assets 350,151A 386,459A Noncurrent Assets: Property, plant and equipment, net of accumulated depreciation of \$79,562 and \$85,143 38,143A 45,420A Operating right-of-use assets, net 9,904A 12,270A Finance right-of-use assets, net 157A 576A Intangible assets, net of accumulated amortization of \$33,711 and \$33,649 665A 1,206A Goodwill 35,287A 35,696A Investment in equity method investee 28,829A Other noncurrent assets 949A 1,218A Total noncurrent assets 113,934A 96,386A TOTAL ASSETS \$464,085A \$482,845A LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable \$9,581A \$13,151A Deferred revenue 1,619A 1,559A Accrued expenses and other current liabilities 15,013A 22,710A Finance lease liability 414A 539A Operating lease liability 1,530A 1,577A Total current liabilities 27,784A 39,536A Noncurrent Liabilities: Finance lease liability 124A 226A Operating lease liability 9,412A 11,162A Other noncurrent liabilities 529A 696A Deferred income taxes 671A 554A Total noncurrent liabilities 10,736A 12,638A TOTAL LIABILITIES 38,520A 52,174A Commitments and contingencies (Note 11) STOCKHOLDERS' EQUITY Preferred stock, par value \$0.000001, 25,000 shares authorized, none issued A Common stock, par value \$0.000001, 120,000 shares authorized, 74,593 and 73,528 shares issued and outstanding A Additional paid-in capital 535,402A 529,543A Accumulated other comprehensive loss (17,200) (14,941) Accumulated deficit (92,637) (83,931) Total stockholders' equity 425,565A 430,671A TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY \$464,085A \$482,845A See accompanying notes to the consolidated financial statements. Table of Contents ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (in thousands, except per share amounts) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 NET REVENUES: Products and services \$39,651A \$89,014A \$147,379A \$326,666A Other 264A 173A 1,003A 2,925A 39,915A 89,187A 148,382A 329,591A COST OF PRODUCTS AND SERVICES SOLD 22,845A 44,847A 82,558A 193,065A Gross profit 17,070A 44,340A 65,824A 136,526A OPERATING EXPENSES: Research and development 5,623A 8,516A 19,960A 26,737A Sales and marketing 7,615A 8,736A 23,994A 29,413A General and administrative 9,831A 10,051A 33,310A 44,186A Loss on impairments 6,183A 4,392A 7,503A Change in the estimated fair value of acquisition-related contingent consideration A (40) A (99) 23,069A 33,446A 81,656A 107,740A Operating (loss) income (5,999) 10,894A (15,832) 28,786A OTHER INCOME 2,781A 2,612A 9,338A 6,752A (Loss) income before income taxes (3,218) 13,506A (6,494) 35,538A INCOME TAX EXPENSE 678A 2,347A 1,041A 1,956A LOSS ON EQUITY INVESTMENT (61) A (1,171) A NET (LOSS) INCOMES (4,507) \$11,159A (\$8,706) \$33,582A (LOSS) INCOME PER SHARE: BASIC \$ (0.06) \$0.15A \$ (0.12) \$0.46A DILUTED \$ (0.06) \$0.15A \$ (0.12) \$0.45A WEIGHTED-AVERAGE SHARES OUTSTANDING: BASIC 74,583A 73,453A 74,330A 73,298A DILUTED 74,583A 74,349A 74,330A 74,197A See accompanying notes to the consolidated financial statements. Table of Contents ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (in thousands) For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 NET (LOSS) INCOMES (4,507) \$11,159A (\$8,706) \$33,582A OTHER COMPREHENSIVE (LOSS) INCOME Currency translation adjustments 1,431A (2,813) (2,259) 843A Unrealized gain on marketable securities A A A 220A COMPREHENSIVE (LOSS) INCOME \$(3,076) \$8,346A \$(10,965) \$34,645A See accompanying notes to the consolidated financial statements. Table of Contents ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (in thousands) For the Nine Months Ended September 30, 2024 2023 OPERATING ACTIVITIES: Net (loss) income (\$8,706) \$33,582A Adjustments to reconcile net (loss) income to net cash provided by operating activities: Stock-based compensation 9,178A 7,602A Depreciation and amortization 8,380A 17,372A Loss on impairments 4,392A 7,503A Other non-cash amortization (569) 3A Provision for credit losses 521A (75) Unrealized foreign currency gain (154) (66) Interest expense on finance leases 20A 42A Loss on equity investment 1,171A A Deferred income taxes 165A (490) Loss on sale of fixed assets (121) A Change in the estimated fair value of acquisition-related contingent consideration A (99) Payment of acquisition-related contingent consideration A (19) Changes in assets and liabilities: Accounts receivable 12,658A 17,468A Inventories 8,659A 36,425A Prepaid expenses and other assets 2,622A 10,530A Accounts payable (4,331) (25,122) Deferred revenue 66A (449) Accrued expenses and other liabilities (7,586) (3,990) Net cash provided by operating activities 27,265A 100,217A INVESTING ACTIVITIES: Purchases of short-term investments (53,244) (74,652) Investment in equity method investee (30,000) A Proceeds from maturities and redemptions of short-term investments 53,052A 94,980A Purchases of property and equipment (3,341) (4,517) Purchase of property and equipment under government contracts A (4,501) Proceeds from funding under government contracts A 24,290A Net cash (used in) provided by investing activities (33,533) 35,600A FINANCING ACTIVITIES: Cash payments for lease liabilities (746) (835) Proceeds from exercise of stock options 214A 76A Payment of acquisition-related contingent consideration A (46) Repurchase of common stock (3,533) (1,863) Net cash used in financing activities (4,065) (2,668) EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH (1,503) 404A NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (1,836) 133,553A CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 290,407A 83,980A CASH AND CASH EQUIVALENTS, END OF PERIOD \$278,571A \$217,533A SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash (refunds) paid for income taxes \$1,637A \$(5,733) Non-cash investing and financing activities: Accrued property and equipment purchases \$103A \$155A Accrued property and equipment purchases under government contracts A A 22A See accompanying notes to the consolidated financial statements. Table of Contents ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES Notes to the Consolidated Financial Statements (Unaudited) 1. A Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation The accompanying interim unaudited consolidated financial statements include the accounts of OraSure Technologies, Inc. (the OraSure) and its wholly-owned subsidiaries, DNA Genotek Inc. (the DNAG), Diversigen, Inc. (the Diversigen), and Novosanis NV (the Novosanis). All intercompany transactions and balances have been eliminated. References herein to we, us, our, or the Company mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of the Company's financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations expected for the full year. Summary of Significant Accounting Policies There have been no changes to the Company's significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 that have had a material impact on the consolidated financial statements and related notes except as discussed herein. Cash Equivalents & Short-Term Investments The Company considers all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates purchased with maturities greater than ninety days. Securities with maturities ninety days or less are considered cash equivalents. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders' equity as a component of accumulated other comprehensive loss. The Company had no available-for-sale securities as of September 30, 2024 and December 31, 2023. Fair Value of Financial Instruments As of September 30, 2024 and December 31, 2023, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of the Company's guaranteed investment certificates are measured as Level 1 instruments as of September 30, 2024. Included in cash and cash equivalents at September 30, 2024 and December 31, 2023 was \$42.5 million and \$71.7 million, respectively, of guaranteed investment certificates. Table of Contents Also included in cash and cash equivalents at September 30, 2024 and December 31, 2023 was \$117.1 million and \$112.7 million, respectively, invested in money market funds. These money market funds have investments in U.S. government securities and are measured as Level 1 instruments. The Company offers a nonqualified deferred compensation plan for certain eligible employees and members of its Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and company stock. The fair value of the plan assets as of September 30, 2024 and December 31, 2023 was \$0.7 million and \$0.8 million, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 financial instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets. Equity Method Investee In January 2024, the Company lead the Series B financing and entered into wide-ranging strategic distribution agreements with KKR Sapphiros L.P. ("Sapphiros"), a privately held consumer diagnostic portfolio company, and certain of its related entities. Through this relationship, the Company expects to be able to offer a more comprehensive range of low-cost diagnostic tests and molecular sample management solutions to the Company's customers globally. As of September 30, 2024, the Company had funded \$30.0A million for its interest in Sapphiros. The Company recorded the investment using the equity method in accordance with Accounting Standards Codification ("ASC") Topic 323,

investments. The Company has elected as its accounting policy to recognize its share of any income or loss in Sapphiros on a three-month lag. The investment in Sapphiros of \$28.8A million as of September 30, 2024 is included in the investment in equity method investee line of the Company's balance sheet and is measured as a Level 3 investment. The Company has no unconditional obligations or guarantees to, or in support of, its equity method investee and its operations. In conjunction with the preparation of the Company's September 30, 2024 financial statements, the Company considered whether the carrying value of the investment in Sapphiros was impaired and concluded that no such impairment existed. There was no similar investment as of December 31, 2023. Foreign Currency Transactions Net foreign exchange gains and (losses) resulting from foreign currency transactions that are included in other income in the Company's consolidated statements of operations were \$(0.2) million and \$(0.1) million for the three months ended September 30, 2024 and 2023, respectively. Net foreign exchange gains and (losses) resulting from foreign currency transactions for the nine months ended September 30, 2024 and 2023 were \$0.1 million and \$(0.7) million, respectively. Impairment of Long-Lived Assets Long-lived assets, which include property, plant and equipment, definite-lived intangible assets, as well as right-of-use assets (ROU assets) of operating and finance leases, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the Company's long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows expected to be generated from the use and eventual disposition of the asset. If indicators of impairment exist, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect the Company's assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. During the first quarter of 2024, the Company identified a triggering event to test for the recoverability of all the property, plant, and equipment and ROU assets of both the Diversigen and Novosanis subsidiaries, given the Company's decision to initiate a strategic plan to transition away from the microbiome molecular sequencing services business and close its Belgian operations. The Company performed an undiscounted cash flow analysis and determined the carrying values of the property, plant and equipment and ROU assets could not be recovered through the sum of the undiscounted future cash flows and were impaired. During the nine months ended September 30, 2024 the Company recognized aggregate pre-tax impairment charges of \$1.2 million and \$0.3 million to its operating and finance ROU assets, respectively. These charges are reported in the Company's consolidated statement of operations. The impact of the impairments on the Company's property, plant, equipment for the nine months ended September 30, 2024 is discussed further in Note 4. Accumulated Other Comprehensive Loss Change in accumulated other comprehensive loss by component is listed below (in thousands): Foreign Currency Total Balance at December 31, 2023 \$(14,941) \$(14,941) Other comprehensive loss (2,259) (2,259) Balance at September 30, 2024 \$(17,200) \$(17,200) Recent Accounting Pronouncements In March 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2024-01, Compensation—Stock Compensation (Topic 718), Scope Application of Profits Interest and Similar Awards. The purpose of this update was to provide illustrative examples to demonstrate how an entity should apply guidance to determine whether profits interests and similar awards should be accounted for in accordance with Topic 718. For public business entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal periods. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. Management is evaluating the impact on the Company's consolidated financial statements. Table of Contents 2. A Government Capital Contracts In September 2021, the Company entered into an agreement for \$109.0 million in funding from the U.S. Department of Defense (the "DOD"), in coordination with the Department of Health and Human Services, to build additional manufacturing capacity in the United States for its IntelSwab® COVID-19 Rapid Test as part of the nation's pandemic preparedness plan. In accordance with the milestone payment schedule, 15% of the total was not billed and funded until the completion of the final validation testing, which occurred in October 2023. The Company began receiving funds from the DOD in January 2022 and has received \$109.0 million as of December 31, 2023. In connection with the completion of the contract in the fourth quarter of 2023, all funds were received. Activity for these capital contracts was accounted for pursuant to International Accounting Standards ("IAS") 20, Accounting for Government Grants and Disclosure of Government Assistance, as there is not direct US GAAP guidance for this type of transaction. Funding received in relation to capital-related costs incurred for government contracts was recorded as a reduction to the cost of property, plant and equipment and reflected within investing activities in the consolidated statements of cash flows; and associated unpaid liabilities and government proceeds receivable were considered non-cash changes in such balances within the operating section of the consolidated statements of cash flows. Amounts earned for the Company's guaranteed profit which covered project management costs were recognized straight-line in other income over the term of the government contract. The Company recognized no such income during the three and nine months ended September 30, 2024. The Company recognized \$0.6 million and \$1.7 million of such income during the three and nine months ended September 30, 2023, respectively. The DOD also reimbursed the Company for certain engineering consulting costs. These expenses are reflected in research and development expenses as incurred with the corresponding amount presented in other income. The Company recognized no such costs during the three and nine months ended September 30, 2024. The Company recognized \$0.4 million and \$2.0 million of such costs during the three and nine months ended September 30, 2023, respectively. The activity corresponding to the government contracts included in the Company's consolidated statements of cash flows for the cumulative period ended December 31, 2023 is as follows (in thousands): December 31, 2023 Cost of assets, cumulative \$86,993A Reduction for funding received to date (86,993) Total property, plant and equipment, net \$A Table of Contents 3. A Inventories (in thousands) September 30, December 31, 2024 2023 Raw materials \$19,948A \$20,727A Work in process 1,435A 1,900A Finished goods 17,487A 24,987A \$38,870A \$47,614A A A A Property, Plant and Equipment, net (in thousands) September 30, December 31, 2024 2023 Land \$1,118A \$1,118A Buildings and improvements 34,003A 34,606A Machinery and equipment 58,618A 64,156A Computer equipment and software 11,680A 17,739A Furniture and fixtures 3,334A 3,748A Construction in progress 8,952A 9,196A 117,705A 130,563A Accumulated depreciation (79,562) (85,143) \$38,143A \$45,420A During the first quarter of 2024, the Company initiated a strategic plan to transition away from the microbiome molecular sequencing services business and to exit operations at its Belgium location. As a result of these decisions, the Company determined that the carrying values of all of Diversigen and Novosanis' property, plant, and equipment were not recoverable and recorded an aggregate pre-tax asset impairment charge of \$1.8 million during the nine months ended September 30, 2024. During the second quarter of 2024, the Company determined a manufacturing line will no longer be utilized. As a result of this decision, the Company determined that the carrying value of the equipment was not recoverable and recorded an aggregate pre-tax impairment charge of \$1.1 million during the nine months ended September 30, 2024. During the nine months ended September 30, 2023, the Company determined several manufacturing lines would no longer be utilized due to changes in forecasted demand for the products the equipment was intended to produce. Additionally, the Company elected not to proceed with certain leasehold improvements to its research and development laboratories. As a result of these decisions, the Company determined that the carrying values of the equipment and leasehold improvements made to date were not recoverable and recorded an aggregate pre-tax asset impairment charge of \$1.3 million during the nine months ended September 30, 2023. Due to the extremely specialized nature of the property, plant, and equipment in each triggering event noted above and due to various market data points, the estimated fair value of all assets was determined to be zero. These charges are reported within loss on impairments in the consolidated statements of operations. Table of Contents 5. A Accrued Expenses and Other Current Liabilities (in thousands) September 30, December 31, 2024 2023 Payroll and related benefits \$9,320A \$14,654A Professional fees 1,264A 2,827A Sales tax payable 1,228A 1,245A Other 3,201A 3,984A \$15,013A \$22,710A A A A Termination Benefits 2023 Reduction in Workforce During the first and second quarters of 2023, the Company executed a reduction in workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands): For the Nine Months Ended September 30, 2023 Cost of products and services sold \$369A Research and development \$566A Sales and marketing \$1,542A General and administrative \$787A \$3,264A As of September 30, 2024 the Company has fully paid the \$3.3 million related to the reduction in workforce. No additional expense associated with the 2023 reduction in workforce was incurred during the nine months ended September 30, 2024. This plan was completed as of June 30, 2024. Q1 2024 Reduction in Workforce During the first quarter of 2024, the Company executed a reduction in workforce largely affecting its COVID-19 manufacturing workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands): For the Nine Months Ended September 30, 2024 Cost of products and services sold \$231A Research and development \$787A Sales and marketing \$69A General and administrative \$17A \$404A As of September 30, 2024 the Company had \$6.0 thousand accrued and had paid \$0.4 million related to the reduction in workforce. No additional expense associated with the Q1 2024 reduction in workforce was incurred during the three months ended September 30, 2024. The Company expects this plan to be completed by December 31, 2024. Table of Contents Q2 2024 Reduction in Workforce During the second quarter of 2024, the Company executed an additional reduction in workforce as the Company notified employees of its intention to consolidate its Novosanis site in Belgium into other locations by the end of December 31, 2024, discontinue the Diversigen molecular services line of business by the end of June 30, 2024, and consolidate facilities by bringing third-party manufacturing activities into its Pennsylvania facilities by the end of the third quarter of 2025. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands): For the Three Months Ended September 30, 2024 Cost of products and services sold \$A \$889A Research and development \$A \$478A Sales and marketing \$A \$125A General and administrative \$A \$160A \$A \$1,652A As of September 30, 2024 the Company had \$0.9 million accrued and had paid \$0.7 million related to the reduction in workforce. No additional expense associated with the Q2 2024 reduction in workforce was incurred during the three months ended September 30, 2024. The Company expects this plan to be completed by September 2025. Q3 2024 Reduction in Workforce During the third quarter of 2024, the Company executed a reduction in workforce largely as the Company notified certain employees of its intention to discontinue its risk assessment business. Additional employees were notified in the fourth quarter of 2024 and additional severance costs will be incurred. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands): For the Three Months Ended September 30, 2024 Cost of products and services sold \$7A Research and development \$A Sales and marketing \$346A General and administrative \$A \$353A As of September 30, 2024 the Company had \$0.3 million accrued and had paid \$7.1 thousand related to the reduction in workforce. The Company expects this plan to be completed by January 2026. Table of Contents 7. A Revenues Revenues by product line. The following table represents total net revenues by product line (in thousands): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 HIV \$18,347A \$16,650A \$45,379A \$46,518A COVID-19 (1), 155A 50,199A 44,222A 216,115A Molecular Sample Management Solutions (2) 12,806A 15,238A 36,237A 41,230A HCV 3,228A 2,901A 10,962A 9,957A Risk assessment testing (3), 911A 2,554A 6,265A 7,540A Other product and service revenues (4), 196A 638A 2,623A 1,739A Molecular Services 9A 834A 1,692A 3,567A Net product and services revenues 39,652A 89,014A 147,380A 326,666A Non-product and service revenues (5) 263A 173A 1,024A 2,925A Net revenues \$39,915A \$89,187A \$148,382A \$329,591A (1) Includes COVID-19 Diagnostics and COVID-19 Molecular revenues. (2) Includes Genomics, Microbiome and Novosanis product revenues. (3) Includes substance abuse testing products revenues. (4) Includes Syphilis revenues. (5) Includes funded research and development contracts, royalty income and grant revenues. Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer (in thousands): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 United States \$25,353A \$77,925A \$115,055A \$296,815A Europe 2,126A 1,992A 5,892A 6,297A Other regions 12,436A 9,270A 27,435A 26,479A \$39,915A \$89,187A \$148,382A \$329,591A Customer and Vendor Concentrations. The following table represents the concentration risk. For the Three Months Ended September 30, For the Nine Months Ended September 30, Revenue Concentration 2024 2023 2024 2023 Commercial customer (1) 11% NANANA Commercial customer (1) 10% NANANA Non-Commercial customer (2) NA 56% 26% 66% September 30, December 31, Accounts Receivable 2024 2023 Commercial customer (1)

[illegible]

2024 from \$2.9Å million for the nine months ended September 30, 2023 as a result of lower funding for research and development activities largely as a result of the end of our agreement with Biomedical Advanced Research Authority ("BARDA") which provided funding to obtain clearance of a premarket notification ("510(k)") and Clinical Laboratory Improvement Amendments of 1988 waiver of our IntelliSwabÅ® tests. The Company has communicated to BARDA that it does not intend to pursue further development of this clearance. Further contributing to the decline in non-product revenues is lower royalty income in 2024 as one of the Company's royalty agreements for sample collection kits expired in June 2023.CONSOLIDATED OPERATING RESULTSConsolidated gross profit margin increased to 44.4% for the nine months ended September 30, 2024 from 41.4% for the nine months ended September 30, 2023. Gross margins in 2023 included \$7.0Å million of accelerated depreciation associated with the wind-down of IntelliSwabÅ® manual assembly in Thailand as the Company began to on-shore and automate manufacturing of this product at its Pennsylvania facilities. In addition, reduced salary and benefits due to the reduction in workforce experienced in 2023 and 2024 contributed to improved overhead absorption. Lastly, lower product scrap expense helped to increase margins for the nine months ended September 30, 2024. These improvement in margins were partially offset by the decline in IntelliSwabÅ® revenues and a shift in product mix of increased revenues from lower margin product. Other non-product revenues which contribute 100% to gross margins also declined for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023.Consolidated operating loss for the nine months ended September 30, 2024 was \$15.8Å million, compared to \$28.8Å million operating income reported for the nine months ended September 30, 2023. Results for the nine months ended September 30, 2024 were negatively impacted by the decrease in revenues and were positively impacted by reduced operating expense. Results for the nine months ended September 30, 2024 included \$4.4 million of impairment losses compared to \$7.5 million for the nine months ended September 30, 2023.Operating expenses for the nine months ended September 30, 2024, excluding the impairment charge, decreased 22.9% to \$77.3Å million from \$100.2Å million for the nine months ended September 30, 2023 reflecting the impact of the Company's cost saving measures and headcount reductions. Research and development expenses decreased 25% to \$20.0 million for the nine months ended September 30, 2024 from \$26.7 million for the nine months ended September 30, 2023, largely due to lower staffing costs due to a decrease in headcount and no related project management fees for our \$109 million manufacturing expansion contract which ended during the fourth quarter of 2023, and a decrease in spend on COVID-19 product development. This overall decrease in spend is partially offset by an increase in severance costs for those employees impacted by the Company's decisions to exit the molecular services business offered by its Diversigen subsidiary and wind-down of operations located in Belgium. Sales and marketing expenses decreased 18% to \$24.0 million for the nine months ended September 30, 2024 from \$29.4 million for the nine months ended September 30, 2023 primarily due to decreased employee costs associated with the reduction in headcount and lower advertising, consulting, and amortization expense. General and administrative expenses decreased 25% to \$33.3 million for the nine months ended September 30, 2024 from \$44.2 million for the nine months ended September 30, 2023 largely due to lower legal fees relating to the Spectrum litigation (discussed further in Part II. Other Information, Item 1. Legal Proceedings, below) and lower employee costs associated with reduced headcount partially offset by an increase in non-cash stock compensation expense. All of the above contributed to the Company's operating loss of \$15.8Å million for the nine months ended September 30, 2024, which included non-cash impairment charges of \$4.4 million, non-cash charges of \$8.4 million for depreciation and amortization, and \$9.2 million for stock-based compensation. The Company's operating income of \$28.8Å million for the nine months ended September 30, 2023 included a non-cash impairment charge of \$7.5 million, non-cash charges of \$17.4 million for depreciation and amortization, and \$7.6 million for stock-based compensation.24Table of ContentsOTHER INCOMEOther income for the nine months ended September 30, 2024 was \$9.3 million compared to \$6.8 million for the nine months ended September 30, 2023. This increase is largely due to higher interest income offset by absence of profit earned under our manufacturing expansion contract with the U.S. government which ended at the end of 2023.CONSOLIDATED INCOME TAXESThe Company continues to believe the full valuation allowance established against its total U.S. deferred tax asset is appropriate as the facts and circumstances necessitating the allowance have not changed. For the nine months ended September 30, 2024 and 2023, the Company recorded U.S. state tax benefit and expense of \$0.2 million and \$2.4 million, respectively. For the nine months ended September 30, 2024 and 2023, the Company recorded foreign tax expense and benefit of \$1.3 million and \$0.4 million, respectively. Liquidity and Capital Resources September 30, 2024December 31, 2023(in thousands)Cash and cash equivalents\$278,571Å \$290,407Å Working capital322,367Å 346,923Å The Company's cash and cash equivalents decreased to \$278.6Å million at SeptemberÅ 31, 2024 from \$290.4Å million at DecemberÅ 31, 2023. \$93.7 million or 34% of the \$278.6Å million in cash and cash equivalents is held by DNAG, the Company's Canadian subsidiary. The Company's working capital decreased to \$322.4Å million at SeptemberÅ 30, 2024 from \$346.9Å million at DecemberÅ 31, 2023. The decrease in cash and cash equivalents and working capital was primarily due to the investment in Sapphiros of \$30.0 million during the nine months ended September 30, 2024. Analysis of the Company's Cash FlowsOperating ActivitiesDuring the nine months ended September 30, 2024, net cash provided by operating activities was \$27.3Å million. Cash flows from operations can be significantly impacted by factors such as timing of receipt from customers, inventory purchases, and payments to vendors. The Company's net loss of \$8.7 million included non-cash charges of depreciation and amortization expense of \$8.4 million, stock-based compensation expense of \$9.2 million, impairment losses of \$4.4 million, and loss on equity investment of \$1.2 million. Cash provided by the working capital accounts included a decrease in accounts receivable of \$12.7 million largely associated with lower overall sales and collections of balances due, a decrease in inventory of \$8.7 million as the Company fulfilled demand for its IntelliSwabÅ® product, and a decrease in prepaid expense and other current assets of \$2.6 million. Uses of cash included a decrease in accounts payable of \$3.4 million due to lower inventory purchases and timing of vendor invoice payments and a decrease in accrued expenses of \$7.6 million as the Company paid out year-end bonuses in March 2024.Investing ActivitiesNet cash used in investing activities was \$33.5Å million for the nine months ended September 30, 2024, which reflects proceeds from the maturities of investments of \$53.1 million, offset by \$53.2 million in purchases of investments. Investing activities also include a \$30.0 million investment in Sapphiros, and \$3.3 million to acquire property and equipment to support the normal operations of the business. Financing ActivitiesNet cash used in financing activities was \$4.1Å million for the nine months ended September 30, 2024, which is largely comprised of \$3.5 million used for the repurchase of common stock to satisfy withholding taxes related to the vesting of restricted shares awarded to the Company's employees. 25Table of ContentsResourcesThe Company expects existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements over the next twelve months. The Company's cash requirements, however, may vary materially from those now planned due to many factors, including, but not limited to, the scope and timing of future strategic acquisitions, the progress of its research and development programs, the scope and results of clinical testing, the cost of any future litigation, the magnitude of capital expenditures, changes in existing and potential relationships with business partners, the timing and cost of obtaining regulatory approvals, the timing and cost of future stock purchases, the costs involved in obtaining and enforcing patents, proprietary rights and any necessary licenses, the cost and timing of expansion of sales and marketing activities, market acceptance of new products, competing technological and market developments, the impact of the current economic environment and other factors. A summary of the Company's obligations to make future payments under contracts existing at DecemberÅ 31, 2023 is included in Item 7, ManagementÅ™'s Discussion and Analysis of Financial Condition and Results of Operations, of its Annual Report on Form 10-K for the year ended DecemberÅ 31, 2023. As of SeptemberÅ 30, 2024, there were no significant changes to this information.Critical Accounting Policies and EstimatesA more detailed review of the Company's critical accounting policies is contained in its Annual Report on Form 10-K for the year ended DecemberÅ 31, 2023 filed with the SEC. No material changes have been made to such critical accounting policies during the nine months ended September 30, 2024.Item 3.Å 4.Å 5.Å 6.Å 7.Å 8.Å 9.Å 10.Å 11.Å 12.Å 13.Å 14.Å 15.Å 16.Å 17.Å 18.Å 19.Å 20.Å 21.Å 22.Å 23.Å 24.Å 25.Å 26.Å 27.Å 28.Å 29.Å 30.Å 31.Å 32.Å 33.Å 34.Å 35.Å 36.Å 37.Å 38.Å 39.Å 40.Å 41.Å 42.Å 43.Å 44.Å 45.Å 46.Å 47.Å 48.Å 49.Å 50.Å 51.Å 52.Å 53.Å 54.Å 55.Å 56.Å 57.Å 58.Å 59.Å 60.Å 61.Å 62.Å 63.Å 64.Å 65.Å 66.Å 67.Å 68.Å 69.Å 70.Å 71.Å 72.Å 73.Å 74.Å 75.Å 76.Å 77.Å 78.Å 79.Å 80.Å 81.Å 82.Å 83.Å 84.Å 85.Å 86.Å 87.Å 88.Å 89.Å 90.Å 91.Å 92.Å 93.Å 94.Å 95.Å 96.Å 97.Å 98.Å 99.Å 100.Å 101.Å 102.Å 103.Å 104.Å 105.Å 106.Å 107.Å 108.Å 109.Å 110.Å 111.Å 112.Å 113.Å 114.Å 115.Å 116.Å 117.Å 118.Å 119.Å 120.Å 121.Å 122.Å 123.Å 124.Å 125.Å 126.Å 127.Å 128.Å 129.Å 130.Å 131.Å 132.Å 133.Å 134.Å 135.Å 136.Å 137.Å 138.Å 139.Å 140.Å 141.Å 142.Å 143.Å 144.Å 145.Å 146.Å 147.Å 148.Å 149.Å 150.Å 151.Å 152.Å 153.Å 154.Å 155.Å 156.Å 157.Å 158.Å 159.Å 160.Å 161.Å 162.Å 163.Å 164.Å 165.Å 166.Å 167.Å 168.Å 169.Å 170.Å 171.Å 172.Å 173.Å 174.Å 175.Å 176.Å 177.Å 178.Å 179.Å 180.Å 181.Å 182.Å 183.Å 184.Å 185.Å 186.Å 187.Å 188.Å 189.Å 190.Å 191.Å 192.Å 193.Å 194.Å 195.Å 196.Å 197.Å 198.Å 199.Å 200.Å 201.Å 202.Å 203.Å 204.Å 205.Å 206.Å 207.Å 208.Å 209.Å 210.Å 211.Å 212.Å 213.Å 214.Å 215.Å 216.Å 217.Å 218.Å 219.Å 220.Å 221.Å 222.Å 223.Å 224.Å 225.Å 226.Å 227.Å 228.Å 229.Å 230.Å 231.Å 232.Å 233.Å 234.Å 235.Å 236.Å 237.Å 238.Å 239.Å 240.Å 241.Å 242.Å 243.Å 244.Å 245.Å 246.Å 247.Å 248.Å 249.Å 250.Å 251.Å 252.Å 253.Å 254.Å 255.Å 256.Å 257.Å 258.Å 259.Å 260.Å 261.Å 262.Å 263.Å 264.Å 265.Å 266.Å 267.Å 268.Å 269.Å 270.Å 271.Å 272.Å 273.Å 274.Å 275.Å 276.Å 277.Å 278.Å 279.Å 280.Å 281.Å 282.Å 283.Å 284.Å 285.Å 286.Å 287.Å 288.Å 289.Å 290.Å 291.Å 292.Å 293.Å 294.Å 295.Å 296.Å 297.Å 298.Å 299.Å 300.Å 301.Å 302.Å 303.Å 304.Å 305.Å 306.Å 307.Å 308.Å 309.Å 310.Å 311.Å 312.Å 313.Å 314.Å 315.Å 316.Å 317.Å 318.Å 319.Å 320.Å 321.Å 322.Å 323.Å 324.Å 325.Å 326.Å 327.Å 328.Å 329.Å 330.Å 331.Å 332.Å 333.Å 334.Å 335.Å 336.Å 337.Å 338.Å 339.Å 340.Å 341.Å 342.Å 343.Å 344.Å 345.Å 346.Å 347.Å 348.Å 349.Å 350.Å 351.Å 352.Å 353.Å 354.Å 355.Å 356.Å 357.Å 358.Å 359.Å 360.Å 361.Å 362.Å 363.Å 364.Å 365.Å 366.Å 367.Å 368.Å 369.Å 370.Å 371.Å 372.Å 373.Å 374.Å 375.Å 376.Å 377.Å 378.Å 379.Å 380.Å 381.Å 382.Å 383.Å 384.Å 385.Å 386.Å 387.Å 388.Å 389.Å 390.Å 391.Å 392.Å 393.Å 394.Å 395.Å 396.Å 397.Å 398.Å 399.Å 400.Å 401.Å 402.Å 403.Å 404.Å 405.Å 406.Å 407.Å 408.Å 409.Å 410.Å 411.Å 412.Å 413.Å 414.Å 415.Å 416.Å 417.Å 418.Å 419.Å 420.Å 421.Å 422.Å 423.Å 424.Å 425.Å 426.Å 427.Å 428.Å 429.Å 430.Å 431.Å 432.Å 433.Å 434.Å 435.Å 436.Å 437.Å 438.Å 439.Å 440.Å 441.Å 442.Å 443.Å 444.Å 445.Å 446.Å 447.Å 448.Å 449.Å 450.Å 451.Å 452.Å 453.Å 454.Å 455.Å 456.Å 457.Å 458.Å 459.Å 460.Å 461.Å 462.Å 463.Å 464.Å 465.Å 466.Å 467.Å 468.Å 469.Å 470.Å 471.Å 472.Å 473.Å 474.Å 475.Å 476.Å 477.Å 478.Å 479.Å 480.Å 481.Å 482.Å 483.Å 484.Å 485.Å 486.Å 487.Å 488.Å 489.Å 490.Å 491.Å 492.Å 493.Å 494.Å 495.Å 496.Å 497.Å 498.Å 499.Å 500.Å 501.Å 502.Å 503.Å 504.Å 505.Å 506.Å 507.Å 508.Å 509.Å 510.Å 511.Å 512.Å 513.Å 514.Å 515.Å 516.Å 517.Å 518.Å 519.Å 520.Å 521.Å 522.Å 523.Å 524.Å 525.Å 526.Å 527.Å 528.Å 529.Å 530.Å 531.Å 532.Å 533.Å 534.Å 535.Å 536.Å 537.Å 538.Å 539.Å 540.Å 541.Å 542.Å 543.Å 544.Å 545.Å 546.Å 547.Å 548.Å 549.Å 550.Å 551.Å 552.Å 553.Å 554.Å 555.Å 556.Å 557.Å 558.Å 559.Å 560.Å 561.Å 562.Å 563.Å 564.Å 565.Å 566.Å 567.Å 568.Å 569.Å 570.Å 571.Å 572.Å 573.Å 574.Å 575.Å 576.Å 577.Å 578.Å 579.Å 580.Å 581.Å 582.Å 583.Å 584.Å 585.Å 586.Å 587.Å 588.Å 589.Å 590.Å 591.Å 592.Å 593.Å 594.Å 595.Å 596.Å 597.Å 598.Å 599.Å 600.Å 601.Å 602.Å 603.Å 604.Å 605.Å 606.Å 607.Å 608.Å 609.Å 610.Å 611.Å 612.Å 613.Å 614.Å 615.Å 616.Å 617.Å 618.Å 619.Å 620.Å 621.Å 622.Å 623.Å 624.Å 625.Å 626.Å 627.Å 628.Å 629.Å 630.Å 631.Å 632.Å 633.Å 634.Å 635.Å 636.Å 637.Å 638.Å 639.Å 640.Å 641.Å 642.Å 643.Å 644.Å 645.Å 646.Å 647.Å 648.Å 649.Å 650.Å 651.Å 652.Å 653.Å 654.Å 655.Å 656.Å 657.Å 658.Å 659.Å 660.Å 661.Å 662.Å 663.Å 664.Å 665.Å 666.Å 667.Å 668.Å 669.Å 670.Å 671.Å 672.Å 673.Å 674.Å 675.Å 676.Å 677.Å 678.Å 679.Å 680.Å 681.Å 682.Å 683.Å 684.Å 685.Å 686.Å 687.Å 688.Å 689.Å 690.Å 691.Å 692.Å 693.Å 694.Å 695.Å 696.Å 697.Å 698.Å 699.Å 700.Å 701.Å 702.Å 703.Å 704.Å 705.Å 706.Å 707.Å 708.Å 709.Å 710.Å 711.Å 712.Å 713.Å 714.Å 715.Å 716.Å 717.Å 718.Å 719.Å 720.Å 721.Å 722.Å 723.Å 724.Å 725.Å 726.Å 727.Å 728.Å 729.Å 730.Å 731.Å 732.Å 733.Å 734.Å 735.Å 736.Å 737.Å 738.Å 739.Å 740.Å 741.Å 742.Å 743.Å 744.Å 745.Å 746.Å 747.Å 748.Å 749.Å 750.Å 751.Å 752.Å 753.Å 754.Å 755.Å 756.Å 757.Å 758.Å 759.Å 760.Å 761.Å 762.Å 763.Å 764.Å 765.Å 766.Å 767.Å 768.Å 769.Å 770.Å 771.Å 772.Å 773.Å 774.Å 775.Å 776.Å 777.Å 778.Å 779.Å 780.Å 781.Å 782.Å 783.Å 784.Å 785.Å 786.Å 787.Å 788.Å 789.Å 790.Å 791.Å 792.Å 793.Å 794.Å 795.Å 796.Å 797.Å 798.Å 799.Å 800.Å 801.Å 802.Å 803.Å 804.Å 805.Å 806.Å 807.Å 808.Å 809.Å 810.Å 811.Å 812.Å 813.Å 814.Å 815.Å 816.Å 817.Å 818.Å 819.Å 820.Å 821.Å 822.Å 823.Å 824.Å 825.Å 826.Å 827.Å 828.Å 829.Å 830.Å 831.Å 832.Å 833.Å 834.Å 835.Å 836.Å 837.Å 838.Å 839.Å 840.Å 841.Å 842.Å 843.Å 844.Å 845.Å 846.Å 847.Å 848.Å 849.Å 850.Å 851.Å 852.Å 853.Å 854.Å 855.Å 856.Å 857.Å 858.Å 859.Å 860.Å 861.Å 862.Å 863.Å 864.Å 865.Å 866.Å 867.Å 868.Å 869.Å 870.Å 871.Å 872.Å 873.Å 874.Å 875.Å 876.Å 877.Å 878.Å 879.Å 880.Å 881.Å 882.Å 883.Å 884.Å 885.Å 886.Å 887.Å 888.Å 889.Å 890.Å 891.Å 892.Å 893.Å 894.Å 895.Å 896.Å 897.Å 898.Å 899.Å 900.Å 901.Å 902.Å 903.Å 904.Å 905.Å 906.Å 907.Å 908.Å 909.Å 910.Å 911.Å 912.Å 913.Å 914.Å 915.Å 916.Å 917.Å 918.Å 919.Å 920.Å 921.Å 922.Å 923.Å 924.Å 925.Å 926.Å 927.Å 928.Å 929.Å 930.Å 931.Å 932.Å 933.Å 934.Å 935.Å 936.Å 937.Å 938.Å 939.Å 940.Å 941.Å 942.Å 943.Å 944.Å 945.Å 946.Å 947.Å 948.Å 949.Å 950.Å 951.Å 952.Å 953.Å 954.Å 955.Å 956.Å 957.Å 958.Å 959.Å 960.Å 961.Å 962.Å 963.Å 964.Å 965.Å 966.Å 967.Å 968.Å 969.Å 970.Å 971.Å 972.Å 973.Å 974.Å 975.Å 976.Å 977.Å 978.Å 979.Å 980.Å 981.Å 982.Å 983.Å 984.Å 985.Å 986.Å 987.Å 988.Å 989.Å 990.Å 991.Å 992.Å 993.Å 994.Å 995.Å 996.Å 997.Å 998.Å 999.Å 1000.Å 1001.Å 1002.Å 1003.Å 1004.Å 1005.Å 1006.Å 1007.Å 1008.Å 1009.Å 1010.Å 1011.Å 1012.Å 1013.Å 1014.Å 1015.Å 1016.Å 1017.Å 1018.Å 1019.Å 1020.Å 1021.Å 1022.Å 1023.Å 1024.Å 1025.Å 1026.Å 1027.Å 1028.Å 1029.Å 1030.Å 1031.Å 1032.Å 1033.Å 1034.Å 1035.Å 1036.Å 1037.Å 1038.Å 1039.Å 1040.Å 1041.Å 1042.Å 1043.Å 1044.Å 1045.Å 1046.Å 1047.Å 1048.Å 1049.Å 1050.Å 1051.Å 1052.Å 1053.Å 1054.Å 1055.Å 1056.Å 1057.Å 1058.Å 1059.Å 1060.Å 1061.Å 1062.Å 1063.Å 1064.Å 1065.Å 1066.Å 1067.Å 1068.Å 1069.Å 1070.Å 1071.Å 1072.Å 1073.Å 1074.Å 1075.Å 1076.Å 1077.Å 1078.Å 1079.Å 1080.Å 1081.Å 1082.Å 1083.Å 1084.Å 1085.Å 1086.Å 1087.Å 1088.Å 1089.Å 1090.Å 1091.Å 1092.Å 1093.Å 1094.Å 1095.Å 1096.Å 1097.Å 1098.Å 1099.Å 1100.Å 1101.Å 1102.Å 1103.Å 1104.Å 1105.Å 1106.Å 1107.Å 1108.Å 1109.Å 1110.Å 1111.Å 1112.Å 1113.Å 1114.Å 1115.Å 1116.Å 1117.Å 1118.Å 1119.Å 1120.Å 1121.Å 1122.Å 1123.Å 1124.Å 1125.Å 1126.Å 1127.Å 1128.Å 1129.Å 1130.Å 1131.Å 1132.Å 1133.Å 1134.Å 1135.Å 1136.Å 1137.Å 1138.Å 1139.Å 1140.Å 1141.Å 1142.Å 1143.Å 1144.Å 1145.Å 1146.Å 1147.Å 1148.Å 1149.Å 1150.Å 1151.Å 1152.Å 1153.Å 1154.Å 1155.Å 1156.Å 1157.Å 1158.Å 1159.Å 1160.Å 1161.Å 1162.Å 1163.Å 1164.Å 1165.Å 1166.Å 1167.Å 1168.Å 1169.Å 1170.Å 1171.Å 1172.Å 1173.Å 1174.Å 1175.Å 1176.Å 1177.Å 1178.Å 1179.Å 1180.Å 1181.Å 1182.Å 1183.Å 1184.Å 1185.Å 1186.Å 1187.Å 1188.Å 1189.Å 1190.Å 1191.Å 1192.Å 1193.Å 1194.Å 1195.Å 1196.Å 1197.Å 1198.Å 1199.Å 1200.Å 1201.Å 1202.Å 1203.Å 1204.Å 1205.Å 1206.Å 1207.Å 1208.Å 1209.Å 1210.Å 1211.Å 1212.Å 1213.Å 1214.Å 1215.Å 1216.Å 1217.Å 1218.Å 1219.Å 1220.Å 1221.Å 1222.Å 1223.Å 1224.Å 1225.Å 1226.Å 1227.Å 1228.Å 1229.Å 1230.Å 1231.Å 1232.Å 1233.Å 1234.Å 1235.Å 1236.Å 1237.Å 1238.Å 1239.Å 1240.Å 1241.Å 1242.Å 1243.Å 1244.Å 1245.Å 1246.Å 1247.Å 1248.Å 1249.Å 1250.Å 1251.Å 1252.Å 1253.Å 1254.Å 1255.Å 1256.Å 1257.Å 1258.Å 1259.Å 1260.Å 1261.Å 1262.Å 1263.Å 1264.Å 1265.Å 1266.Å 1267.Å 1268.Å 1269.Å 1270.Å 1271.Å 1272.Å 1273.Å 1274.Å 1275.Å 1276.Å 1277.Å 1278.Å 1279.Å 1280.Å 1281.Å 1282.Å 1283.Å 1284.Å 1285.Å 1286.Å 1287.Å 1288.Å 1289.Å 1290.Å 1291.Å 1292.Å 1293.Å 1294.Å 1295.Å 1296.Å 1297.Å 1298.Å 1299.Å 1300.Å 1301.Å 1302.Å 1303.Å 1304.Å 1305.Å 1306.Å 1307.Å 1308.Å 1309.Å 1310.Å 1311.Å 1312.Å 1313.Å 1314.Å 1315.Å 1316.Å 1317.Å 1318.Å 1319.Å 1320.Å 1321.Å 1322.Å 1323.Å 1324.Å 1325.Å 1326.Å 1327.Å 1328.Å 1329.Å 1330.Å 1331.Å 1332.Å 1333.Å 1334.Å 1335.Å 1336.Å 1337.Å 1338.Å 1339.Å 1340.Å 1341.Å 1342.Å 1343.Å 1344.Å 1345.Å 1346.Å 1347.Å 1348.Å 1349.Å 1350.Å 1351.Å 1352.Å 1353.Å 1354.Å 1355.Å 1356.Å 1357.Å 1358.Å 1359.Å 1360.Å 1361.Å 1362.Å 1363.Å 1364.Å 1365.Å 1366.Å 1367.Å 1368.Å 1369.Å 1370.Å 1371.Å 1372.Å 1373.Å 1374.Å 1375.Å 1376.Å 1377.Å 1378.Å 1379.Å 1380.Å 1381.Å 1382.Å 1383.Å 1384.Å 1385.Å 1386.Å 1387.Å 1388.Å 1389.Å 1390.Å 1391.Å 1392.Å 1393.Å 1394.Å 1395.Å 1396.Å 1397.Å 1398.Å 1399.Å 1400.Å 1401.Å 1402.Å 1403.Å 1404.Å 1405.Å 1406.Å 1407.Å 1408.Å 1409.Å 1410.Å 1411.Å 1412.Å 1413.Å 1414.Å 1415.Å 1416.Å 1417.Å 1418.Å 1419.Å 1420.Å 1421.Å 1422.Å 1423.Å 1424.Å 1425.Å 1426.Å 1427.Å 1428.Å 1429.Å 1430.Å 1431.Å 1432.Å 1433.Å 1434.Å 1435.Å 1436.Å 1437.Å 1438.Å 1439.Å 1440.Å 1441.Å 1442.Å 1443.Å 1444.Å 1445.Å 1446.Å 1447.Å 1448.Å 1449.Å 1450.Å 1451.Å 1452.Å 1453.Å 1454.Å 1455.Å 1456.Å 1457.Å 1458.Å 1459.Å 1460.Å 1461.Å 1462.Å 1463.Å 1464.Å 1465.Å 1466.Å 1467.Å 1468.Å 1469.Å 1470.Å 1471.Å 1472.Å 1473.Å 1474.Å 1475.Å 1476.Å 1477.Å 1478.Å 1479.Å 1480.Å 1481.Å 1482.Å 1483.Å 1484.Å 1485.Å 1486.Å 1487.Å 1488.Å 1489.Å 1490.Å 1491.Å 1492.Å 1493.Å 1494.Å 1495.Å 1496.Å 1497.Å 1498.Å 1499.Å 1500.Å 1501.Å 1502.Å 1503.Å 1504.Å 1505.Å 1506.Å 1507.Å 1508.Å 1509.Å 1510.Å 1511.Å 1512.Å 1513.Å 1514.Å 1515.Å 1516.Å 1517.Å 1518.Å 1519.Å 1520.Å 1521.Å 1522.Å 1523.Å 1524.Å 1525.Å 1526.Å 1527.Å 1528.Å 1529.Å 1530.Å 1531.Å 1532.Å 1533.Å 1534.Å 1535.Å 1536.Å 1537.Å 1538.Å 1539.Å 1540.Å 1541.Å 1542.Å 1543.Å 1544.Å 1545.Å 1546.Å 1547.Å 1548.Å 1549.Å 1550.Å 1551.Å 1552.Å 1553.Å 1554.Å 1555.Å 1556.Å 1557.Å 1558.Å 1559.Å 1560.Å 1561.Å 1562.Å 1563.Å 1564.Å 1565.Å 1566.Å 1567.Å 1568.Å 1569.Å 1570.Å 1571.Å 1572.Å 1573.Å 1574.Å 1575.Å 1576.Å 1577.Å 1578.Å 1579.Å 1580.Å 1581.Å 1582.Å 1583.Å 1584.Å 1585.Å 1586.Å 1587.Å 1588.Å 1589

certify that:1.I have reviewed this report on Form 10-Q of OraSure Technologies, Inc.2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors:a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: November 7, 2024/s/ Kenneth J. McGrathKenneth J. McGrathChief Financial Officer (Principal Financial Officer) / EX-32.1 4 osur-09302024xexx321.htm EX-32.1 DocumentExhibit 32.1CERTIFICATION PURSUANT TO18 U.S.C. Â§1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report of OraSure Technologies, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Carrie Eglinton Manner, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/ Carrie Eglinton MannerCarrie Eglinton MannerPresident and Chief Executive OfficerNovember 7, 2024 EX-32.2 5 osur-09302024xexx322.htm EX-32.2 DocumentExhibit 32.2CERTIFICATION PURSUANT TO18 U.S.C. Â§ 1350,AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report of OraSure Technologies, Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Kenneth J. McGrath, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/ Kenneth J. McGrathKenneth J. McGrathChief Financial OfficerNovember 7, 2024 EX-101.SCH 6 osur-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952151 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952152 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952153 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952154 - Statement - Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952155 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952156 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952157 - Disclosure - Government Capital Contracts link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952158 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952159 - Disclosure - Property, Plant and Equipment, Net link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952160 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952161 - Disclosure - Termination Benefits link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952162 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952163 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952164 - Disclosure - Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952165 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9952166 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954472 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954473 - Disclosure - Government Capital Contracts (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954474 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954475 - Disclosure - Property, Plant and Equipment, Net (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954476 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954477 - Disclosure - Termination Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954478 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954479 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954480 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954481 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954482 - Disclosure - Summary of Significant Accounting Policies - Summary of Changes in Accumulated Other Comprehensive Loss by Component (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954483 - Disclosure - Government Capital Contracts - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954484 - Disclosure - Government Capital Contracts - Summary of Government Contracts Balances Included in Consolidated Statements of Cash flows (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954485 - Disclosure - Inventories - Schedule of Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954486 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954487 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954488 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954489 - Disclosure - Termination Benefits - Summary of One-Time Termination Benefits (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954490 - Disclosure - Termination Benefits - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954491 - Disclosure - Revenues - Summary of Total Net Revenues by Product Line (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954492 - Disclosure - Revenues - Summary of Total Net Revenues by Geographic Area (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954493 - Disclosure - Revenues - Concentration Risk (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954494 - Disclosure - Revenues - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954495 - Disclosure - Income Taxes - Summary Of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954496 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954497 - Disclosure - Income (Loss) Per Share - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink 9954498 - Disclosure - Stockholders' Equity - Summary of Reconciliation of Changes in Stockholders' Equity (Detail) link:presentationLink link:calculationLink link:definitionLink link:definitionLink EX-101.CAL 7 osur-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 osur-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 osur-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Vesting of restricted stock and performance stock units (in shares) Stock Issued During Period, Shares, Vesting Of Restricted Stock And Performance Stock Units Stock issued during period, shares, vesting of restricted stock and performance stock units. Adjustments to reconcile net (loss) income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Work in process Inventory, Work in Process, Gross Cover [Abstract] Cover [Abstract] NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Accrued property and equipment purchases under government contracts Accrued Property and Equipment Purchases under Government Contracts Accrued property and equipment purchases under government contracts. Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Commercial Customer One Commercial Customer One [Member] Commercial Customer One Awards Close in Time to MNPI Disclosures [Table] Cash (refunds) paid for income taxes Income Taxes Paid, Net Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable Increase (Decrease) in Accounts Receivable Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Land Land [Member] Finance lease, impairment loss Finance Lease, Impairment Loss Unrealized gain on marketable securities Unrealized gain on marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Foreign income tax expense (benefit) Foreign Income Tax Expense (Benefit), Continuing Operations Sales tax payable Sales and Excise Tax Payable, Current Operating lease liability Operating Lease, Liability, Noncurrent Total noncurrent assets Assets, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Interest expense on finance leases Finance Lease, Interest Expense Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Deferred revenue Contract with Customer, Liability, Current United States UNITED STATES Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Money Market Fund Money Market Funds [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Summary of Changes in Accumulated Other Comprehensive Loss by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Prepaid expenses Prepaid Expense, Current Equity Components Equity Components [Axis] Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Short-term investments Debt Securities, Available-for-Sale Q1 2024 Reduction in Workforce Q1 2024 Reduction in Workforce [Member] Q1 2024 Reduction in Workforce Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Common Stock Options Unvested Restricted Stock and Unvested Performance Stock Units Common Stock Options Unvested Restricted Stock And Unvested Performance Units [Member] Common stock options unvested restricted stock and unvested performance units. COVID-19 C O V I D19 [Member] COVID-19. Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Payables and Accruals [Abstract] Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical Geographical [Axis] Proceeds from maturities and redemptions of short-term investments Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Tabular List, Table Tabular List [Table Text Block] Sales and marketing Selling and Marketing Expense [Member] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Number of anti-dilutive securities excluded from EPS computation Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Impair

services sold Cost of Sales [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Accrued property and equipment purchases Noncash or Part Noncash Acquisition, Fixed Assets Acquired Loss on impairments Loss on impairments Asset Impairment Charges Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Computer equipment and software Computer Equipment And Software [Member] Computer equipment and software. Document Type Document Type Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Termination Benefits [Line Items] Termination Benefits [Line Items] Termination benefits. Risk assessment testing Risk Assessment Testing [Member] Risk assessment testing. CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Fair value of plan assets Deferred Compensation Plan Assets Product and Services Revenues Sales [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Furniture and fixtures Furniture and Fixtures [Member] Intangible assets, net of accumulated amortization of \$33,711 and \$33,649 Finite-Lived Intangible Assets, Net Antidilutive Securities Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] NET REVENUES: Revenues [Abstract] Current Fiscal Year End Date Current Fiscal Year End Date Noncurrent Assets: Assets, Noncurrent [Abstract] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Summary of One-Time Termination Benefits Summary Of One-Time Termination Benefits [Table Text Block] Summary of one-time termination benefits. Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount All Award Types Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation Of Revenue [Line Items] Disaggregation of Revenue [Line Items] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Research and Development Expenses and Other Income Research and Development Expenses and Other Income [Member] Research and development expenses and other income. Additional Paid-in Capital Additional Paid-in Capital [Member] Finance lease liability Finance Lease, Liability, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] DILUTED (in USD per share) Earnings Per Share, Diluted Payment of reduction in workforce Payment Of Reduction In Workforce Payment of reduction in workforce. Deferred Revenue Revenue from Contract with Customer [Policy Text Block] Accumulated amortization of intangible assets Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Type of Restructuring [Domain] Type of Restructuring [Domain] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Net foreign exchange gains (losses) Gain (Loss), Foreign Currency Transaction, before Tax Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer Customer [Axis] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Disaggregation Of Revenue [Table] Disaggregation of Revenue [Table] Unrealized foreign currency gain Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Sales and marketing Selling and Marketing Expense INCOME TAX EXPENSE Income tax expense (benefit) Income tax expense (benefit) Income Tax Expense (Benefit) SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Supplemental Cash Flow Information [Abstract] Total revenue Net revenues Revenue from Contract with Customer, Excluding Assessed Tax State income tax expense (benefit) State and Local Income Tax Expense (Benefit), Continuing Operations Accrued reduction in workforce Accrued Reduction in Workforce Accrued reduction in workforce. Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating (loss) income Operating Income (Loss) Equity Method Investee Equity Method Investments [Policy Text Block] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Payroll and related benefits Employee-related Liabilities, Current Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Summary of Government Contracts Balances Included in Consolidated Statements of Cash flows Summary Of Government Contracts Balances Included In Consolidated Statements Of Cash Flow [Table Text Block] Summary of government contracts balances included in consolidated statements of cash flow. Operating lease, impairment loss Operating Lease, Impairment Loss Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Buildings and improvements Building and Building Improvements [Member] Percentage withheld under government contracts subject to validation testing Percentage Withheld Under Government Contracts Subject to Validation Testing "Percentage of total capital costs incurred under government contract not reimbursed until completion of final validation testing. Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Inventories Inventories Inventory, Net Products and services Product And Services [Member] Products and services. Product and Service Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Summary of Reconciliation of Changes in Stockholder's Equity Schedule of Stockholders Equity [Table Text Block] OPERATING EXPENSES: Operating Expenses [Abstract] Schedule of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments Financial Instruments [Domain] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Termination Benefits [Abstract] Termination Benefits [Abstract] Termination benefits. Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Operating right-of-use assets, net Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Provision for credit losses Accounts Receivable, Credit Loss Expense (Reversal) Commercial Customer Two Commercial Customer Two [Member] Commercial Customer Two Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Investment in equity method investee Payments to acquire equity method investments Payments to Acquire Equity Method Investments Other Other Income [Member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Exercise Price Award Exercise Price Termination Benefits [Table] Termination Benefits [Table] Termination benefits. Income (Loss) Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Common stock issued upon exercise of options Stock Issued During Period, Value, Stock Options Exercised STOCKHOLDERS' EQUITY Equity, Attributable to Parent [Abstract] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Long-term Contract Long-Term Contract with Customer [Member] Restructuring Plan [Axis] Restructuring Plan [Axis] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] PEO PEO [Member] Contract with Customer, Duration Contract with Customer, Duration [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name OTHER INCOME Other Nonoperating Income (Expense) One-time Termination Benefits One-time Termination Benefits [Member] Long-Lived Tangible Asset [Axis] LOSS ON EQUITY INVESTMENT Loss on equity investment Income (Loss) from Equity Method Investments (Loss) income before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Schedules of Concentration of Risk, by Risk Factor Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Total noncurrent liabilities Liabilities, Noncurrent Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Deferred income taxes Deferred Income Tax Liabilities, Net Q3 2024 Reduction In Workforce Q3 2024 Reduction In Workforce [Member] Q3 2024 Reduction In Workforce Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Noncurrent Liabilities: Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Income Statement Location Statement of Income Location, Balance [Axis] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Guaranteed Investment Certificates Guaranteed Investment Certificates [Member] Guaranteed investment certificates. Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key General and administrative General and Administrative Expense [Member] Customer and Vendor Concentrations Major Customers, Policy [Policy Text Block] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Accrued Expenses and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Foreign Currency Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Finance right-of-use assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Stockholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component Equity Component [Domain] Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument Financial Instrument [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Change in the estimated fair value of acquisition-related contingent consideration Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accumulated Other Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Deferred revenue recognized Deferred Revenue, Revenue Recognized Current Liabilities: Liabilities, Current [Abstract] Proceeds from funding under government contract Proceeds From Funding Under Government Contract Proceeds from funding under government contract Purchase of property and equipment under government contracts Purchase Of Property And Equipment Under Government Contracts Purchase of property and equipment under government contracts Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Level 1 Instruments Fair Value, Inputs, Level 1 [Member] Currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Loss on sale of fixed assets Gain (Loss) on Disposition of Assets Total current assets Assets, Current Statement of Cash Flows [Abstract] Other Other Revenues [Member] Other revenues. Non-cash investing and financing activities Noncash Investing and Financing Items [Abstract] Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Repurchase of common stock Payments for Repurchase of Common Stock Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Purchase and retirement of common shares Stock Repurchased and Retired During Period, Value Income Taxes Income Tax Disclosure [Text Block] (LOSS) INCOME PER SHARE: Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Accumulated deficit Retained Earnings (Accumulated Deficit) Purchase and retirement of common shares (in shares) Stock Repurchased and Retired During Period, Shares Inventories Increase (Decrease) in Inventories General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Other non-cash amortization Increase Decrease In Other Non Cash Amortization Increase decrease in other non-cash amortization. Depreciation and amortization Depreciation, Depletion and Amortization Gross profit Gross Profit Machinery and equipment Machinery and Equipment [Member] Fair Value as of Grant Date Award Grant Date Fair Value Revenue from contract with customer [Line Items] Revenue From Contract With Customer [Line Items] Revenue from contract with customer. Customer Concentration Risk Customer Concentration Risk [Member] Molecular Sample Management Solutions Molecular Sample Management Solutions [Member] Molecular products. Other product and services revenues Other Product And Services Revenues [Member] Other Product And Services Revenues [Member] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Non-product and services revenues Other Non Product Revenues [Member] Other non product revenues. Geographical Geographical [Domain] Property, Plant and Equipment Property, Plant and Equipment [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Disaggregation of Revenue by Product and Geographic Area Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type Concentration Risk Type [Axis] Common stock, par value \$0.000001, 120,000 shares authorized, 74,593 and 73,528 shares issued and outstanding Common Stock, Value, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Investment in equity method investee Equity Securities, FV-NI, Noncurrent Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, par value \$0.000001, 25,000 shares authorized, none issued Preferred Stock, Value, Issued Cash and Cash Equivalents [Domain] BASIC (in USD per share) Earnings Per Share, Basic Q2 2024 Reduction in Workforce Q2 2024 Reduction in Workforce [Member] Q2 2024 Reduction In Workforce Accounts payable Increase (Decrease) in Accounts Payable Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Up-Front Payment Up-Front Payment [Member] Up-Front Payment Cash payments for lease liabilities Finance Lease, Principal Payments Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] WEIGHTED-AVERAGE SHARES OUTSTANDING: Weighted Average Number of Shares Outstanding, Diluted [Abstract] TOTAL ASSETS Assets COST OF PRODUCTS AND SERVICES SOLD Cost of Goods and Services Sold Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Reduction for funding received to date Funding Received Amount Funding received amount Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 11) Commitments and Contingencies Contract With Customer, Payment Type [Axis] Contract With Customer, Payment Type [Axis] Contract With Customer, Payment Type Termination Date Trading Arrangement Termination Date Entity Address, City or Town Entity Address, City or Town Government capital contracts funding amount Government Contract Receivable Schedule of Accrued Expenses and Other Current Liabilities Schedule Of Accrued Expenses And Other Current Liabilities Table [Table Text Block] Schedule of accrued expenses and other current liabilities. Molecular Services Molecular Services [Member] Molecular services. NET (LOSS) INCOME NET (LOSS) INCOME Net loss Net Income (Loss)

Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities. Cash and Cash Equivalents Cash and Cash Equivalents [Axis] Revenues Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Restructuring Plan [Domain] Restructuring Plan [Domain] Other Other Accrued Liabilities, Current Name Forgone Recovery, Individual Name Document Period End Date Document Period End Date Finance lease liability Finance Lease, Liability, Current Finished goods Inventory, Finished Goods, Net of Reserves Cash Equivalents & Short-Term Investments Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] 2023 Reduction in Workforce 2023 Reduction in Workforce [Member] 2023 Reduction in Workforce Contract With Customer, Payment Type [Domain] Contract With Customer, Payment Type [Domain] Contract With Customer, Payment Type [Domain] Insider Trading Arrangements [Line Items] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts Receivable Accounts Receivable [Member] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Government Contract Government Contract [Member] Customer Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] BASIC (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Reimbursement of engineering cost Reimbursement of Engineering Cost Reimbursement of engineering cost. Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Professional fees Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Contract with Customer, Duration Contract with Customer, Duration [Axis] Construction in progress Construction in Progress [Member] Net Consolidated Revenue Revenue Benchmark [Member] Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Entity Filer Category Entity Filer Category Beginning balance (in shares) Ending balance (in shares) Shares, Issued Income Statement Location Statement of Income Location, Balance [Domain] Purchases of short-term investments Payments to Acquire Debt Securities, Available-for-Sale Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 osur-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover Page - shares 9 Months Ended Sep. 30, 2024 01, 2024 Cover [Abstract] A A Document Type 10-Q A Document Quarterly Report true A Document Period End Date Sep. 30, 2024 A Document Transition Report false A Entity File Number 001-16537 A Entity Registrant Name ORASURE TECHNOLOGIES, INC A Entity Incorporation, State or Country Code DE A Entity Tax Identification Number 36-4370966 A Entity Address, Address Line One 220 East First Street A Entity Address, City or Town Bethlehem A Entity Address, State or Province PA A Entity Address, Postal Zip Code 18015 A City Area Code 610 A Local Phone Number 882-1820 A Title of 12(b) Security Common Stock, 0.000001 par value per share A Trading Symbol OSUR A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Accelerated Filer A Entity Small Business false A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 74,594,154 Entity Central Index Key 0001116463 A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q3 A Amendment Flag false A Current Fiscal Year End Date --12-31 A X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:MonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:YearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Current Assets: A A Cash and cash equivalents \$ 278,571 \$ 290,407 Accounts receivable, net of allowance of \$1,237 and \$1,216 26,954 40,171 Inventories 38,870 47,614 Prepaid expenses 3,038 6,041 Other current assets 2,718 2,226 Total current assets 350,151 386,459 Noncurrent Assets: A A Property, plant and equipment, net of accumulated depreciation of \$79,562 and \$85,143 38,143 45,420 Operating right-of-use assets, net 9,904 12,270 Finance right-of-use assets, net 157 576 Intangible assets, net of accumulated amortization of \$33,711 and \$33,649 665 1,206 Goodwill 35,287 35,696 Investment in equity method investee 28,829 0 Other noncurrent assets 949 1,218 Total noncurrent assets 113,934 96,386 TOTAL ASSETS 464,085 482,845 Current Liabilities: A A Accounts payable 9,581 13,151 Deferred revenue 1,619 1,559 Accrued expenses and other current liabilities 15,013 22,710 Finance lease liability 41 539 Operating lease liability 1,530 1,577 Total current liabilities 27,784 39,536 Noncurrent Liabilities: A A Finance lease liability 124 226 Operating lease liability 9,412 11,162 Other noncurrent liabilities 529 696 Deferred income taxes 671 554 Total noncurrent liabilities 10,736 12,638 TOTAL LIABILITIES 38,520 52,174 Commitments and contingencies (Note 11) STOCKHOLDERS' EQUITY A A Preferred stock, par value 0.000001, 25,000 shares authorized, none issued 0 0 Common stock, par value 0.000001, 120,000 shares authorized, 74,593 and 73,528 shares issued and outstanding 0 0 Additional paid-in capital 535,402 529,543 Accumulated other comprehensive loss (17,200) (14,941) Accumulated deficit (92,637) (83,931) Total stockholders' equity 425,565 430,671 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY \$ 464,085 \$ 482,845 X - DefinitionAccrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: osur_AccruedExpensesAndOtherCurrentLiabilities Namespace Prefix: osur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix:

us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionValue received from shareowners in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards

<https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1)Reference 4: [http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1 + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details Name: us-gaap ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1)Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap EquitySecuritiesFVNINoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap FinanceLeaseLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap FinanceLeaseLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated amortization, of right-of-use asset from finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap FinanceLeaseRightOfUseAsset Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: <a href=)Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://www.xbrl.org/2003/role/exampleRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482593/350-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 7: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1)Reference 9: [http://www.xbrl.org/2003/role/exampleRef-Topic 10 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap Goodwill Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap InventoryNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 27: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/214747877/944-210-S99-1)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(32\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(21\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(bb\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)

1Reference 6:

<http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 4.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-599-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-599-2) + Details Name: us-gaap StockholdersEquityNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstractNamespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Balance Sheets (Parenthetical) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] A Allowance for doubtful accounts 1,237 \$ 1,216 Accumulated depreciation of property and equipment 79,562 85,143 Accumulated amortization of intangible assets \$ 33,711 \$ 33,649 Preferred stock, par value (in USD per share) \$ 0.000001 \$ 0.000001 Preferred stock, shares authorized (in shares) 25,000,000 25,000,000 Preferred stock, shares issued (in shares) 0 0 Common stock, par value (in USD per share) \$ 0.000001 \$ 0.000001 Common stock, shares authorized (in shares) 120,000,000 120,000,000 Common stock, shares issued (in shares) 74,593,000 73,528,000 Common stock, shares outstanding (in shares) 74,593,000 73,528,000 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(8\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-599-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(14\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4> + Details Name: us-gaap AllowanceForDoubtfulAccountsReceivableCurrentNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1) + Details Name: us-gaap CommonStockParOrStatedValuePerShareNamespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1) + Details Name: us-gaap CommonStockSharesAuthorizedNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1) + Details Name: us-gaap CommonStockSharesIssuedNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-599-3) + Details Name: us-gaap CommonStockSharesOutstandingNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1) + Details Name: us-gaap FiniteLivedIntangibleAssetsAccumulatedAmortizationNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap PreferredStockParOrStatedValuePerShareNamespace Prefix: us-gaap_Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(16\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-599-1) + Details Name: us-gaap PreferredStockSharesAuthorizedNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13) + Details Name: us-gaap PreferredStockSharesIssuedNamespace Prefix: us-gaap_Data Type: xbrli:sharesItemBalance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StatementOfFinancialPositionAbstractNamespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Consolidated Statements of Operations - USD (\$) \$ in Thousands \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 NET REVENUES: A A A Total revenue \$ 39,915 \$ 89,187 \$ 148,382 \$ 329,591 COST OF PRODUCTS AND SERVICES SOLD 22,845 44,847 82,558 193,065 Gross profit 17,070 44,340 65,824 136,526 OPERATING EXPENSES: A A A Research and development 5,623 8,516 19,960 26,737 Sales and marketing 7,615 8,736 23,994 29,413 General and administrative 9,831 10,051 33,310 44,186 Loss on impairments 0 6,183 4,392 7,503 Change in the estimated fair value of acquisition-related contingent consideration 0 (40) 0 (99) Total operating expenses 23,069 33,446 81,656 107,740 Operating (loss) income (5,999) 10,894 (15,832) 28,786 OTHER INCOME 2,781 2,612 9,338 6,752 (Loss) income before income taxes (3,218) 13,506 (6,494) 35,538 INCOME TAX EXPENSE 678 2,347 1,041 1,956 LOSS ON EQUITY INVESTMENT (611) 0 (1,171) 0 NET (LOSS) INCOME \$ (4,507) \$ 11,159 \$ (8,706) \$ 33,582 (LOSS) INCOME PER SHARE: A A A BASIC (in USD per share) \$ (0.06) \$ 0.15 \$ (0.12) \$ 0.46 DILUTED (in USD per share) \$ (0.06) \$ 0.15 \$ (0.12) \$ 0.45 WEIGHTED-AVERAGE SHARES OUTSTANDING: A A A BASIC (in shares) 74,583 73,453 74,330 73,298 DILUTED (in shares) 74,583 74,349 74,330 74,197 Products and services A A A NET REVENUES: A A A Total revenue \$ 39,651 \$ 89,014 \$ 147,379 \$ 326,666 Other A A A NET REVENUES: A A A Total revenue \$ 264 \$ 173 \$ 1,003 \$ 2,925 X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4> + Details Name: us-gaap AssetImpairmentChargesNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4) + Details Name: us-gaap BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(2\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SAB Topic 11.L\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-599-1) + Details Name: us-gaap CostOfGoodsAndServicesSoldNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstractNamespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3)

Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dtr-type:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(e\)\(4\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(27\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7> + Details Name: us-gaap EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-type:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(2\)\(a\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1) + Details Name: us-gaap GeneralAndAdministrativeExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 9: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 23: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> + Details Name: us-gaap GrossProfit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6:

graph 2-SubParagraph (a)-SubTopic 20-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(h))-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477520/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fasb.org/1943274

translation adjustments 1,431 (2,813) 843 Unrealized gain on marketable securities 0 0 220 COMPREHENSIVE (LOSS) INCOME \$ (3,076) \$ 8,346 \$ (10,965) \$ 34,645 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1:

<https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(1)(Note 1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -SubTopic 10 -Topic 740 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-9> + Details Name: us-gaap_DeferredIncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22> + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense on finance lease liability. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-4>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-50-4> + Details Name: us-gaap_FinanceLeaseInterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-4>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-5> + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-6>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481956/830-20-45-1>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481926/830-20-50-1>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_ForeignCurrencyTransactionGainLossUnrealized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_GainLossOnDispositionOfAssets1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481664/323-10-45-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-2A>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-23>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482685/740-10-50-22>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482913/230-10-50-2> + Details Name: us-gaap_IncomeTaxPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478345/912-310-45-11>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5:

https://asc.fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type: debit Period Type: duration X - DefinitionAmount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45

each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and company stock. The fair value of the plan assets as of September 30, 2024 and December 31, 2023 was \$0.7 million and \$0.8 million, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 financial instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets. Foreign Currency Transactions Net foreign exchange gains and (losses) resulting from foreign currency transactions that are included in other income in the Company's consolidated statements of operations were \$(0.2) million and \$(0.1) million for the three months ended September 30, 2024 and 2023, respectively. Net foreign exchange gains and (losses) resulting from foreign currency transactions for the nine months ended September 30, 2024 and 2023 were \$0.1 million and \$(0.7) million, respectively. Impairment of Long-Lived Assets Long-lived assets, which include property, plant and equipment, definite-lived intangible assets, as well as right-of-use assets (ROU assets) of operating and finance leases, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the Company's long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows expected to be generated from the use and eventual disposition of the asset. If indicators of impairment exist, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect the Company's assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. During the first quarter of 2024, the Company identified a triggering event to test for the recoverability of all the property, plant, and equipment and ROU assets of both the Diversigen and Novosanis subsidiaries, given the Company's decision to initiate a strategic plan to transition away from the microbiome molecular sequencing services business and close its Belgian operations. The Company performed an undiscounted cash flow analysis and determined the carrying values of the property, plant and equipment and ROU assets could not be recovered through the sum of the undiscounted future cash flows and were impaired. During the nine months ended September 30, 2024 the Company recognized aggregate pre-tax impairment charges of \$1.2 million and \$0.3 million to its operating and finance ROU assets, respectively. These charges are reported in the Company's consolidated statement of operations. The impact of the impairments on the Company's property, plant, equipment for the nine months ended September 30, 2024 is discussed further in Note 4. Accumulated Other Comprehensive Loss Change in accumulated other comprehensive loss by component is listed below (in thousands): Foreign Currency Total Balance at December 31, 2023 \$(14,941) \$(14,941) Other comprehensive loss (2,259) (2,259) Balance at September 30, 2024 \$(17,200) \$(17,200) Recent Accounting Pronouncements In March 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2024-01, Compensation—Stock Compensation (Topic 718), Scope Application of Profits Interest and Similar Awards. The purpose of this update was to provide illustrative examples to demonstrate how an entity should apply guidance to determine whether profits interests and similar awards should be accounted for in accordance with Topic 718. For public business entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal periods. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. Management is evaluating the impact on the Company's consolidated financial statements. X - References No definition available. + Details Name: us-gaap Accounting Policies Abstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for all significant accounting policies of the reporting entity. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1) Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1) Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7> + Details Name: us-gaap Property Plant And Equipment Disclosure TextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities Nine Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] A Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities (in thousands) September 30, December 31, 2024 2023 Payroll and related benefits \$9,320 A \$14,654 A Professional fees 1,264 A 2,827 A Sales tax payable 1,228 A 1,245 A Other 3,201 A 3,984 A \$15,013 A \$22,710 A X - Definition The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period. + References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1> + Details Name: us-gaap Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current TextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlock Item Type Balance Type: na Period Type: duration X - References No definition available. + Details Name: us-gaap Payables And Accruals Abstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Termination Benefits Nine Months Ended Sep. 30, 2024 Termination Benefits [Abstract] A Termination Benefits Termination Benefits 2023 Reduction in Workforce During the first and second quarters of 2023, the Company executed a reduction in workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands): For the Nine Months Ended September 30, 2023 Cost of products and services sold \$369 A Research and development \$566 A Sales and marketing 1,542 A General and administrative 787 A \$3,264 A As of September 30, 2024 the Company has fully paid the \$3.3 million related to the reduction in workforce. No additional expense associated with the 2023 reduction in workforce was incurred during the nine months ended September 30, 2024. This plan was completed as of June 30, 2024. Q1 2024 Reduction in Workforce During the first quarter of 2024, the Company executed a reduction in workforce largely affecting its COVID-19 manufacturing workforce. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands): For the Nine Months Ended September 30, 2024 Cost of products and services sold \$231 A Research and development 87 A Sales and marketing 69 A General and administrative 17 A \$404 A As of September 30, 2024 the Company had \$6.0 thousand accrued and had paid \$0.4 million related to the reduction in workforce. No additional expense associated with the Q1 2024 reduction in workforce was incurred during the three months ended September 30, 2024. The Company expects this plan to be completed by December 31, 2024. Q2 2024 Reduction in Workforce During the second quarter of 2024, the Company executed an additional reduction in workforce as the Company notified employees of its intention to consolidate its Novosanis site in Belgium into other locations by the end of December 31, 2024, discontinue the Diversigen molecular services line of business by the end of June 30, 2024, and consolidate facilities by bringing third-party manufacturing activities into its Pennsylvania facilities by the end of the third quarter of 2025. This was accounted for pursuant to ASC 420, Exit or Disposal Cost Obligations. The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands): For the Three Months Ended September 30, 2024 Cost of products and services sold \$9 A Research and development 4 A Sales and marketing 346 A General and administrative 6 A \$353 A As of September 30, 2024 the Company had \$0.3 million accrued and had paid \$7.1 thousand related to the reduction in workforce. The Company expects this plan to be completed by January 2026. X - Definition Termination benefits. + References No definition available. + Details Name: osur Termination Benefits Abstract Namespace Prefix: osur_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition Termination benefits. + References No definition available. + Details Name: osur Termination Benefits TextBlock Namespace Prefix: osur_ Data Type: dtr-types:1:textBlock Item Type Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues Nine Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] A Revenues Revenues Revenues by product line. The following table represents total net revenues by product line (in thousands): For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024 2023 2024 2023 HIV \$18,347 A \$16,650 A \$45,379 A \$46,518 A COVID-19 (1) 1,155 A 50,199 A 44,222 A 216,115 A Molecular Sample Management Solutions (2) 12,806 A 15,238 A 36,237 A 41,230 A HCV 3,228 A 2,901 A 10,962 A 9,957 A Risk assessment testing (3) 1,911 A 2,554 A 6,265 A 7,540 A Other product and service revenues (4) 1,196 A 638 A 2,623 A 1,739 A Molecular Services 9 A 834 A 1,692 A 3,567 A Net product and services revenues 39,652 A 89,014 A 147,380 A 326,666 A Non-product and services revenues (5) 263 A 173 A 1,002 A 2,925 A Net revenues 93,915 A \$89,187 A \$148,382 A \$329,591 A (1) Includes COVID-19 Diagnostics and COVID-19 Molecular revenues. (2) Includes Genomics, Microbiome and Novosanis product revenues. (3) Includes substance abuse testing products revenues. (4) Includes Syphilis revenues. (5) Includes funded research and development contracts, royalty income and grant revenues. Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer (in thousands): For the Three

Months Ended September 30, 2024 For the Nine Months Ended September 30, 2024 202320242023United States\$25,353Å \$77,925Å \$115,055Å \$296,815Å Europe2,126Å 1,992Å 5,892Å 6,297Å Other regions12,436Å 9,270Å 27,435Å 26,479Å \$39,915Å \$89,187Å \$148,382Å \$329,591Å Customer and Vendor Concentrations. The following table represents the concentration risk.For the Three Months Ended September 30, For the Nine Months Ended September 30, Revenue Concentration2024202320242023Commercial customer (1)11%NANANANCommercial customer (1)10%NANANANNon-Commercial customer (2)N56%26%66%September 30, December 31, Accounts Receivable20242023Commercial customer (1)21%NANon-Commercial customer (2)N40% (1) Each commercial customer is different. (2) Same non-commercial customer.The Company currently purchases certain products and critical components of its products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of its products to its customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on its business, as well as its financial condition and results of operations. Deferred Revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of SeptemberÅ 30, 2024 and DecemberÅ 31, 2023 included customer prepayments of \$1.6 million and \$1.2 million, respectively. Deferred revenue as of DecemberÅ 31, 2023 also included \$0.4 million associated with a long-term contract that had variable pricing based on volume. The average price over the life of the contract was determined and revenue was recognized at that average price. The \$0.4 million associated with the long-term contract at DecemberÅ 31, 2023 met the criteria to be recognized as revenue during the nine months ended September 30, 2024, and as such there was no equivalent balance remaining in deferred revenue at SeptemberÅ 30, 2024. Deferred revenue recognized for the three months ended September 30, 2024 and 2023, was \$0.5 million and \$0.4 million, respectively. Deferred revenue recognized for the nine months ended September 30, 2024 and 2023, was \$3.3 million and \$2.2 million, respectively. X - ReferencesNo definition available. + Details Name: us-gaap RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12](http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Å Income Taxes Income TaxesThe components of income tax expense (benefit) are as follows (in thousands):For the Three Months Ended September 30, For the Nine Months Ended September 30, 2024202320242023State income tax expense (benefit)$18Å $1,131Å (209)2,388Å Foreign income tax expense (benefit)660Å 1,216Å 1,250Å (432)$678Å $2,347Å $1,041Å $1,956Å During the three months ended September 30, 2024 and 2023, the Company recorded income tax expense of $0.7Å million and $2.3Å million, respectively. The three months ended September 30, 2024 net tax expense decrease is due to having a U.S. pretax loss and foreign pretax income in 2024 compared to a U.S. and foreign pretax income for the three months ended September 30, 2023. During the nine months ended September 30, 2024 and 2023, the Company recorded income tax expense of $1.0Å million and $2.0Å million, respectively. Foreign pre-tax income increased during the nine months ended September 30, 2024 compared to a foreign pre-tax loss during the nine months ended September 30, 2023. In addition, there was lower state pre-tax income for nine months ended September 30, 2024 compared to 2023. Income tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of the Company's total deferred tax liability as of SeptemberÅ 30, 2024 and at DecemberÅ 31, 2023 relate to the tax effects of the basis difference arising from accelerated tax depreciation of fixed assets.A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. A full valuation allowance was recorded on the Company's U.S. deferred tax assets as of SeptemberÅ 30, 2024 and DecemberÅ 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SAB Topic 6.1.5.Q1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SAB Topic 6.1.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(h\)\(2\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14)Reference 11: <http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph \(SAB Topic 11.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-599-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Income (Loss) Per Share 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Å Income (Loss) Per Share Income (Loss) Per ShareBasic income (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings (loss) per share is computed in a manner similar to basic earnings (loss) per share except that the weighted-average number of shares outstanding is increased to include incremental shares from the assumed vesting or exercise of dilutive securities, such as common stock options, unvested restricted stock or performance stock units, unless the impact is antidilutive. The number of incremental shares is calculated by assuming that outstanding stock options were exercised and unvested restricted shares and performance stock units were vested, and the proceeds from such exercises or vesting were used to acquire shares of common stock at the average market price during the reporting period. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.For the three and nine months ended September 30, 2024, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 389 shares and 999 shares, respectively, were excluded from the computation of diluted loss per share. For the three and nine months ended September 30, 2023, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 2,027 and 2,048 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive. X - ReferencesNo definition available. + Details Name: us-gaap EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract] Å Stockholders' Equity Stockholders' EquityReconciliation of the changes in stockholders' equity for the three and nine months ended September 30, 2024 and 2023: Common StockAdditionalPaid-in Capital AccumulatedOtherComprehensive Loss Accumulated Deficit Total Shares AmountBalance at December 31, 202373,528$Å $529,543Å $(14,941)$(83,931)$430,671Å Common stock issued upon exercise of options32Å $214Å Å $214Å Vesting of restricted stock and performance stock units593Å $593Å Å $593Å Purchase and retirement of common shares(194)Å $1,462)Å $1,462)Å $1,462)Stock-based compensationÅ $2,968Å $2,968Å Net lossÅ $3,584)Å $3,584)Currency translation adjustmentsÅ $2,556)Å $2,556)Balance at March 31, 202473,959$Å $531,263Å $(17,497)$(87,515)$426,251Å Vesting of restricted stock and performance stock units1,033Å $1,033Å Å $1,033Å Purchase and retirement of common shares(424)Å $1,984)Å $1,984)Stock-based compensationÅ $3,322Å $3,322Å Net lossÅ $18,615)Å $18,615)Currency translation adjustmentsÅ $1,134)Å $1,134)Balance at June 30, 202474,568$Å $532,601Å $(18,631)$(88,130)$425,840Å Vesting of restricted stock and performance stock units44Å $44Å Å $44Å Purchase and retirement of common shares(19)Å $87)Å $87)Å $87)Stock-based compensationÅ $2,888Å $2,888Å Net lossÅ $4,507)Å $4,507)Currency translation adjustmentsÅ $1,431Å $1,431Å Balance at September 30, 202474,593$Å $535,402Å $(17,200)$(92,637)$425,565Å Common StockAdditionalPaid-in Capital AccumulatedOtherComprehensive Loss Accumulated DeficitTotalSharesAmountBalance at December 31, 202272,734$Å $520,446Å $(18,435)$(137,586)$364,425Å Common stock issued upon exercise of options12Å $66Å $66Å Vesting of restricted stock and performance stock units737Å $737Å Å $737Å Purchase and retirement of common shares(229)Å $1,203)Å $1,203)Å $1,203)Stock-based compensationÅ $2,655Å $2,655Å Net incomeÅ $27,219Å $27,219Å Currency translation adjustmentsÅ $797Å $797Å Unrealized gain on marketable securitiesÅ $220Å $220Å Balance at March 31, 202373,254$Å $521,964Å $(17,418)$(110,367)$394,179Å Vesting of restricted stock and performance stock units241Å $241Å Å $241Å Purchase and retirement of common shares(82)Å $460)Å $460)Å $460)Stock-based compensationÅ $2,357Å $2,357Å Net lossÅ $2,859Å $2,859Å Balance at June 30, 202373,413$Å $523,861Å $(14,559)$(115,163)$394,139Å Common stock issued upon exercise of options2Å $10Å $10Å Vesting of restricted stock and performance stock units99Å $99Å Å $99Å Purchase and retirement of common shares(31)Å $200)Å $200)Å $200)Stock-based compensationÅ $2,590Å $2,590Å Net incomeÅ $11,159Å $11,159Å Currency translation adjustmentsÅ $2,813Å $2,813Å Balance at September 30, 202373,483$Å $526,261Å $(17,372)$(104,004)$404,885Å X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(h\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479698/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479698/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479698/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479698/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476448/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-599-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph \(SX 210.4-08\(e\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)

https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] A Commitments and Contingencies Commitments and Contingencies Litigation From time to time, the Company is involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on the Company’s future financial position or results of operations. In March 2021, the Company filed a complaint against Spectrum Solutions, LLC (“Spectrum”) in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum filed an answer asserting that its device does not infringe the Company’s patent and that the Company’s patent is invalid. In August 2021, the Company amended its complaint to add a second patent to this litigation. Spectrum responded to the Company’s amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the litigation and subsequently filed a request for review of the second patent at the Patent and Trademark Office (“PTO”), which was granted by the PTO. The District Court issued multiple pretrial orders, resolving the infringement, antitrust, and inequitable conduct claims without trial. First, the District Court granted Spectrum’s motion for summary judgment of noninfringement. The Company appealed the grant of summary judgment to the Court of Appeals on June 8, 2023. The Company is pursuing the appeal with respect to the first patent, with oral argument expected in the first quarter of 2025. Second, the Court denied Spectrum’s motion to supplement its allegations of alleged antitrust violations, finding that if such an amendment were allowed, Spectrum’s claims would not survive a motion for summary judgment. Spectrum thereafter withdrew its antitrust and inequitable conduct counterclaims. Spectrum did not appeal the District Court’s denial of its motion to amend. On February 7, 2024, the PTO issued a Final Written Decision regarding the second patent in the litigation, holding that claims 1, 3-8, 11 and 12 of U.S. Patent No. 11,002,646 B2 are unpatentable. On March 8, 2024, the Company filed a Request for Rehearing by the Director of the PTO of the Final Written Decision. On March 27, 2024, the Company’s Request for Rehearing was denied. On September 15, 2023, Spectrum filed a separate petition for inter partes review of a third patent, which DNAG did not assert in the District Court. On March 26, 2024, the PTO issued a Decision Granting Institution of Inter Partes Review and scheduled oral argument for January 13, 2025. On July 2, 2024, the Company filed a Motion to Amend the claims of the third patent, which remains pending. X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2023 Pay vs Performance Disclosure A A A A A A A A NET (LOSS) INCOME \$ (4,507) \$ (615) \$ (3,584) \$ 11,159 \$ (4,796) \$ 27,219 \$ (8,706) \$ 33,582 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd PvpTable Namespace Prefix: ecd Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Inter Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual A - Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd Rule10b51ArrAdoptedFlag Namespace Prefix: ecd Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd Rule10b51ArrTrmtdFlag Namespace Prefix: ecd Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd TradingArrByIndTable Namespace Prefix: ecd Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] A Principles of Consolidation and Basis of Presentation and Summary of Significant Accounting Policies Principles of Consolidation and Basis of Presentation The accompanying interim unaudited consolidated financial statements include the accounts of OraSure Technologies, Inc. (the “OraSure”) and its wholly-owned subsidiaries, DNA Genotek Inc. (the “DNAG”), Diversigen, Inc. (the “Diversigen”), and Novosanis NV (the “Novosanis”). All intercompany transactions and balances have been eliminated. References herein to the “Company,” “we,” “our,” “us,” or “the Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated. The unaudited financial statements, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of the Company’s financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the results of operations expected for the full year. Summary of Significant Accounting Policies There have been no changes to the Company’s significant accounting policies described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 that have had a material impact on the consolidated financial statements and related notes except as discussed herein. Cash Equivalents & Short-Term Investments Cash Equivalents & Short-Term Investments The Company considers all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates purchased with maturities greater than ninety days. Securities with maturities ninety days or less are considered cash equivalents. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss. Fair Value of Financial Instruments Fair Value of Financial Instruments As of September 30, 2024 and December 31, 2023, the carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate their respective fair values based on their short-term nature. Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories: Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). All of the Company’s guaranteed investment certificates are measured as Level 1 instruments as of September 30, 2024. Included in cash and cash equivalents at September 30, 2024 and December 31, 2023 was \$42.5 million and \$71.7 million, respectively, of guaranteed investment certificates. Also included in cash and cash equivalents at September 30, 2024 and December 31, 2023 was \$117.1 million and \$112.7 million, respectively, invested in money market funds. These money market funds have investments in U.S. government securities and are measured as Level 1 instruments. The Company offers a nonqualified deferred compensation plan for certain eligible employees and members

of its Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds and company stock. The fair value of the plan assets as of September 30, 2024 and December 31, 2023 was \$0.7 million and \$0.8 million, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 financial instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets. Equity Method Investee Equity Method InvesteeIn January 2024, the Company lead the Series B financing and entered into wide-ranging strategic distribution agreements with KKR Sapphiros L.P. ("Sapphiros"), a privately held consumer diagnostic portfolio company, and certain of its related entities. Through this relationship, the Company expects to be able to offer a more comprehensive range of low-cost diagnostic tests and molecular sample management solutions to the Company's customers globally. As of September 30, 2024, the Company had funded \$30.0Å million for its interest in Sapphiros. The Company recorded the investment using the equity method in accordance with Accounting Standards Codification ("ASC") Topic 323, InvestmentsÅ Equity Method and Joint VenturesÅ Overall. In accordance with the equity method, the Company's equity investment is presented net of its share of any gains or losses of the investee. The Company has elected as its accounting policy to recognize its share of any income or loss in Sapphiros on a three-month lag. The investment in Sapphiros of \$28.8Å million as of September 30, 2024 is included in the investment in equity method investee line of the Company's balance sheet and is measured as a Level 3 investment. The Company has no unconditional obligations or guarantees to, or in support of, its equity method investee and its operations. In conjunction with the preparation of the Company's September 30, 2024 financial statements, the Company considered whether the carrying value of the investment in Sapphiros was impaired and concluded that no such impairment existed. There was no similar investment as of December 31, 2023. Foreign Currency Transactions Foreign Currency TransactionsNet foreign exchange gains and (losses) resulting from foreign currency transactions that are included in other income in the Company's consolidated statements of operations Impairment of Long-Lived Assets Impairment of Long-Lived AssetsLong-lived assets, which include property, plant and equipment, definite-lived intangible assets, as well as right-of-use assets (ROU assets) of operating and finance leases, are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the Company's long-lived assets by determining whether the carrying value of such assets can be recovered through the sum of the undiscounted future cash flows expected to be generated from the use and eventual disposition of the asset. If indicators of impairment exist, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of these assets, which is generally determined based on the present value of the expected future cash flows associated with the use of the assets. Expected future cash flows reflect the Company's assumptions about selling prices, volumes, costs and market conditions over a reasonable period of time. During the first quarter of 2024, the Company identified a triggering event to test for the recoverability of all the property, plant, and equipment and ROU assets of both the Diversigen and Novosanis subsidiaries, given the Company's decision to initiate a strategic plan to transition away from the microbiome molecular sequencing services business and close its Belgian operations. The Company performed an undiscounted cash flow analysis and determined the carrying values of the property, plant and equipment and ROU assets could not be recovered through the sum of the undiscounted future cash flows and were impaired. Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss Change in accumulated other comprehensive loss by component is listed below (in thousands): Foreign Currency Total Balance at December 31, 2023 \$(14,941) \$(14,941) Other comprehensive loss (2,259) (2,259) Balance at September 30, 2024 \$(17,200) \$(17,200) Recent Accounting Pronouncements Recent Accounting PronouncementsIn March 2024, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2024-01, CompensationÅ Stock Compensation (Topic 718), Scope Application of Profits Interest and Similar Awards. The purpose of this update was to provide illustrative examples to demonstrate how an entity should apply guidance to determine whether profits interests and similar awards should be accounted for in accordance with Topic 718. For public business entities, the amendments in this ASU are effective for fiscal years beginning after December 15, 2024, and interim periods within those fiscal periods. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. Management is evaluating the impact on the Company's consolidated financial statements. Customer and Vendor Concentrations The Company currently purchases certain products and critical components of its products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, the Company could be subject to increased costs and substantial delays in the delivery of its products to its customers. Third-party suppliers also manufacture certain products. The Company's inability to have a timely supply of any of these components and products could have a material adverse effect on its business, as well as its financial condition and results of operations. Deferred Revenue Deferred Revenue. The Company records deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of September 30, 2024 and December 31, 2023 included customer prepayments of \$1.6 million and \$1.2 million, respectively. Deferred revenue as of December 31, 2023 also included \$0.4 million associated with a long-term contract that had variable pricing based on volume. The average price over the life of the contract was determined and revenue was recognized at that average price. The \$0.4 million associated with the long-term contract at December 31, 2023 met the criteria to be recognized as revenue during the nine months ended September 30, 2024, and as such there was no equivalent balance remaining in deferred revenue at September 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap Accounting PoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 21D -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D + Details Name: us-gaap EquityMethodInvestmentsPolicy Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/830/tableOfContent + Details Name: us-gaap ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4 + Details Name: us-gaap ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap InvestmentPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16 + Details Name: us-gaap MajorCustomersPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Å Summary of Changes in Accumulated Other Comprehensive Loss by Component Change in accumulated other comprehensive loss by component is listed below (in thousands): Foreign Currency Total Balance at December 31, 2023 \$(14,941) \$(14,941) Other comprehensive loss (2,259) (2,259) Balance at September 30, 2024 \$(17,200) \$(17,200) X - ReferencesNo definition available. + Details Name: us-gaap Accounting PoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Government Capital Contracts (Tables) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Å Summary of Government Contracts Balances Included in Consolidated Statements of Cash flows The activity corresponding to the government contracts included in the Company's consolidated statements of cash flows for the cumulative period ended December 31, 2023 is as follows (in thousands): December 31, 2023 Cost of assets, cumulatives \$86,993Å Reduction for funding received to date (86,993) Total property, plant and equipment, net \$Å X - DefinitionSummary of government contracts balances included in consolidated statements of cash flow. + ReferencesNo definition available. + Details Name: osur SummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowTableTextBlock Namespace Prefix: osur Data Type: dtr-types:1:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Inventories (Tables) 9 Months Ended Sep. 30, 2024 Inventory Disclosure [Abstract] Å Schedule of Inventories September 30, December 31, 2024 2023 Raw materials \$19,948Å \$20,727Å Work in process 1,435Å 1,900Å Finished goods 17,487Å 24,987Å Total \$38,870Å \$47,614Å X - ReferencesNo definition available. + Details Name: us-gaap InventoryDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1 + Details Name: us-gaap ScheduleOfInventoryCurrentTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Property, Plant and Equipment, Net (Tables) 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] A Schedule of Property, Plant and Equipment, Net September 30,December 31,20242023Land\$1,118A \$1,118A Buildings and improvements34,003A \$34,606A Machinery and equipment58,618A \$64,156A Computer equipment and software1,680A 17,739A Furniture and fixtures3,334A \$3,748A Construction in progress8,952A 9,196A 117,705A 130,563A Accumulated depreciation(79,562)(85,143)\$38,143A \$45,420A X - ReferencesNo definition available. + Details Name: us-gaap PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Current Liabilities (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] A Schedule of Accrued Expenses and Other Current Liabilities September 30,December 31,20242023Payroll and related benefits\$9,320A \$14,654A Professional fees1,264A 2,827A Sales tax payable1,228A 1,245A Other3,201A 3,984A \$15,013A \$22,710A X - DefinitionSchedule of accrued expenses and other current liabilities. + ReferencesNo definition available. + Details Name: osur ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock Namespace Prefix: osur Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap PayablesAndAccrualsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Termination Benefits (Tables) 9 Months Ended Sep. 30, 2024 Termination Benefits [Abstract] A Summary of One-Time Termination Benefits The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):For the Nine Months Ended September 30,2023Cost of products and services sold\$369A Research and development566A Sales and marketing1,542A General and administrative787A \$3,264A The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):For the Nine Months Ended September 30,2024Cost of products and services sold\$31A Research and development87A Sales and marketing69A General and administrative17A \$404A The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):For the Three Months Ended September 30,For the Nine Months Ended September 30,20242024Cost of products and services sold\$A \$889A Research and developmentA \$478A Sales and marketingA \$125A General and administrativeA \$160A \$A \$1,652A The charges for termination benefits included in the Company's consolidated statements of operations are as follows (in thousands):For the Three Months Ended September 30,2024Cost of products and services sold\$7A Research and developmentA \$A Sales and marketing346A General and administrativeA \$353A X - DefinitionSummary of one-time termination benefits. + ReferencesNo definition available. + Details Name: osur SummaryOfOneTimeTerminationBenefitsTableTextBlock Namespace Prefix: osur Data Type: dtr-types:1:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTermination benefits. + ReferencesNo definition available. + Details Name: osur TerminationBenefitsAbstract Namespace Prefix: osur Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] A Disaggregation of Revenue by Product and Geographic Area Revenues by product line. The following table represents total net revenues by product line (in thousands):For the Three Months Ended September 30,For the Nine Months Ended September 30,2024202320242023HIV\$18,347A \$16,650A \$45,379A \$46,518A COVID-19 (1),155A 50,199A \$4,222A 216,115A Molecular Sample Management Solutions (2)12,806A 15,238A 36,237A 41,230A HCV3,228A 2,901A 10,962A 9,957A Risk assessment testing (3)1,911A 2,554A 6,265A 7,540A Other product and service revenues (4)1,196A 638A 2,623A 1,739A Molecular Services9A 834A 1,692A 3,567A Net product and services revenues39,652A 89,014A 147,380A 326,666A Non-product and services revenues (5)263A 173A 1,002A 2,925A Net revenues\$39,915A \$89,187A \$148,382A \$329,591A (1)Includes COVID-19 Diagnostics and COVID-19 Molecular revenues.(2)Includes Genomics, Microbiome and Novosanis product revenues.(3)Includes substance abuse testing products revenues.(4)Includes Syphilis revenues.(5)Includes funded research and development contracts, royalty income and grant revenues.Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer (in thousands):For the Three Months Ended September 30,For the Nine Months Ended September 30,2024202320242023United States\$25,353A \$77,925A \$115,055A \$296,815A Europe2,126A 1,992A 5,892A 6,297A Other regions12,436A 9,270A 27,435A 26,479A \$39,915A \$89,187A \$148,382A \$329,591A Schedules of Concentration of Risk, by Risk Factor The following table represents the concentration risk.For the Three Months Ended September 30,For the Nine Months Ended September 30,Revenue Concentration2024202320242023Commercial customer (1)11%NANANANon-Commercial customer (2)NA56%26%66%September 30,December 31,Accounts Receivable20242023Commercial customer (1)21%NANANon-Commercial customer (2)NA40%(1) Each commercial customer is different.(2) Same non-commercial customer. X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21 + Details Name: us-gaap SchedulesOfConcentrationOfRiskByRiskFactorTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Tables) 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] A Schedule of Components of Income Tax Expense (Benefit) The components of income tax expense (benefit) are as follows (in thousands):For the Three Months Ended September 30,For the Nine Months Ended September 30,2024202320242023State income tax expense (benefit)\$18A \$1,131A \$(209)\$2,388A Foreign income tax expense (benefit)660A 1,216A 1,250A (432)\$678A \$2,347A \$1,041A \$1,956A X - ReferencesNo definition available. + Details Name: us-gaap IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] A Summary of Reconciliation of Changes in Stockholder's Equity Common StockAdditionalPaid-in Capital AccumulatedOtherComprehensive Loss Accumulated Deficit Total Shares AmountBalance at December 31, 202373,528\$A \$529,543A \$(14,941)\$(83,931)\$430,671A Common stock issued upon exercise of options32A \$214A A \$214A Vesting of restricted stock and performance stock units593A A \$A A A Purchase and retirement of common shares(194)A (1,462)A A (1,462)A (1,462)Stock-based compensationA A \$2,968A A A \$2,968A Net lossA A \$A A A (3,584)(3,584)Currency translation adjustmentsA A \$A A A (2,556)A (2,556)Balance at March 31, 202473,959\$A \$531,263A \$(17,497)\$(87,515)\$426,251A Vesting of restricted stock and performance stock units1,033A A A A A A Purchase and retirement of common shares(424)A A (1,984)A A (1,984)Stock-based compensationA A \$3,322A A A \$3,322A Net lossA A \$A A A (615)(615)Currency translation adjustmentsA A \$A A A (1,134)A (1,134)Balance at June 30, 202474,568\$A \$532,601A \$(18,631)\$(88,130)\$425,840A Vesting of restricted stock and performance stock units44A A A A A A Purchase and retirement of common shares(19)A (87)A A (87)Stock-based compensationA A \$2,888A A A \$2,888A Net lossA A \$A A A (4,507)(4,507)Currency translation adjustmentsA A \$A A A 1,431A A 1,431A Balance at September 30, 202474,593\$A \$535,402A \$(17,200)\$(92,637)\$425,565A Common StockAdditionalPaid-in CapitalAccumulatedOtherComprehensive LossAccumulated DeficitTotalSharesAmountBalance at December 31, 202272,734\$A \$520,446A \$(18,435)\$(137,586)\$364,425A Common stock issued upon exercise of options12A \$66A A A \$66A Vesting of restricted stock and performance stock units73A A A A A A Purchase and retirement of common shares(229)A A (1,203)A A (1,203)Stock-based compensationA A \$2,655A A A \$2,655A Net incomeA A \$A A A \$2,219A 27,219A Currency translation adjustmentsA A \$A A A 797A A 797A Unrealized gain on marketable securitiesA A \$A A A 220A A 220A Balance at March 31, 202373,254\$A \$521,964A \$(17,418)\$(110,367)\$394,179A Vesting of restricted stock and performance stock units241A A A A A A Purchase and retirement of common shares(82)A A (460)A A (460)Stock-based compensationA A \$2,357A A A \$2,357A Net lossA A \$A A A (4,796)(4,796)Currency translation adjustmentsA A \$A A A 2,859A A 2,859A Balance at June 30, 202373,413\$A \$523,861A \$(14,559)\$(115,163)\$394,139A Common stock issued upon exercise of options2A A A 10A A A 10A Vesting of restricted stock and performance stock units99A A A A A A Purchase and retirement of common shares(31)A A (200)A A (200)Stock-based compensationA A \$2,590A A A \$2,590A Net incomeA A \$A A A \$1,159A 11,159A Currency translation adjustmentsA A \$A A A (2,813)A (2,813)Balance at September 30, 202373,483A \$A \$526,261A \$(17,372)\$(104,004)\$404,885A X - ReferencesNo definition available. + Details Name: us-gaap EquityAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 + Details Name: us-gaap ScheduleOfStockholdersEquityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information (Detail) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Dec. 31, 2023 New Accounting Pronouncements or Change in Accounting Principle [Line Items] A A A Short-term investments A A A \$ 0 Cash and cash equivalents \$ 278,571,000 A \$ 278,571,000 A 290,407,000 Fair value of plan assets 700,000 A 700,000 A 800,000 Payments to acquire equity method investments A \$ 30,000,000 \$ 0 A Investment in equity method investee 28,829,000 A 28,829,000 A 0 Net foreign exchange gains (losses) (200,000) \$ (100,000) 100,000 \$ (700,000) A Operating lease, impairment loss A 1,200,000 A A Finance lease, impairment loss A 300,000 A A Money Market Fund | Level I Instruments A A A New Accounting Pronouncements or Change in Accounting Principle [Line Items] A A A Cash and cash equivalents 117,100,000 A 117,100,000 A 112,700,000 Guaranteed Investment Certificates | Level I Instruments A A A New Accounting Pronouncements or Change in Accounting Principle [Line Items] A A A Cash and cash equivalents \$ 42,500,000 A \$ 42,500,000 A \$ 71,700,000 X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-

us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionAmount of the balance sheet date of assets held under deferred compensation agreements. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(17\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(17))) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 77: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 78: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 79: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 80: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 81: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 82: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 83: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 84: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 85: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 86: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6Reference 87: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 88: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 89: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 90: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 91: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 92: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 93: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 94: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 95: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 96: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 97: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 98: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3Reference 99: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1Reference 100: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss from impairment of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 25 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479365/842-20-25-6 + Details Name: us-gaap_OperatingLeaseImpairmentLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireEntityMethodInvestments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=osur_GuaranteedInvestmentCertificatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Summary of Changes in Accumulated Other Comprehensive Loss by Component (Detail) \$ in Thousands 9 Months Ended Sep. 30, 2024 USD (\$) AOCI Attributable to Parent, Net of Tax [Roll Forward] A Beginning Balance \$ 430,671 Other comprehensive loss (2,259) Ending Balance 425,565 Accumulated Other Comprehensive Loss \$ AOCI Attributable to Parent, Net of Tax [Roll Forward] A Beginning Balance (14,941) Other comprehensive loss (2,259) Ending Balance \$ (17,200) X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_AOCIAttributableToParentNetOfTaxRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Section 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Government Capital Contracts - Additional Information (Details) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Oct. 31, 2023 Sep. 30, 2021 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Government capital contracts funding amount A A A A \$ 109,000,000.0 A A A \$ 109,000,000.0 A A Research and Development Expenses and Other Income | Government Contract A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Reimbursement of engineering cost 0 400,000 0 2,000,000.0 A A Other | Government Contract A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A Net revenues \$ 0 \$ 600,000 \$ 0 \$ 1,700,000 A A X - DefinitionPercentage of total capital costs incurred under government contract not reimbursed until completion of final validation testing. + ReferencesNo definition available. + Details Name: osur_PercentageWithheldUnderGovernmentContractsSubjectToValidationTesting Namespace Prefix: osur_Data Type: dtr-type=1.percentItemType Balance Type: na Period Type: instant X - DefinitionReimbursement of engineering cost. + ReferencesNo definition available. + Details Name: osur_ReimbursementOfEngineeringCost Namespace Prefix: osur_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of receivables that are derived from government contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478345/912-310-45-1 + Details Name: us-gaap_GovernmentContractReceivable Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=osur_ResearchAndDevelopmentExpensesAndOtherIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=

OtherIncomeMember NameSpace Prefix: Data Type: na Balance Type: Period Type: XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Government Capital Contracts - Summary of Government Contracts Balances Included in Consolidated Statements of Cash flows (Detail) - USD (\$) in in Thousands Sep. 30, 2024 Dec. 31, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A Cost of assets, cumulative \$ 117,705 \$ 130,563 Total property, plant and equipment, net \$ 38,143 45,420 Government Contract A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A Cost of assets, cumulative A 86,993 Reduction for funding received to date A (86,993) Total property, plant and equipment, net A \$ 0 X - DefinitionFunding received amount + ReferencesNo definition available. + Details Name: osur_FundingReceivedAmount Namespace Prefix: osur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:

monetaryItemType Balance Type: credit Period Type: instant XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Termination Benefits - Summary of One-time Termination Benefits (Details) - USD (\$) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 2023 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 Á Q1 2024 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 1,652,000 Á One-time Termination Benefits | Q3 2024 Reduction In Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 353,000 Á Á One-time Termination Benefits | Cost of products and services sold | 2023 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 Á 369,000 One-time Termination Benefits | Cost of products and services sold | Q1 2024 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 231,000 Á One-time Termination Benefits | Cost of products and services sold | Q2 2024 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 889,000 Á One-time Termination Benefits | Cost of products and services sold | Q3 2024 Reduction In Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 7,000 Á Á One-time Termination Benefits | Research and development | 2023 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 Á 566,000 One-time Termination Benefits | Research and development | Q1 2024 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 87,000 Á One-time Termination Benefits | Research and development | Q2 2024 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 478,000 Á One-time Termination Benefits | Research and development | Q3 2024 Reduction In Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 Á Á One-time Termination Benefits | Sales and marketing | 2023 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 Á 1,542,000 One-time Termination Benefits | Sales and marketing | Q1 2024 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 69,000 Á One-time Termination Benefits | Sales and marketing | Q2 2024 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 125,000 Á One-time Termination Benefits | Sales and marketing | Q3 2024 Reduction In Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 346,000 Á Á One-time Termination Benefits | General and administrative | 2023 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 Á 787,000 One-time Termination Benefits | General and administrative | Q1 2024 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 17,000 Á One-time Termination Benefits | General and administrative | Q2 2024 Reduction in Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 160,000 Á One-time Termination Benefits | General and administrative | Q3 2024 Reduction In Workforce Á Á Á Termination Benefits [Line Items] Á Á Á Termination benefits 0 Á Á X- DefinitionTermination benefits. + ReferencesNo definition available. + Details Name: osur_TerminationBenefits Namespace Prefix: osur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X- DefinitionTermination benefits. + ReferencesNo definition available. + Details Name: osur_TerminationBenefits Namespace Prefix: osur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X- Details Name: us-gaap_RestructuringPlanAxis=osur_A2023ReductionInWorkforceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_RestructuringPlanAxis=osur_Q2024ReductionInWorkforceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Termination Benefits - Additional Information (Details) 3 Months Ended 9 Months Ended Sep. 30, 2024 USD (\$) Sep. 30, 2024 USD (\$) 2023 Reduction in Workforce Á Á Termination Benefits [Line Items] Á Á Payment of reduction in workforce 3,300,000 \$ 3,300,000 Termination benefits 0 Q1 2024 Reduction in Workforce Á Á Termination Benefits [Line Items] Á Á Payment of reduction in workforce 400,000 400,000 Termination benefits 0 Accrued reduction in workforce 6,000.0 6,000.0 Q2 2024 Reduction in Workforce Á Á Termination Benefits [Line Items] Á Á Payment of reduction in workforce 700,000 700,000 Accrued reduction in workforce 900,000 900,000 Q3 2024 Reduction In Workforce Á Á Termination Benefits [Line Items] Á Á Payment of reduction in workforce 7,100 7,100 Accrued reduction in workforce 300,000 300,000 X- DefinitionAccrued reduction in workforce. + ReferencesNo definition available. + Details Name: osur_AccruedReductionInWorkforce Namespace Prefix: osur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X- DefinitionPayment of reduction in workforce. + ReferencesNo definition available. + Details Name: osur_PaymentOfReductionInWorkforce Namespace Prefix: osur_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X- DefinitionTermination benefits. + ReferencesNo definition available. + Details Name: osur_TerminationBenefits Namespace Prefix: osur_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X- DefinitionTermination benefits. + ReferencesNo definition available. + Details Name: osur_TerminationBenefits Namespace Prefix: osur_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X- Details Name: us-gaap_RestructuringPlanAxis=osur_A2023ReductionInWorkforceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_RestructuringPlanAxis=osur_Q2024ReductionInWorkforceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_RestructuringPlanAxis=osur_Q3024ReductionInWorkforceMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Revenues - Summary of Total Net Revenues by Product Line (Detail) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation Of Revenue [Line Items] Á Á Á Net revenues \$ 39,915 \$ 89,187 \$ 148,382 \$ 329,591 Product and Services Revenues Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Net revenues 18,347 16,650 45,379 46,518 Product and Services Revenues | COVID-19 Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Net revenues 2,155 50,199 44,222 216,115 Product and Services Revenues | Molecular Sample Management Solutions Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Net revenues 12,806 15,238 36,237 41,230 Product and Services Revenues | HCV Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Net revenues 3,228 2,901 10,962 9,957 Product and Services Revenues | Risk assessment testing Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Net revenues 1,911 2,554 6,265 7,540 Product and Services Revenues | Other product and services revenues Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Net revenues 1,196 638 2,623 1,739 Product and Services Revenues | Molecular Services Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Net revenues 9,834 1,692 3,567 Other | Non-product and services revenues Á Á Á Disaggregation Of Revenue [Line Items] Á Á Á Net revenues \$ 263 \$ 173 \$ 1,002 \$ 2,925 X- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (j) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (k) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 14: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (m) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (n) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (o) -Publisher FASB -URI https://asc.fasb.org/1943274/21474797

Reference 6:

[2,889](#) [7,234](#) [6,000](#) [2,968](#) [2,590](#) [2,357](#) [2,655](#) A Net loss (4,507) (615) (3,584) 11,159 (4,796) 27,219 (8,706) 33,582 Currency translation adjustments 1,431 (1,134) (2,556) (2,859) 797 (2,259) 843 Unrealized gain on marketable securities 0 A A 220 0 Ending Balance \$ 425,565 \$ 425,840 \$ 426,251 \$ 404,885 \$ 394,139 \$ 394,179 \$ 425,565 \$ 404,885 Common Stock A A A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Beginning balance (in shares) 74,568 73,959 73,528 73,413 73,254 72,734 73,528 72,734 Beginning Balance \$ 0 \$ 0 \$ 0 \$ 0 \$ 0 \$ 0 Common stock issued upon exercise of options (in shares) A A 32 2 21 12 A Vesting of restricted stock and performance stock units (in shares) 44 1,033 593 99 737 A Purchase and retirement of common shares (in shares) (19) (424) (194) (31) (82) (229) A Ending balance (in shares) 74,593 74,568 73,959 73,483 73,413 73,254 74,593 73,483 Ending Balance \$ 0 \$ 0 \$ 0 \$ 0 \$ 0 Additional Paid-in Capital A A A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Beginning Balance 532,601 531,263 529,543 523,861 521,964 520,446 529,543 520,446 Common stock issued upon exercise of options A A 214 10 66 A Purchase and retirement of common shares (87) (1,984) (1,462) (200) (460) (1,203) A Stock-based compensation 2,888 3,322 2,968 2,590 2,357 2,655 A Ending Balance 535,402 532,601 531,263 526,261 523,861 521,964 535,402 526,261 Accumulated Other Comprehensive Loss A A A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Beginning Balance (18,631) (17,497) (14,941) (14,559) (17,418) (18,435) (14,941) (18,435) Currency translation adjustments 1,431 (1,134) (2,556) (2,813) 2,859 797 A Unrealized gain on marketable securities A A A 220 A Ending Balance (17,200) (18,631) (17,497) (17,372) (14,559) (17,418) (17,200) (17,372) Accumulated Deficit A A A A Increase (Decrease) in Stockholders' Equity [Roll Forward] A A A A Beginning Balance (88,130) (87,515) (83,931) (115,163) (110,367) (137,586) (83,931) (137,586) Net loss (4,507) (615) (3,584) 11,159 (4,796) 27,219 A Ending Balance \$ (92,637) \$ (88,130) \$ (87,515) \$ (104,004) \$ (115,163) \$ (110,367) \$ (92,637) \$ (104,004) X DefinitionStock issued during period, shares, vesting of restricted stock and performance stock units. + ReferencesNo definition available. + Details Name: osur_StockIssuedDuringPeriodSharesVestingOfRestrictedStockAndPerformanceStockUnits Namespace Prefix: osur_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fiasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-12+Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: \[http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \\(g\\)-Publisher FASB-URI https://asc.fasb.org/1943274/214746176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \\(g\\)\\(3\\)-Publisher FASB-URI https://asc.fasb.org/1943274/214748666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \\(SX 210.5-03\\(20\\)\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\(SX 210.4-08\\(g\\)\\(1\\)\\(ii\\)\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \\(c\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \\(f\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \\(b\\)\\(2\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \\(f\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \\(a\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \\(b\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\(SX 210.7-04\\(18\\)\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \\(SX 210.6-07\\(9\\)\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \\(SX 210.6-09\\(1\\)\\(d\\)\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(i\\)\\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \\(SX 210.13-01\\(a\\)\\(4\\)\\(ii\\)\\)-Publisher FASB-URI https://asc.f\]\(#\)](#)

```

Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 555 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedAndRetiredDuringPeriodValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrli.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrli.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrli.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrli.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 59 Financial Report.xlsx ID#E: XBRL DOCUMENT begin 644 Financial Report.xlsx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l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r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lt
```

MX80>*;DQNU1U"YU>AMKO9JDJG\$+LF0I#@3R'EIQ_-YX'GP:4I|WR=(B>[&H& M:IP<90?CK?%S0KGG_6'F3NNJ|")J:BY;EM%O|HWVE7;
M7_Z&MUWZ&5ULK5=<]NV&QOTKIVR+P,E)G)2)9VPZG4V; MKVLGN0J|W@-0\$A(:\$F (THKZZ^_9!< /25;2I@|M9I!)8+!9G=<\\N^'1ER|JY
|J|50EON:9<<[&RZ|JGAP?NV2IE&?^T_ X MX7\$NM1FG|_ K20 M"W6CJH_ ^Q^_ 3=24ITKH|0UHE3S9X,+R9+ROE-X!&?M%jYSF|!6YE9^YG^
M>)4^&XQ)(Y6II"(1\$O_GP)0@?-FC2Q^SM*?F;QV9FTJDKF_U_ MIJ7RV>#10*1J+NNLNK:K?ZFPH0=7[C
M3T/8N;C1"/Z.G.&F\$A=8FM3;;,0[VVF\$ZV<.(B_ #I>5UB:!!PG89E+O|ST MCF4>BS?65\$LG7IA4I?WYQU"YT7L;|Z<[A5XHXJ1..!D/Q70|O;|'WDECAQ.6
M=W*O%T;_ N_ %S%4EWR?_"V13:#+\$KBX*ZL<= YE1|G|A6?7FE^H|9|6-E7|YOO|>|> M|VJU>|_J_3|4/2P6'36Q>2+;FK;2I5*ES41M9I|I2J4@:4?
ACKHWS,C(3#A(4 MPD;E,"?)ZE2"@BKZ2?6>E?F|I4XH_#EL9F=H'=#14KDXSP<|_9I.JV>=A
M"/AU.3MD335FKY8VR|9'=F6PJ*MG3|=ECS_ ^=L+L+:LRME*?^|+PXMKAS977+|_E33-(43+|HZS;|G: #TX.4@L5|HI;#,%;#EI DJ+B5TP M&
K:'8;90A0*AU"02X.40Z^~#4HD|"/3Q/1R/7H.2"/MV">LR=AE#"6"C'4N M55?7;WL3#H41L^CCP,&5-(-9>Z%47VA|*V@2;_ (Z%A26Z<8Q,_>9A0&+
M"%Q?XYS;UDV@O<(-,V=6P*|_I'6Y1ZP2 4(I(R-QD\$F_NC-CXSKG2U9)UV MSB5="6.AIO*F @62Z-AVZU<4=&-C|KJ4|);G|!H(RIYB,CWZ/BF,-EV#
(6LE2 M*\$H&XCE,EL|4*4XF,Y|"(I|JH|_2N6!8Q"!1.XSBQ>&O% %:2\$Y" F480/- MT6B<94 07">Z>QVYS|Z|^Z ,A*ZI?9U|YT5|(I6)/R'_0A/P'>T|^E71+|>)+
MK6|EQN?RL|R+,W&SA?6|/BB8^96Y50&^NV+W/RB>O2Z<.CNN3A&ZV(-T9Q3@ MD:19)1RY"H|-\$+(\$0GDK=29GF3|"68<5NR,B4#NS
2)9>2U!)AK5*,OKB4 M2%19L?T)ID5=0#&PMRED_7_":0"0"&G6HM4KK'D3;08YJ3.. IK M'(H(4G?E(K(>*HU'H+QOAWZZ+1 W-
EY6,\$IM9JR PS?74|W_ E26T|>./89 M|PH+=4+!D-6K?7:2Z3_Q>@/F|9TTL|1"#W'G^L\$A\$U-Z-T4|/#+YC-Q%YTT1A
M>)>ZQ@IC8Q*S!>4;_B4L#%R99W7&4=B#KK\NE1+(N/P&%IHM_?2#QM|/JR+ MN9>T|T^T;UKU91-7AG0KOI.
(/^P4"|;KKK5)@=X6C(D_Q4R\$%X#H%+|'3 ME,WS'|9T VE^X3&OT'E8R'5X@LEX6M:P-(4:XP@=15':KQH09_|"J2 V41@B
MV|=8<0\$KUH11CGVU(E|U!%)U\$B^>;T91T9YY |_APUG>;"!G1#K,RUG.@ON MN@0|:'TS15L,M*OGP*%|U|*UM,X23A|=|MDPS+P\$V#@|29_#%R
7X M8B2>@V+9%:WG SUY|<(2%7@B7J|ME8G)\$_!^1+2+V<%O(,0+%_!+|^4D< A&,_^K^0_ M KMI<Z@,RLQ4|4|JU:_ M261T&|L_VY|)_Y=R8|LX/H,
[1]4>#(Y'4WZ&DVFT|M5|DIZ-<#2U|>Z+PV M+6|=?N,+E T|7%T,Q(+BR+)|+;|^93"Z+=|>-3C+78^9|("H)DO8*T^>_54 M|!%.Q5\$#8^!|!0HG=CFR-
1(NU4T+*B0J+*S*[5D&]G*W&.*:YM+*^_J4_GK/? MVC*H\$)|.S!+>_ 67*FLXM9&YVD ZG9? \$ UVF1X4LD;K;^\$V|U%5-RA*9P6N* M9DW"8>- ;|
(|D\$DE\$71(|!A|)93RW5?|JEOG(D?NIC4%F/L1TI|=#X\$@>PVI) MBRX-6D|T;T\$5^1 Z1 EPRGN|)"PJ.IP1MLP\$3&B^B\$F9Z8D,K^4H|W^'|ZW4|;H
M'H>|W85M>D>3D">2P)5JYY.6VDG=>B\$YZA=,%%UWBS_WC-/GX|*^Y36V_# M73|0QTG/&_I&
|IIONUX8X6|/2">|I8NP|LVGC;EI,"_<U/OB=IF"/82S8ZT M+@|)ENAUH-H@|#\$-P(W4M.3QMR>KJ71|P|P-B&PA&EH?A1:A)4'L+66 6 M|)1D;@|'"&(E<&
(MPDPA*VV|KVD;W|&X1@V2@|J7R[D&L*A9XI:T!|!(=7E.Q MO=1%WPR^<^Z*1@JW^>,EQ&_KEEHNP;F%"5F <@S@>="QJRO<+& \$ VMXAR|-F2
M\$P\$ID|M_#.SH|4|40 0&9:FN&|13>0%YF=\$<+;W5E|)|#>RQ?6*(,|1IV,1^ F MR#=#9\$^G W7D)NVY|_5\$H@M20Q|F3_-NB\$>BJW2/-

[illegible]

[C,~%SY&68/XWV\$%UV1/2,,8LZ M 9>X08!>|~*B(K*Y^4U/-_ZH@.WUVQSS^V3N!,A[?P51K25>E)BN&H 4L MB>2[1(-F(-/,.DG<@M?>1C8/RV)S+
[VU#~%F<X_-XAJ_4EJ0X4UL M09G;N,V\$@92A5^+8A=HHX M^5#;0&+>]5H1N-TBP1471"UH;6^~%H1>D[13H-MPYD^C5)M/AVMW^%YE>QE^=QQ(O9)
M00F-Q^SXTPSM:<+|J\$VE-D^%?3[=-T2T[/@RRN^/J3*!H091^*B*6\$@Z,F79M-M3CS3R@1YQ!1!\$7MF&1=63/V-3NY#6::D;4(80!EAJ#JXP+B,,I-
KQK81J-M52=TCGU2F4I-W#2HI-MT30=-<G&^7E>|H7H6UM.SN+<Z@0^PNR(JXV=BS&5- I3V+!^6|MNZ+|JOIONS+ M;KD#OI*!K1V7W?
+|ONR4>^M5#RMAPH%TY MT.YTX_-J-80#=-|(B#8^V26[XWYN^D[28?](1Q704 MKJ)!^1ZC6\$G=ICY+/@Q/ZB|6Y<#3YHO.S)>.,+)|P!Q/F8L^6F+
5|LQ#<@C5<M-J|<C.OK>.,-X1HEDQ80XFS,6\$+3%4^TR8AP1KF\$5|Y\$X4AV89-MNE4AP+UOLJ\$ZUA9(-?
U1<="R7,THM~RJ7>+!+FG\$5;|GC9VJ;QO.O:D9G?8LAYNQ6L)MVZ|H9RNV.,EQ&Z;|!&N2TA
MYK!M&NSNU<45Q:1Y6+2BHGMJMRD|OLVW85:LNQ36?P^7UVVMC:O|PVJ|=O MS,G";+GNF!.WV+A|QA?{J}|H5VLD06+8J}%3&U5-M3WBQ-
5F<2+;+|K63J6 MY(X_4\$JL#!10 (-+F(9EE_@C67+@,/?D^M 9>+&PO=VJR-W-H965TQ6C8 F^CF> M%00<(F,9%Z6;
.,+1~%>|S.M4G+7#S-17J4^3=S=OZ?,ZAPU_-J#1<-M_V|PIH0%\$9+986M:VKH>^CDBBA;C6SVILBF0*,)NPL3HW^MPQQ9OQ9+D\$)
MG!9#)C1C9C(RD<((HC%)>3,S(M)Y?(-=FLK^JN**&K4Y8E+8D\$ZH3,L>EHG1C^~?>|RL/TFIR>?" G%GV?R%Q3\$>NA;J"@-ME>E&S-
7HLE-CYDI9.12^2H6110\$|6V-OYL6%#6)M>@M/GY|H14YR@PGJW5Y5E+~" M>@V|+C0&8U>Y-6U2^6X(S?
OVMW08|JUZ1R);~NKH,HJ;&+K+2Q^X1J#4:W M<FC.2|RJ+~S!G.#RMS@GYT-C\$WJA9,~)ACACOO(?9 MJ+~1+*=@&9D60,I,&Y_B-
I>%)0MP!=S^&UL-MK55=-YLPF%TQK%JNF\$MK9R^%*%J%#H?)D7-NCY>W#>|E@U-K-~|J,*~(M)C3;PU|<-T^TR8E<3-V\$HD;4)0Q6
LEF|+IXN0^XJ[GEGJ# M|JV2\$S-(W/G)<+!&J5^NA-|94M&F^2<(&8;?67M7NU^\$U|<~" #0"TF;62< M;#A,I VJ; &XY1A|025AP|WAP50|HBTC-
|=H4O:8# #JBO|>=>|E@^0M-M^TFFKUDUM5^6UQ1=<-KKJ^YF1B^E%/92%=QD>A=)**EYTB^V@(*S|X^M2,\$(?%\$OH14P|T&|K^%VSH^M?
1ZV/@>P>2^0)O.\$E8D2KFL!>2QU0N4|MIY0|LM83!.*&Y75>RQ^C,+7VJ M@/@|6;G^#V|H7E5^>Y(WGCW>^>^?>D^M2Z2^D0!-/1G6\$A80,W96&?2N+9
M,(WM=-#<93G1%|41|W|Q%<@;|H^G41">M%#P%;|J)N9>U07^Y%#<2# M<~U37IMDY|>|DC^N9E;?>Y^168*!|=H0-MQEI?;|N4D+NS%A22%#>:
|O-MF++P+|/Z31R#10=1P51Z-8^RNQ|^1^3&E-QL6-|(DHK#5..NV8(M>+<PO=VJR-W-H965TSFP#C;N!=K!-KMP|/C\$3;1^51)2D|^?>(7|,<9+..AK(4^7G*
MMB;|&49QF090FUFU9OIBDBDAG+>7EMS99S6HB\$9^C-~" 2%+&G6Y50P!<QO.%MSV2|<^J^N9SG:(OOL?B:KYD|,QN4F^0XXX1F@-!
PG@>|U;VHQ+^B+M!)O#- M,5^E"/>Z39UB|>+&I1CA!<="02#YM<663?P|=O(LC-\$,-ZA(Q&=Z^1/717D^Z(Z)+S-!H8ZU#1-57-"T318, M4I)5W^BQ%|*3-
TS^?>=8|JL@E;GE;J9%>,RK#LDT+>Z-\$P%2WLU\$&I39DM-MJR&96L9|P>1=O(|\$D%D PNE;@~?E@>@ON9?>
M18(1W8#!1|/#Z@<M\$DGO|?7C|Z@UX:4@&ONQHP64HGYM^LE_-48UP|N^MH7V&X3W.KX%C70;LEU-
^FHX^0Y,AV6Z4X-W91-8+9C6|VB>>|1#~#P|T<9 M#CX(G/-+~56V^X>6VW9&YZC^~N2-T,CA#-MZ(T,(J&4P(T^?S#*M2M=8?HEIGK-f)
<H1H^EST00(C#X&+|WCXAJPG/(NF>|>@U;Y#H-M%R10-O^FT3027X\$>QUQ|X21\$W8)5;Q/HUS/M2T|>^A|0-2-B@9ZB@-9EW;
M1R-HJ0H,F@#*~;=^*8,(X^U9_@;<()MGYXTG(0P0^H+W0U*!<-C.ING> M%B2)2;E)5-2RGVUQXJKEN8@UJ6K-
|)8KVQHMM6JV|)VK<#%4F(LM+X49, #)MVC9&K3W;4MZ-AAJ@WS+5_2MK-U0&G#P|;|A**=O,2>^GRU3\$U%6.AJ>MN-MG05TINS;0=|RL10CH?
6E;|T+~|8L+>4;UO0A?H)PU83YK00.1|WK7N-P-E M!=-!>JAU|KBBG\$3-3&L93R|>|&BC836K|U0="ZLG|4MACH?6E-T3^#0B M+^W20&,#-
Z|E|6!-XLS|VJH;..QOWAA+IY^C(36+|PSCIET^C/N0&8^XV2WQLF> M8B9CGTY;PIEW.G01,W@|-(KF)U|D|H^?T)L2S(<.\$KR1=-9U(-N>58/5ZD30
M0Q/-E A%#H>|C^%5,1^OZ&40%|HL=-S7A?|3^J02P.\$<@-N8AF69@E-MY3^H-P S14-ID-IX;|JW;W)K&ULM5AM3|JLP M^#<B-15
TR8Q|U-M6EK61@<0%>8D\$5&-N^1;XS;6DCBSW1<-6PGI F^B+& C-M2YLX=|Y7G^M;|E(|^)-H-DMS;~28MCGVQ+&A18+^*Y.K)DO\$>2W7+
M5|8H.,&Q43!E:YG2G,PY\$NLLP-SNE^1L,|(->1ZZ0%8S\$~TJVHG&-MM^LWC/W1-^?QS+TCDA*%E(CL/K:D#-2HJDJO&W@EJU3:W8O+ZG?S;^V=N
ME^~G+|U)8YG,K+&8K+&ZU1^2BJLO|HJ^D+@E:KSB;5K&-AQ51(EE7%<@<9 M\$>?>YBG|<)<YC**;UJH-M81-Z^1JU8-H
(Z13BM-T7>@>J=-|ON02\$S3^TKB-BI\$|H^0&1S=W^A^W^ M HFI+~46M2%|46WGM-R|J1V^3|)C|^1-MUPN(44A|T^Y#G>H&_9|7J
|O<^<3-KT8NMMX+AU+7B&Y|DF)|ORZ4,^J7-M)|-NS?>L@?=-T0CT6!%V1FJ8XG^|0^*WCWQATYG|K^#@D+(6\$1^*R5H\$&=
MH\$?>A@0B#U9M^LP)3KK^2<@R5D9^#ZEV03.-|TPSO8XF1,^;0N^CH8\$-M=I^T6-AHZ&S(I7<-9N#GO=|W#++H=|T-O9-
Q.0L+^#%1N<Q^|T!#QI?1^2Q>%>Q M;X00|2)12-S.%#>I-TB|H^VC-D+(6\$1\$R5C4F=C^<
|MWX^%|(2@M@J^U\$<3M\$N218J^|X^H|@J2H+H0BM9-MT^|XZ-8>WH^KT|NJ^T\$|065;16|_>W;^LHT3V6K|Q<4^%6^>R^#4M-J_7L|
<1,W|ZLG|K^9V|>JAGE68&PO=VJR-W-H965T F-FXTU|PZVTW;?^MM)0|F%4B-MM^%|S|GO;|U9,OXH@|)-
H5M!13Y>RANKMD>108~%BC53,9X@+4;4K4M-M^<X^~*VHC1^126G M^W-OP>~)JRAE)2PX\$G518ATY1MY9K|6--=)5HP| MZL^=&HY&@&H)%
(8/6W@1E0JHT4Q|6^T^H>J87JZ|W|>Y=95EA-3-&OY-4 MYE-K;^\$4,EQ3><^VZ#~\$VJ A%#A?M&VK74LE-1^LJ(5^X^E,T-WK7KT!X
MP0F|U|B|JQO?XK<W01LR\$VN;)8XG&C21UJ?7^35^9M3%|J8;4^BTN)5>S1-ED M2)LDO(84O=NI?2%-(%RFZ(O,@-9S3F4\$GTB>\$4HD43-
OD^M<R8-2F@|B&?>I^M4+4<)|TE7|Y6,|1Y<4K=(%B|FK;9!M&B;V5)\$TF|VT^<-OG<^?PG5?%>=MU|A0P|/CLOGT.BY^Z1^!EMEKG(C6|C4|X^>?
|Y(O@|JRB4|8U<^%4H!>W^M&B^YVK-AP(VCL&PH-Z|<2%\$YA-ZBL5P#=@QZ|P^N)\$S=BCN?S)|%M|SOP0OG-MW^5XS@U|UV3E0+7.6\$&|&9&#>
|9QBXR;C;^KWG(FJZ0D-M04<:G^?E+..A&Q&F^*,8Q&LLPOZ3O2@XP#LN|L;,>)|N|C^"LW1+K^>0Q#M4-M=MI8^X)NCCFAT-MEFC?A:#?
A9C80DG+>B?>2\$<CK>9^*C@>2LQ6>W^=WBJUXOU;?@9S4I-M^*009U5-5+7-V-)^M>5^TRJ9FAN^ZQ^>-DM50?M-
^SJMUDX|H^#ID64928X;R^+UVSP6750WJ(C_ZY&1|U>NU4H^399^K-VJ7-MEUS-2(9RZ6J),+ROP>YD^%<97C^<1>WZKJ|V7S^!UR>?DR-V\$A%UGI
M^5J|>5H-G)6|C|C|55|OBK;X\$HJ/266554-5J/S;&3D;+U26-(W+&211-MNOT_-(8T610Z00W)H&WK\$-6-_/6-@|VG@-PW|VIGM^J=0^B^%|X|>W3R
MZNA2K71HUFUW+D_|2JM|YOU9Y^<..H;^?FV1>JH;U+R1R;R-5.&=ZWEX&3-MW3J|I+EAW^JG=X^?PB|PB@NOB?>P6SHMOO|8JW|@E?>
QXV0SBS780WY!M;==EJ|UX?R4KN2JH_V^;G|&M^?7ANQ<|9Y<=>..1@M=R|H|ADQ|<+>Y?>Y
MK;DXOCDCSH;MYIC5>OX>O4K&N9^K^VW4HM3Y5&QO&B|V(1+M>3D|;52Q\$!-D;/=-RZ?-AG%|),@,0,\$_V=B7ZMSFR^M=OY5'.6R63XN|^
M^WVDE4@Q-1(SK-QU5@>D|=BVJ;QLL|J4L76O:T8K|6J7X8|A|G^%&M;@|
MPQ*^LX23EOSAU<BY22|K;F,4;2,SP<K;S<8I;U11I)5),@,0,*V<|V>0-ME,X.16M|JF-K^4C,L.1L9|D9:4GU**3V/@K|YUC^HB4|L|WND&(^)&8|&|T
M(^D\$^&)&\$^0F5\$V@U\$P-6X-X^3M(RUA4@UT-BU;S;X-YDHFIVCN>=L<|M#~3VOYKI#JU1^H)E)HMB81EPT0;2B10-4\$2LWT4T-2SZH^QJM*
(DT:D\$K-MC|/\$R&C)CSA^4X6K<@G.-)ALSSK94^2J@F4FFFFV|AB7^Y|L\$5-U01^S?13 M#@XQ+/MP?G^QD|XO/G|H|^6G^YX/7B=0C>
<#5PN#1Q;PK>YI7MX?RBD2/151-MH-L,LS7^N&<#Y16^*+U-5(S^V^LH<4C^!>SFLCTPXC^U@GBPNZ.UMS4&JF-M.9I-/I)
#B5|D16J6FO8Y^D5|<Q^TY53-2-RL(LGAE3|?TD&R05;6^*0^F9 MTZ&LQ_/PV?>@5-5\$R@UTT|1Z|P|TJ\$@-U43C9I0?7|G>-G:TXCBT8@
MR;X|A-CLO8:NOB^4C-G1-1%PP0?RCZ0-4\$2LWT4Z./1R>^U^*.TT:NW M>LSM/M2C>C7-T15CT1R#B;UJ=-CLO8:NJJ#4C-G1&6-
QL@-E^2@JH)E|K1MRIRICU5.CK^9P=O>>O>V>RL|>#L|3K-HUL^DVIKZF25%95Z9-0NE9LZ-(M|BSFXC/H(O\$51,H=-/34B,7A0Z-
M-3^NPTRI+TYU96S,^+I+6,1D-X?M^U7V&>+~1WEZ7E0>9)9^*KL^9X>B/7UB2U0^V+~AVFH8@-4HS^H\$D^5|K-MJ%,C\$<4I-\$RUA9^%>A1;|^+
L|W\$CS3?_HOCDA|?<3H_%V^HDA!\$S9P^MC5)L@.(V!@4A)|J9E^A!BF-HW6L;PEGW&_|S^10G9K>.*A1Y6Z49FW
MAG5Z+8&OY>54&H?T;E&+7^6C@?^D10-82,W4H-1C.N\$&O6\$>P|QH-L-MDND1?>T9.Y3Q3ZMOHY|X@>CT6^RO"/@WH>3;,>#(O|65S7S;_M?
UK-7-|&@<H:UNJ^U?2;04^>P1^E0?>P1^NE\$?) U01^S?QJR\$> %>|)M8-M2S^T6Y?>U>|>4V^WFA|4XK1-L3-VLB|X=|A2U?0BE9DZ|YJ@>^*Y-1%
M4#6!4C|/U^P48(KG@FZ|VO/G^>Y#7^H^?&OY|)H<@E.JXC;\$V)K&>^87W1-M02\$)I69.06L^@%>X+LA>10Z\$&IF7YJZ-DP)7!!MVB-
^|Rf8DYW9VW-\$03 M-(O3BN|^Z51F8=QG?AP51X1%2HJ|V0|&<HKU-OJE(O2-0T:E8(|ZMX^M^=-U01^S?13; M9?A1M^?%TJZTIG1Z-
M<70U2&4FCD3FK^X-5R-1,4#6!4C|/U;#;\$,05RO^N\$MJO59GG>W8G,K!AD>9-V5H|LU6|49GVIK62%#87W08^VX^>N^8D/4?&MH2-\$51,H=-
/4<4^?&4^?&V-M10=BD|0L4;M7?3F=-5NPL7SC^|3J5V^JC-M|H=C^>6^?>8^>V^SAGHOM/L;9KLM&KLP0X02PHGE;2DY>34M;UGY=J^A|N5
M;=>J|=V|RL^*D2KF6X4KFUO^ESV^S3#VJJ3K8|?<|Q|02P,\$%>@N8AF-M6=TXO(R^P H|^ID-IX;|JW;W)K&ULM5AM M3|JLP;XK\$5C9-3-
H(G/25M96@;|K2D@>9X|T#R-YMA|W-DNA7|_VPEY68+M.X/V;~N^M|SY|N<K2F|XO-1Z3);C|VY%\$LCU^7A E^#>2D,0EEIEE^
M6^RRN+IBR^44@((G)>8-R)DH|D^+4<^>4RG6GY-10VCR MDLP=X3^ER67^*KK|Q|B.K|<K;C!M+>A?RYSTN|HJL+FMV^+|NANF%#M-WBK7-
+EJ^K^Y|@-LZTLVV9-M9K7L(761%|U(|C-S+~DMB^ZWI@.HIP<O-I29-MG,(+OY;=(^2VN&@EL M|B3VR++A9DO>FF5;Y7^3W=H@(
4VU-1CD^ZRD0^<SAWRQK,L9XN|5X/L-Y-M)VP>9QPE|)JWF^?>HOE,Y%|>A2CQ7N|TUB+((S-P)2#?SR@5SPMU0^F9-MFOP4L#!10(-
+F(9EGR|8.+@&8,XM-9>+&PO=VJR-W-H965T M-1TN|YJ M-X|0@BV#>23O^?>5G7SGE-HGB-WJN8HT|FF^>Y&5G-U|U;E^W>+!H-M^GT^J|)-L
XDF%6^>~M6%6^|J;MV%5^T?5AV?>BX&@@@|DXY<|H\$;S-M6OZA&TB.QNO,,DGRDRFV=4PRY.3>~;|DBT3Z^V:E7,%|27ZS&40H8-9^V0
M/WY^=RE?>.<2-94Q^T&O^9!&|+>+&5.^?KJZ@UZA,\$&PUWPK@FOAQD.9W5>MRC|>W2-DP+V8Z)8GX^<O^M5RE9H81-6N|F-M|OJGF|
WDL7B7UW52ZZEY^9\$>~DVP9Q=^#3&5RQJ8H|H|A|Q-A3-20,H-MAX%>2G&LNC&A^WV2/ZH|;CJ2E|F-T5V-K-C)ZK^PZ?JL>U^N1YV|VH4
M|49ARS5=HH;YFB;)9W^X#E,Z:M<~M7L|NM.@3&0+!O\$<)>Y|TWU/SWMOITX^M2|B%A/E,^4F3ET3YTS^X\$6|Q)&
(6\$>\$P\$ISJ@NSNA|RE|FVXHR.;K9YV-MHUS/P;9+&HVV9JKM^2HDV3Q.E^>|K@UAUU?UT9T-TX>9U|>P^Z^E3\$!)&
M(6\$>=\$R|C^=7QCN3/FBOQ8&\$44B8^P13BH-Q@&8+U^EUYK^M53B;BT+HKHP-MQ|U%#;#S-5A^FV.2?&J\$+UY;|
|AED5(VW^HVVW3PGLU1|JN8^|SOKHZ)QBV/V^P;2F;|?&F8N@V2((5-MBUDBT8Q^VWP6Z?>IMJV3IRLDC8+2?^B:6L^&6+|7(H^B!!;124YD/1U!|U
M)A+WVJ#CBN)TUQ?&9RVI&C^&Z;4GLAID,4=M2?F&69B8Q@>4|P9|G=E-M1+W\$5M6^JDG3T9&&6E^5-TM3Z-E|3NN?
0^U^~#TB@HS8>Bj25j3^7NM47^M|<+>3?>W+9>=.*>9^<V6G2CL^YGO5(-|SS|>+>^ACT&B-03LF0>O^A^H^)
M(9@0Q9)M^#9^&4E/263IV=H#0^2O.A^K+H^>|)D\$A^("Z3"-||;Y4^2U-M1(W+)+T6Z:B-5.C^0>-AEC1-5^%MMO?C&JB^*T|)^OB1K9UH^!FF&NGW
M:L^TXY<-BB7(ZSBD431)S|~;|J9H&1Z9W0\$H-DT;Z3=H-MW145|6C^?K>^#Y1&06D^%\$TM5V,SR>AGK#-^W-M@*
T^DKSH6CJ-J|&9YK&F=3^!>65H#0^2O.A&J)&EMI|K^<^H65J|K+Y-M.X.D)BA&|3T0A=D&V|T+7GD?8+E^>~M28I:MB8|<|Y-9+D|L3Y;|SY^
M5V9Y;9V O1^3K#E!;52;BUN!5.Y|L(786)01%;9DT99Z-V;M|JRW|Y|FF-MV|W|R^7D&ULM5A=#.JH1-8SG&^RORIK-C9SSS;E|LE6.^3.R;7XLZ-T|Q
M;~29R384Y|0A5:4)+5G4^>H^M|TJ1|^2K|B40.)0A2|P64HEL8Y_-U&CMRF)Q|<|3|: MYX4S=XCA^U^<5:0|GQNA
5^!IMN2WY#|>|JY\$Y\$F|J2E9|POV=8RP&K^*^DZ-MLEA!5=3M^K>|>*(^34-|<1X)C@/D|P+H+S6-MNKI7?^K(KWK9NM|S|@8 M<284;
(5^!&5^FKQHHM-P1;R^6FZ4);B^B^X?&#=#|C>8@;>@F6|5P|9@Z^<^MHQ|)ONTOW-W|S#^*HDQZNE7^L-SMD\$K|=#>M6.8|K^<47V|^<=
M5X5S-P=Q-84 M%49V& Q1^2G^>D,GA\$-8HC^)(R^R>|C-4|JWU|MT|+8N;\$|DB.N|G22-M3-MIE,LUBF6!<Y;#O<^_4^7P=29^TUBL4RS1)^9(3M
G)WA6)6C9WM&QA|C-M.^<H^#@<B.ZD5|BK)MS^&L\$1A,O+^H^H^<#3L^0TG^4V3V+PQJUR.48D^Y<H4)<^>^>@QIY?O|16N9F|7JCV=Y#|U
MOVE5B|6p|;K4A|H-|YF+U01.F^>#=\$%M^FMS2W2|5^5-T^P%G3WZ^~+PJ^*O-MJM|U4V3L^*2N@.34N^Z^U.66>J&^T|4^U-M
TXV38OECG|JN8RQRC%5+>34A-#^0|OH^X-(<4\$L#!10 (-+F(9ED>M;ME(5P0^&PO=VJR-W-H965T64I\$94Y&|@>~;D^*QT^C-
S(|O9FFP|ZRD=QR)75\$0-O66-MYNPP=WSG^VU^2K^E^ER%B;W-G1M-BOVQ M^Q|>6?V7T(\$ZVD;Z51;+>J,Z=-YX^<HHH3A.I\$43|V=-ES7-4M?
Q|PUOFA: M>+>KJ3,?FM7-|I)ERS_-TOE9N<R.BE^|+>Y3T|<^KK&QH7L^R87ZC0|4V-MC@<HV0G)BEJLKJ#(RNHO^5)WQ(E
<H^02T(S>#^X)|+|B|,^P%>@Q^&F^4 M^T|G@O^~(P^H>G|J^K,3T=^DL6;LP|BNK6BZ0UCGE&K#LY^|>)>#>G;Z63
MBWNZ|^6.^00.+5F9T%>R8BR-S|03^FBFDF3YS-JLN1,*YK-7^FN1|/\$+~"6K%# M+R0^9^X^E^#>81^ILJ^3YJ|J9G-0|J9BKN40M81;M;=-
/9A9^86;ID!-#U.NF<^|OVN9S_USAJVKW>0L|>2AH^%+>~"QKOPE5CZ M)DG8K1^9>>9GORF^O(B-M2@%|<-L);GUXWGU^
)VDKLEZS^B+>KNF^J|^LZDCAHR@<6 M|K;=Y|>~?J|M^<NYC+&Z.LF)R^A.60;P\$|GN>+>2-J+TWSJ-U^~#>06D1^T^&I6H6MOZ

[illegible]

[illegible]

```
"name": "groupType", "disclosure": "subGroupType", "tables": "menuCat", "Tables": "order", "22", "firstAnchor": { "contextRef": "c-1", "name":  
"osur:SummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation":  
"body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": { "contextRef": "c-1", "name":  
"osur:SummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation":  
"body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R23": { "role": "http://www.orusure.com/role/inventoriesTables", "longName": "9954474 - Disclosure - Inventories  
(Tables)", "shortName": "Inventories (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us:  
gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": { "contextRef": "c-1", "name": "us:  
gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R24": { "role": "http://www.orusure.com/role/PropertyPlantandEquipmentNetTables", "longName": "9954475 - Disclosure -  
Property, Plant and Equipment, Net (Tables)", "shortName": "Property, Plant and Equipment, Net (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order":  
"24", "firstAnchor": { "contextRef": "c-1", "name": "us:gaap:PropertyPlantAndEquipmentTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": true,  
"reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "uniqueAnchor": { "contextRef": "c-1", "name": "us:gaap:PropertyPlantAndEquipmentTableTextBlock", "unitRef": null, "xsi:nil": false,  
"lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R25": { "role":  
"http://www.orusure.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "longName": "9954476 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses  
and Other Current Liabilities (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "osur:ScheduleOfAccruedExpensesandOtherCurrentLiabilitiesTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R26": { "role":  
"http://www.orusure.com/role/TerminationBenefitsTables", "longName": "9954477 - Disclosure - Termination Benefits (Tables)", "shortName": "Termination Benefits (Tables)", "isDefault": false, "groupType":  
"disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "osur:SummaryOfOneTimeTerminationBenefitsTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "span", "div": "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R27": { "role": "http://www.orusure.com/role/RevenuesTables", "longName": "9954478 - Disclosure - Revenues (Tables)", "shortName": "Revenues (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us:  
gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R28": { "role": "http://www.orusure.com/role/IncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R29": { "role": "http://www.orusure.com/role/StockholdersEquityTables", "longName": "9954480 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": false, "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us:gaap:ScheduleOfStockholdersEquityTableTextBlock", "unitRef": null, "xsi:nil": false, "lang": "en-US", "decimals": null, "ancestors": [ { "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R30": { "role": "http://www.orusure.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "longName": "9954481 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-4", "name": "us:gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsi:nil": false, "lang": "en-US", "decimals": "0", "ancestors": [ { "span", "div": "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R31": { "role": "http://www.orusure.com/role/SignificantAccountingPoliciesAdditionalInformationDetail", "longName": "9954482 - Disclosure - Summary of Significant Accounting Policies - Summary of Changes in Accumulated Other Comprehensive Loss by Component (Detail)", "shortName": "Summary of Significant Accounting Policies - Summary of Changes in Accumulated Other Comprehensive Loss by Component (Detail)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-4", "name": "us:gaap:StockholdersEquity", "unitRef": "usd", "xsi:nil": false, "lang": "en-US", "decimals": "3", "ancestors": [ { "span", "id": "tr", "table", "div": "us:gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R32": { "role": "http://www.orusure.com/role/GovernmentCapitalContractsAdditionalInformationDetails", "longName": "9954483 - Disclosure - Government Capital Contracts - Additional Information (Details)", "shortName": "Government Capital Contracts - Additional Information (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-4", "name": "us:gaap:GovernmentContractReceivable", "unitRef": "usd", "xsi:nil": false, "lang": "en-US", "decimals": "5", "ancestors": [ { "span", "div": "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R33": { "role": "http://www.orusure.com/role/GovernmentCapitalContractsSummaryofGovernmentContractsBalancesIncludedinConsolidatedStatementsOfCashflows(Detail)", "longName": "9954484 - Disclosure - Government Capital Contracts - Summary of Government Contracts Balances Included in Consolidated Statements of Cash flows (Detail)", "shortName": "Government Capital Contracts - Summary of Government Contracts Balances Included in Consolidated Statements of Cash flows (Detail)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us:gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsi:nil": false, "lang": "en-US", "decimals": "3", "ancestors": [ { "span", "id": "tr", "table", "div": "us:gaap:PropertyPlantAndEquipmentTableTextBlock", "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R34": { "role": "http://www.orusure.com/role/InventoriesScheduleofInventoriesDetail", "longName": "9954485 - Disclosure - Inventories - Schedule of Inventories (Detail)", "shortName": "Inventories - Schedule of Inventories (Detail)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us:gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsi:nil": false, "lang": "en-US", "decimals": "3", "ancestors": [ { "span", "id": "tr", "table", "div": "ix:continuation": "us:gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R35": { "role": "http://www.orusure.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetail", "longName": "9954486 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail)", "shortName": "Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment (Detail)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us:gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsi:nil": false, "lang": "en-US", "decimals": "3", "ancestors": [ { "span", "id": "tr", "table", "div": "us:gaap:PropertyPlantAndEquipmentTableTextBlock", "ix:continuation": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R36": { "role": "http://www.orusure.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetail", "longName": "9954487 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Detail)", "shortName": "Property, Plant and Equipment, Net - Additional Information (Detail)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us:gaap:AssetImpairmentCharges", "unitRef": "usd", "xsi:nil": false, "lang": "en-US", "decimals": "3", "ancestors": [ { "span", "id": "tr", "table", "div": "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R37": { "role": "http://www.orusure.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofAccruedExpensesandOtherCurrentLiabilitiesDetail", "longName": "9954488 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)", "isDefault": false, "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us:gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsi:nil": false, "lang": "en-US", "decimals": "3", "ancestors": [ { "span", "id": "tr", "table", "div": "ix:continuation": "osur:ScheduleOfAccruedExpensesandOtherCurrentLiabilitiesTableTextBlock", "body", "html": true, "reportCount": 1, "baseRef": "osur-20240930.htm", "first": true, "unique": true }, { "R38": { "role": "http://www.orusure.com/role/TerminationBenefitsSummaryofOneTimeTerminationBenefitsDetails", "longName": "9954489 - Disclosure - Termination Benefits - Summary of One-Time Termination Benefits (Details)", "shortName": "Termination Benefits - Summary of One-Time Termination Benefits (Details)", "isDefault": false, "groupType": "disclosure", "subGroupType":
```

[illegible]

[illegible]

Authorized,"documentation":"The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } } , "auth_ref": { "r51","r610"} } , "us-gaap:CommonStockSharesIssued":{"xbrlytpe":"sharesItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"CommonStockSharesIssued","presentation":"http://www.orsure.com/role/ConsolidatedBalanceSheetsParentalchil","lang":{"en-us":{"role":{"terseLabel":"Common stock, shares issued (in shares)","label":"Common Stock, Shares, Issued","documentation":"Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } , "auth_ref": { "r51"} } } , "us-gaap:CommonStockSharesOutstanding":{"xbrlytpe":"sharesItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"CommonStockSharesOutstanding","presentation":"http://www.orsure.com/role/ConsolidatedBalanceSheetsParentalchil","lang":{"en-us":{"role":{"terseLabel":"Common stock, shares outstanding (in shares)","label":"Common Stock, Shares, Outstanding","documentation":"Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } } , "auth_ref": { "r14","r51","r610","r629","r933","r934"} } } , "us-gaap:CommonStockValue":{"xbrlytpe":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"CommonStockValue","crd":{"credit","calculation":"http://www.orsure.com/role/ConsolidatedBalanceSheets"},"parentTag":"us-gaap:StockholdersEquity","weight":1.0,"order":2.0 } } , "presentation":"http://www.orsure.com/role/ConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"terseLabel":"Common stock, par value \$0.000001, 120,000 shares authorized, 74,593 and 73,528 shares issued and outstanding","label":"Common Stock, Value, Issued","documentation":"Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } , "auth_ref": { "r51","r552","r720"} } } , "ecd:CompActualPaidVsGoSelectedMeasureTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"CompActualPaidVsGoSelectedMeasureTextBlock","presentation":"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Compensation Actually Paid vs. Company Selected Measure"},"label":"Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } } , "auth_ref": { "r801"} } } , "ecd:CompActualPaidVsNetIncomeTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"CompActualPaidVsNetIncomeTextBlock","presentation":"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Compensation Actually Paid vs. Net Income"},"label":"Compensation Actually Paid vs. Net Income [Text Block]" } } } , "auth_ref": { "r800"} } } , "ecd:CompActualPaidVsOtherMeasureTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"CompActualPaidVsOtherMeasureTextBlock","presentation":"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Compensation Actually Paid vs. Other Measure"},"label":"Compensation Actually Paid vs. Other Measure [Text Block]" } } } , "auth_ref": { "r802"} } } , "ecd:CompActualPaidVsTotalShareholderRtnTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"CompActualPaidVsTotalShareholderRtnTextBlock","presentation":"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Compensation Actually Paid vs. Total Shareholder Return"},"label":"Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } } , "auth_ref": { "r799"} } } , "us-gaap:ComprehensiveIncomeNetOfTax":{"xbrlytpe":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ComprehensiveIncomeNetOfTax","crd":{"credit","calculation":"http://www.orsure.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"},"parentTag":null,"weight":null,"order":null,"root":true } } } , "presentation":"http://www.orsure.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"},"lang":{"en-us":{"role":{"totalLabel":"COMPREHENSIVE (LOSS) INCOME","label":"Comprehensive Income (Loss), Net of Tax, Attributable to Parent","documentation":"Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } } , "auth_ref": { "r21","r135","r137","r141","r545","r562","r563"} } } , "us-gaap:ComprehensiveIncomePolicyTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ComprehensiveIncomePolicyTextBlock","presentation":"http://www.orsure.com/role/SummaryOfSignificantAccountingPoliciesTextBlock"},"lang":{"en-us":{"role":{"terseLabel":"Accumulated Other Comprehensive Loss"},"label":"Comprehensive Income, Policy [Policy Text Block]" , "documentation":"Disclosure of accounting policy for comprehensive income." } } } , "auth_ref": { "r799"} } } , "osur:ComputerEquipmentAndSoftwareMember":{"xbrlytpe":"domainItemtype","nsuri":"http://www.orsure.com/20240930","localname":"ComputerEquipmentAndSoftwareMember","presentation":"http://www.orsure.com/role/PropertyPlantandEquipmentNetScheduleOfPropertyPlantandEquipmentDetail"},"lang":{"en-us":{"role":{"terseLabel":"Computer equipment and software"},"label":"Computer Equipment And Software [Member]" , "documentation":"Computer equipment and software." } } } , "auth_ref": { "r1"} } } , "us-gaap:ConcentrationRiskBenchmarkDomain":{"xbrlytpe":"domainItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ConcentrationRiskBenchmarkDomain","presentation":"http://www.orsure.com/role/RevenuesConcentrationRiskDetail"},"lang":{"en-us":{"role":{"terseLabel":"Concentration Risk Benchmark"},"label":"Concentration Risk Benchmark [Domain]" , "documentation":"The denominator in a calculation of a disclosed concentration risk percentage." } } } , "auth_ref": { "r32","r33","r39","r40","r198","r663"} } } , "us-gaap:ConcentrationRiskByBenchmarkAxis":{"xbrlytpe":"stringItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ConcentrationRiskByBenchmarkAxis","presentation":"http://www.orsure.com/role/RevenuesConcentrationRiskDetail"},"lang":{"en-us":{"role":{"terseLabel":"Concentration Risk Benchmark"},"label":"Concentration Risk Benchmark [Axis]" , "documentation":"Information by benchmark of concentration risk." } } } , "auth_ref": { "r32","r33","r39","r40","r198","r589","r663"} } } , "us-gaap:ConcentrationRiskByTypeAxis":{"xbrlytpe":"stringItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ConcentrationRiskByTypeAxis","presentation":"http://www.orsure.com/role/RevenuesConcentrationRiskDetail"},"lang":{"en-us":{"role":{"terseLabel":"Concentration Risk Type"},"label":"Concentration Risk Type [Axis]" , "documentation":"Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } } , "auth_ref": { "r32","r33","r39","r40","r198","r663","r835"} } } , "us-gaap:ConcentrationRiskPercentage":{"xbrlytpe":"percentItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ConcentrationRiskPercentage"},"presentation":"http://www.orsure.com/role/RevenuesConcentrationRiskDetail"},"lang":{"en-us":{"role":{"terseLabel":"Percentage of concentration risk"},"label":"Concentration Risk, Percentage" , "documentation":"For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the 'benchmark' (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } } , "auth_ref": { "r32","r33","r39","r40","r198"} } } , "us-gaap:ConcentrationRiskTypeDomain":{"xbrlytpe":"domainItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ConcentrationRiskTypeDomain","presentation":"http://www.orsure.com/role/RevenuesConcentrationRiskDetail"},"lang":{"en-us":{"role":{"terseLabel":"Concentration Risk Type"},"label":"Concentration Risk Type [Domain]" , "documentation":"For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } } , "auth_ref": { "r32","r33","r39","r40","r198","r663"} } } , "us-gaap:ConstructionInProgressMember":{"xbrlytpe":"domainItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ConstructionInProgressMember","presentation":"http://www.orsure.com/role/PropertyPlantandEquipmentNetScheduleOfPropertyPlantandEquipmentDetail"},"lang":{"en-us":{"role":{"terseLabel":"Construction in progress"},"label":"Construction In Progress [Member]" , "documentation":"Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } } , "auth_ref": { "r1"} } } , "us-gaap:ContractWithCustomerDurationAxis":{"xbrlytpe":"stringItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ContractWithCustomerDurationAxis","presentation":"http://www.orsure.com/role/RevenuesAdditionalInformationDetail"},"lang":{"en-us":{"role":{"terseLabel":"Contract with Customer, Duration"},"label":"Contract with Customer, Duration [Axis]" , "documentation":"Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts." } } } , "auth_ref": { "r701","r878"} } } , "us-gaap:ContractWithCustomerDurationDomain":{"xbrlytpe":"domainItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ContractWithCustomerDurationDomain","presentation":"http://www.orsure.com/role/RevenuesAdditionalInformationDetail"},"lang":{"en-us":{"role":{"terseLabel":"Contract with Customer, Duration"},"label":"Contract with Customer, Duration [Domain]" , "documentation":"Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts." } } } , "auth_ref": { "r701","r878"} } } , "us-gaap:ContractWithCustomerLiabilityCurrent":{"xbrlytpe":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"ContractWithCustomerLiabilityCurrent","crd":{"credit","calculation":"http://www.orsure.com/role/ConsolidatedBalanceSheets"},"parentTag":"us-gaap:LiabilitiesCurrent","weight":1.0,"order":2.0 } } } , "presentation":"http://www.orsure.com/role/ConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"terseLabel":"Deferred revenue"},"label":"Contract with Customer, Liability, Current" , "documentation":"Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } } , "auth_ref": { "r303","r304","r323"} } } , "osur:ContractWithCustomerPaymentTypeAxis":{"xbrlytpe":"stringItemtype","nsuri":"http://www.orsure.com/20240930","localname":"ContractWithCustomerPaymentTypeAxis","presentation":"http://www.orsure.com/role/RevenuesAdditionalInformationDetail"},"lang":{"en-us":{"role":{"terseLabel":"Contract With Customer, Payment Type [Axis]" , "documentation":"Contract With Customer, Payment Type [Domain]" , "documentation":"Contract With Customer, Payment Type [Domain]" , "documentation":"Contract With Customer, Payment Type [Domain]" , "documentation":"Contract With Customer, Payment Type [Domain]" } } } , "auth_ref": { "r701","r878"} } } , "us-gaap:CostOfGoodsAndServicesSold":{"xbrlytpe":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"CostOfGoodsAndServicesSold","crd":{"debit","calculation":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"parentTag":"us-gaap:GrossProfit","weight":1.0,"order":2.0 } } } , "presentation":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"COST OF PRODUCTS AND SERVICES SOLD"},"label":"Cost of Goods and Services Sold" , "documentation":"The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } } , "auth_ref": { "r65","r66","r508"} } } , "us-gaap:CostOfSalesMember":{"xbrlytpe":"domainItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"CostOfSalesMember","presentation":"http://www.orsure.com/role/TerminationBenefitsSummaryOfOneTimeTerminationBenefitsDetails"},"lang":{"en-us":{"role":{"terseLabel":"Cost of products and services sold"},"label":"Cost of Sales [Member]" , "documentation":"Primary financial statement caption encompassing cost of sales." } } } , "auth_ref": { "r1"} } } , "dei:CoverAbstract":{"xbrlytpe":"stringItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"CoverAbstract","lang":{"en-us":{"role":{"terseLabel":"Cover [Abstract]" , "documentation":"Cover page." } } } , "auth_ref": { "r1"} } } , "dei:CurrentFiscalYearEndDate":{"xbrlytpe":"gMonthDayItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"CurrentFiscalYearEndDate","presentation":"http://www.orsure.com/role/CoverPage"},"lang":{"en-us":{"role":{"terseLabel":"Current Fiscal Year End Date"},"label":"Current Fiscal Year End Date" , "documentation":"End date of current fiscal year in the format -MM-DD." } } } , "auth_ref": { "r1"} } } , "us-gaap:CustomerConcentrationRiskMember":{"xbrlytpe":"domainItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"CustomerConcentrationRiskMember","presentation":"http://www.orsure.com/role/RevenuesConcentrationRiskDetail"},"lang":{"en-us":{"role":{"terseLabel":"Customer Concentration Risk"},"label":"Customer Concentration Risk [Member]" , "documentation":"Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } } , "auth_ref": { "r77","r198"} } } , "us-gaap:DeferredCompensationPlanAssets":{"xbrlytpe":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"DeferredCompensationPlanAssets","crd":{"debit","presentation":"http://www.orsure.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"},"lang":{"en-us":{"role":{"terseLabel":"Fair value of plan assets"},"label":"Deferred Compensation Plan Assets" , "documentation":"Carrying amount as of the balance sheet date of assets held under deferred compensation agreements." } } } , "auth_ref": { "r843"} } } , "us-gaap:DeferredIncomeTaxExpenseBenefit":{"xbrlytpe":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"DeferredIncomeTaxExpenseBenefit","crd":{"debit","calculation":"http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows"},"parentTag":"us-gaap:NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":8.0 } } } , "presentation":"http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows"},"lang":{"en-us":{"role":{"terseLabel":"Deferred income taxes"},"label":"Deferred Income Tax Expense (Benefit)" , "documentation":"Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } } , "auth_ref": { "r10","r105","r851"} } } , "us-gaap:DeferredIncomeTaxLiabilitiesNet":{"xbrlytpe":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"DeferredIncomeTaxLiabilitiesNet","crd":{"credit","calculation":"http://www.orsure.com/role/ConsolidatedBalanceSheets"},"parentTag":"us-gaap:LiabilitiesNoncurrent","weight":1.0,"order":4.0 } } } , "presentation":"http://www.orsure.com/role/ConsolidatedBalanceSheets"},"lang":{"en-us":{"role":{"terseLabel":"Deferred income taxes"},"label":"Deferred Income Tax Liabilities, Net" , "documentation":"Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } } , "auth_ref": { "r361","r362","r549"} } } , "us-gaap:DeferredRevenueRevenueRecognized":{"xbrlytpe":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"DeferredRevenueRevenueRecognized","crd":{"credit","presentation":"http://www.orsure.com/role/RevenuesAdditionalInformationDetail"},"lang":{"en-us":{"role":{"terseLabel":"Deferred revenue recognized"},"label":"Deferred Revenue, Revenue, Recognized" , "documentation":"Amount of revenue recognized that was previously reported as deferred or unearned revenue." } } } , "auth_ref": { "r1"} } } , "us-gaap:DepreciationDepletionAndAmortization":{"xbrlytpe":"monetaryItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"DepreciationDepletionAndAmortization","crd":{"debit","calculation":"http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows"},"parentTag":"us-gaap:NetCashProvidedByUsedInOperatingActivities","weight":1.0,"order":16.0 } } } , "presentation":"http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows"},"lang":{"en-us":{"role":{"terseLabel":"Depreciation and amortization"},"label":"Depreciation, Depletion and Amortization" , "documentation":"The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } } , "auth_ref": { "r10","r184","r189","r194","r686","r687"} } } , "us-gaap:DisaggregationOfRevenueLineItems":{"xbrlytpe":"stringItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"DisaggregationOfRevenueLineItems","presentation":"http://www.orsure.com/role/RevenuesSummaryOfTotalNetRevenuesByProductLineDetail"},"lang":{"en-us":{"role":{"terseLabel":"Disaggregation Of Revenue [Line Items]" , "documentation":"Disaggregation of Revenue [Line Items]" , "documentation":"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth_ref": { "r322","r697","r698","r699","r700","r701","r702","r703"} } } , "us-gaap:DisaggregationOfRevenueTable":{"xbrlytpe":"stringItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"DisaggregationOfRevenueTable","presentation":"http://www.orsure.com/role/RevenuesSummaryOfTotalNetRevenuesByGeographicAreaDetail"},"lang":{"en-us":{"role":{"terseLabel":"Disaggregation Of Revenue [Table]" , "documentation":"Disaggregation of Revenue [Table]" , "documentation":"Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } } , "auth_ref": { "r322","r697","r698","r699","r700","r701","r702","r703"} } } , "us-gaap:DisaggregationOfRevenueTableTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"DisaggregationOfRevenueTableTextBlock","presentation":"http://www.orsure.com/role/RevenuesTables"},"lang":{"en-us":{"role":{"terseLabel":"Disaggregation of Revenue by Product and Geographic Area"},"label":"Disaggregation of Revenue [Table Text Block]" , "documentation":"Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } } , "auth_ref": { "r878"} } } , "dei:DocumentFiscalPeriodFocus":{"xbrlytpe":"fiscalPeriodItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"DocumentFiscalPeriodFocus","presentation":"http://www.orsure.com/role/CoverPage"},"lang":{"en-us":{"role":{"terseLabel":"Document Fiscal Period Focus"},"label":"Document Fiscal Period Focus" , "documentation":"Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-Q statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } } , "auth_ref": { "r1"} } } , "dei:DocumentFiscalYearFocus":{"xbrlytpe":"gYearItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"DocumentFiscalYearFocus","presentation":"http://www.orsure.com/role/CoverPage"},"lang":{"en-us":{"role":{"terseLabel":"Document Fiscal Year Focus"},"label":"Document Fiscal Year Focus" , "documentation":"This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } } , "auth_ref": { "r1"} } } , "dei:DocumentPeriodEndDate":{"xbrlytpe":"dateItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"DocumentPeriodEndDate","presentation":"http://www.orsure.com/role/CoverPage"},"lang":{"en-us":{"role":{"terseLabel":"Document Period End Date"},"label":"Document Period End Date" , "documentation":"For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } } , "auth_ref": { "r1"} } } , "dei:DocumentQuarterlyReport":{"xbrlytpe":"booleanItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"DocumentQuarterlyReport","presentation":"http://www.orsure.com/role/CoverPage"},"lang":{"en-us":{"role":{"terseLabel":"Document Quarterly Report"},"label":"Document Quarterly Report" , "documentation":"Boolean flag that is true only for a form used as an quarterly report." } } } , "auth_ref": { "r751"} } } , "dei:DocumentTransitionReport":{"xbrlytpe":"booleanItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"DocumentTransitionReport","presentation":"http://www.orsure.com/role/CoverPage"},"lang":{"en-us":{"role":{"terseLabel":"Document Transition Report"},"label":"Document Transition Report" , "documentation":"Boolean flag that is true only for a form used as a transition report." } } } , "auth_ref": { "r783"} } } , "dei:DocumentType":{"xbrlytpe":"submissionItemtype","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"DocumentType","presentation":"http://www.orsure.com/role/CoverPage"},"lang":{"en-us":{"role":{"verboseLabel":"Document Type"},"label":"Document Type" , "documentation":"The type of document being provided (such as 10-K, 10-Q, 405BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } } , "auth_ref": { "r1"} } } , "ecd:DvdsOrOtherErngsPdOnEqtyAwrdsNtOthrwsRfctdInTtlCompForCvrdYrMember":{"xbrlytpe":"domainItemtype","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"DvdsOrOtherErngsPdOnEqtyAwrdsNtOthrwsRfctdInTtlCompForCvrdYrMember","presentation":"http://xbrl.sec.gov/ecd/role/PvpDisclosure"},"lang":{"en-us":{"role":{"terseLabel":"Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"},"label":"Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } } , "auth_ref": { "r794"} } } , "us-gaap:EarningsPerShareAbstract":{"xbrlytpe":"stringItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"EarningsPerShareAbstract","presentation":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"(LOSS) INCOME PER SHARE"},"label":"Earnings Per Share [Abstract]" } } } , "auth_ref": { "r1"} } } , "us-gaap:EarningsPerShareBasic":{"xbrlytpe":"perShareItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"EarningsPerShareBasic","presentation":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"BASIC (in USD per share)" , "label":"Earnings Per Share, Basic" , "documentation":"The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r173","r175","r177","r178","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareDiluted":{"xbrlytpe":"perShareItemtype","nsuri":"http://fasb.org/us-gaap/2024","localname":"EarningsPerShareDiluted","presentation":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"DILUTED (in USD per share)" , "label":"Earnings Per Share, Diluted" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r428","r429","r546","r564","r683"} } } , "us-gaap:EarningsPerShareTextBlock":{"xbrlytpe":"textBlockItemtype","nsuri":"http://www.orsure.com/role/ConsolidatedStatementsOfOperations"},"lang":{"en-us":{"role":{"terseLabel":"Earnings Per Share [Text Block]" , "documentation":"The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } } , "auth_ref": { "r142","r162","r163","r164","r165","r166","r167","r175","r177","r178","r179","r183","r390","r400","r4

“http://fasb.org/us-gaap/2024”, “localname”: “EarningsPerShareTextBlock”, “presentation”: “http://www.orsure.com/role/incomeLossPerShare”, “lang”: “en-us”, “role”: “terseLabel”, “Income (loss) Per Share”, “label”: “Earnings Per Share [Text Block]”, “documentation”: “The entire disclosure for earnings per share.” } } , “auth ref”: “r472”, “r180”, “r181”, “r182” } } , “us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations”, “crdr”: “debit”, “calculation”: “http://www.orsure.com/role/ConsolidatedStatementOfCashFlows”, “parentTag”: “us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect”, “weight”: 1.0, “order”: 4.0 } } , “presentation”: [“http://www.orsure.com/role/ConsolidatedStatementOfCashFlows”, “lang”: “en-us”, “role”: “terseLabel”, “EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH”, “label”: “Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations”, “documentation”: “Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.” } } , “auth ref”: “r894” } } , “us-gaap:EmployeeRelatedLiabilitiesCurrent”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EmployeeRelatedLiabilitiesCurrent”, “crdr”: “credit”, “calculation”: “http://www.orsure.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail”, “parentTag”: “osur:AccruedExpensesAndOtherCurrentLiabilities”, “weight”: 1.0, “order”: 1.0 } } , “presentation”: [“http://www.orsure.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleofAccruedExpensesAndOtherCurrentLiabilitiesDetail”, “lang”: “en-us”, “role”: “terseLabel”, “Payroll and related benefits”, “label”: “Employee-related liabilities, current”, “documentation”: “Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).” } } , “auth ref”: “r44” } } , “us-gaap:EmployeeStockOptionMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EmployeeStockOptionMember”, “presentation”: “http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure”, “lang”: “en-us”, “role”: “terseLabel”, “Employee Stock Option”, “label”: “Share-Based Payment Arrangement, Option [Member]”, “documentation”: “Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.” } } , “auth ref”: [] } } , “dei:EntityAddressLine1”: { “xbrltype”: “normalizedStringItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressAddressLine1”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Address, Address Line One”, “label”: “Entity Address, Address Line One”, “documentation”: “Address Line 1 such as Attn, Building Name, Street Name”, “auth ref”: [] } } , “dei:EntityAddressCityOrTown”: { “xbrltype”: “normalizedStringItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressCityOrTown”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Address, City or Town”, “label”: “Entity Address, City or Town”, “documentation”: “Name of the City or Town”, “auth ref”: [] } } , “dei:EntityAddressPostalZipCode”: { “xbrltype”: “normalizedStringItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressPostalZipCode”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Address, Postal Zip Code”, “label”: “Entity Address, Postal Zip Code”, “documentation”: “Code for the postal or zip code”, “auth ref”: [] } } , “dei:EntityAddressStateOrProvince”: { “xbrltype”: “stateOrProvinceItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityAddressStateOrProvince”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Address, State or Province”, “label”: “Entity Address, State or Province”, “documentation”: “Name of the state or province”, “auth ref”: [] } } , “dei:EntityCentralIndexKey”: { “xbrltype”: “centralIndexKeyItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityCentralIndexKey”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Central Index Key”, “label”: “Entity Central Index Key”, “documentation”: “A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.” } } , “auth ref”: “r749” } } , “dei:EntityCommonStockSharesOutstanding”: { “xbrltype”: “sharesItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityCommonStockSharesOutstanding”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “verboselabel”, “Entity Common Stock Shares Outstanding”, “label”: “Entity Common Stock, Shares Outstanding”, “documentation”: “Indicate number of shares or other units outstanding of each of registrant’s classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock/items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] into the Instrument [Domain] of the Entity Listings, Instrument.” } } , “auth ref”: [] } } , “dei:EntityCurrentReportingStatus”: { “xbrltype”: “yesNoItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityCurrentReportingStatus”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Current Reporting Status”, “label”: “Entity Current Reporting Status”, “documentation”: “Indicate ‘Yes’ or ‘No’ whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant’s current or most recent filing containing the related disclosure.” } } , “auth ref”: [] } } , “dei:EntityEmergingGrowthCompany”: { “xbrltype”: “booleanItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityEmergingGrowthCompany”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Emerging Growth Company”, “label”: “Entity Emerging Growth Company”, “documentation”: “Indicate if registrant meets the emerging growth company criteria.” } } , “auth ref”: “r749” } } , “dei:EntityFileNumber”: { “xbrltype”: “fileNumberItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityFileNumber”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity File Number”, “label”: “Entity File Number”, “documentation”: “Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.” } } , “auth ref”: [] } } , “dei:EntityFilerCategory”: { “xbrltype”: “filerCategoryItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityFilerCategory”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Filer Category”, “label”: “Entity Filer Category”, “documentation”: “Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant’s current or most recent filing containing the related disclosure.” } } , “auth ref”: “r749” } } , “dei:EntityIncorporationStateCountryCode”: { “xbrltype”: “edgeStateCountryItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityIncorporationStateCountryCode”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Incorporation, State or Country Code”, “label”: “Entity Incorporation, State or Country Code”, “documentation”: “Two-character EDGAR code representing the state or country of incorporation.” } } , “auth ref”: [] } } , “dei:EntityInteractiveDataCurrent”: { “xbrltype”: “yesNoItemtype”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityInteractiveDataCurrent”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Interactive Data Current”, “label”: “Entity Interactive Data Current”, “documentation”: “Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).” } } , “auth ref”: “r833” } } , “dei:EntityRegistrantName”: { “xbrltype”: “normalizedStringItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityRegistrantName”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Registrant Name”, “label”: “Entity Registrant Name”, “documentation”: “The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.” } } , “auth ref”: “r749” } } , “dei:EntityShellCompany”: { “xbrltype”: “booleanItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityShellCompany”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Shell Company”, “label”: “Entity Shell Company”, “documentation”: “Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.” } } , “auth ref”: “r749” } } , “dei:EntitySmallBusiness”: { “xbrltype”: “booleanItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntitySmallBusiness”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Small Business”, “label”: “Entity Small Business”, “documentation”: “Indicates that the company is a Smaller Reporting Company (SRC).” } } , “auth ref”: “r749” } } , “dei:EntityTaxIdentificationNumber”: { “xbrltype”: “employerIdItemType”, “nsuri”: “http://xbrl.sec.gov/dei/2024”, “localname”: “EntityTaxIdentificationNumber”, “presentation”: “http://www.orsure.com/role/CoverPage”, “lang”: “en-us”, “role”: “terseLabel”, “Entity Tax Identification Number”, “label”: “Entity Tax Identification Number”, “documentation”: “The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.” } } , “auth ref”: “r749” } } , “ecd:EqtyAwrdsAdjFnTextBlock”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://xbrl.sec.gov/ecd/2024”, “localname”: “EqtyAwrdsAdjFnTextBlock”, “presentation”: “http://xbrl.sec.gov/ecd/role/PvpDisclosure”, “lang”: “en-us”, “role”: “terseLabel”, “Equity Awards Adjustments, Footnote”, “label”: “Equity Awards Adjustments, Footnote [Text Block]” } } , “auth ref”: “r788” } } , “ecd:EqtyAwrdsAdjExclValRptdInSummryCompstnTblMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://xbrl.sec.gov/ecd/2024”, “localname”: “EqtyAwrdsAdjExclValRptdInSummryCompstnTblMember”, “presentation”: “http://xbrl.sec.gov/ecd/role/PvpDisclosure”, “lang”: “en-us”, “role”: “terseLabel”, “Equity Awards Adjustments, Excluding Value Reported in Compensation Table [Member]”, “label”: “Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]” } } , “auth ref”: “r829” } } , “ecd:EqtyAwrdsAdjnsMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://xbrl.sec.gov/ecd/2024”, “localname”: “EqtyAwrdsAdjnsMember”, “presentation”: “http://xbrl.sec.gov/ecd/role/PvpDisclosure”, “lang”: “en-us”, “role”: “terseLabel”, “Equity Awards Adjustments”, “label”: “Equity Awards Adjustments [Member]” } } , “auth ref”: “r829” } } , “ecd:EqtyAwrdsInSummryCompstnTblForApbllyrMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://xbrl.sec.gov/ecd/2024”, “localname”: “EqtyAwrdsInSummryCompstnTblForApbllyrMember”, “presentation”: “http://xbrl.sec.gov/ecd/role/PvpDisclosure”, “lang”: “en-us”, “role”: “terseLabel”, “Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table”, “label”: “Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]” } } , “auth ref”: “r829” } } , “osur:EquipmentAndLeaseholdImprovementsMember”: { “xbrltype”: “domainItemType”, “nsuri”: “http://www.orsure.com/20240930”, “localname”: “EquipmentAndLeaseholdImprovementsMember”, “presentation”: “http://www.orsure.com/role/PropertyPlantandEquipmentNetAdditionalInformationDetail”, “lang”: “en-us”, “role”: “terseLabel”, “Equipment and Leasehold Improvements”, “label”: “Equipment and Leasehold Improvements [Member]”, “documentation”: “Equipment and Leasehold Improvements” } } , “auth ref”: [] } } , “us-gaap:EquityAbstract”: { “xbrltype”: “stringItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EquityAbstract”, “lang”: “en-us”, “role”: “terseLabel”, “Equity [Abstract]”, “label”: “Equity [Abstract]” } } , “auth ref”: [] } } , “us-gaap:EquityComponentDomain”: { “xbrltype”: “domainItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EquityComponentDomain”, “presentation”: “http://www.orsure.com/role/StockholdersEquitySummaryofReconciliationofChangesInStockholdersEquityDetail”, “lang”: “en-us”, “role”: “terseLabel”, “Equity Component”, “label”: “Equity Component [Domain]”, “documentation”: “Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.” } } , “auth ref”: “r14”, “r11”, “r138”, “r139”, “r140”, “r154”, “r155”, “r156”, “r159”, “r166”, “r168”, “r170”, “r183”, “r241”, “r247”, “r266”, “r302”, “r373”, “r374”, “r386”, “r387”, “r388”, “r391”, “r399”, “r400”, “r409”, “r411”, “r412”, “r413”, “r414”, “r416”, “r427”, “r432”, “r453”, “r454”, “r455”, “r456”, “r457”, “r459”, “r462”, “r475”, “r560”, “r579”, “r580”, “r581”, “r597”, “r650” } } , “us-gaap:EquityMethodInvestmentsPolicy”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EquityMethodInvestmentsPolicy”, “presentation”: “http://www.orsure.com/role/SummaryofSignificantAccountingPoliciesPolicies”, “lang”: “en-us”, “role”: “terseLabel”, “Equity Method Investee”, “label”: “Equity Method Investments [Policy Text Block]”, “documentation”: “Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.” } } , “auth ref”: “r8”, “r41”, “r236” } } , “us-gaap:EquitySecuritiesFVNINoncurrent”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “EquitySecuritiesFVNINoncurrent”, “crdr”: “debit”, “calculation”: “http://www.orsure.com/role/ConsolidatedBalanceSheets”, “parentTag”: “us-gaap:AssetsNoncurrent”, “weight”: 1.0, “order”: 6.0 } } , “presentation”: “http://www.orsure.com/role/ConsolidatedBalanceSheets”, “lang”: “en-us”, “role”: “terseLabel”, “Level I Instruments”, “label”: “Fair Value, Inputs, Level I [Member]”, “documentation”: “Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.” } } , “auth ref”: “r286”, “r325”, “r330”, “r432”, “r439”, “r479”, “r704”, “r705”, “r706”, “r708” } } , “us-gaap:FairValueMeasurementsFairValueHierarchyDomain”: { “xbrltype”: “domainItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “FairValueMeasurementsFairValueHierarchyDomain”, “presentation”: “http://www.orsure.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail”, “lang”: “en-us”, “role”: “terseLabel”, “Fair Value Hierarchy and NAV”, “label”: “Fair Value Hierarchy and NAV [Domain]”, “documentation”: “Categories used to prioritize the inputs to valuation techniques to measure fair value.” } } , “auth ref”: “r286”, “r325”, “r326”, “r327”, “r328”, “r329”, “r330”, “r430”, “r432”, “r433”, “r434”, “r435”, “r438”, “r439”, “r441”, “r479”, “r480”, “r481”, “r695”, “r696”, “r704”, “r705”, “r706”, “r708”, “r712” } } , “us-gaap:FairValueOffFinancialInstrumentsPolicy”: { “xbrltype”: “textBlockItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “FairValueOffFinancialInstrumentsPolicy”, “presentation”: “http://www.orsure.com/role/SummaryofSignificantAccountingPoliciesPolicies”, “lang”: “en-us”, “role”: “terseLabel”, “Fair Value of Financial Instruments”, “label”: “Fair Value of Financial Instruments, Policy [Policy Text Block]”, “documentation”: “Disclosure of accounting policy for determining the fair value of financial instruments.” } } , “auth ref”: “r12” } } , “us-gaap:FinanceLeaseImpairmentLoss”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “FinanceLeaseImpairmentLoss”, “crdr”: “debit”, “presentation”: “http://www.orsure.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail”, “lang”: “en-us”, “role”: “terseLabel”, “Finance lease, impairment loss”, “label”: “Finance Lease, Impairment Loss”, “documentation”: “Amount of impairment loss from right-of-use asset from finance lease.” } } , “auth ref”: “r461” } } , “us-gaap:FinanceLeaseInterestExpense”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “FinanceLeaseInterestExpense”, “crdr”: “debit”, “calculation”: “http://www.orsure.com/role/ConsolidatedStatementOfCashFlows”, “parentTag”: “us-gaap:NetCashProvidedByUsedInOperatingActivities”, “weight”: 1.0, “order”: 16.0 } } , “presentation”: “http://www.orsure.com/role/ConsolidatedStatementOfCashFlows”, “lang”: “en-us”, “role”: “terseLabel”, “Interest expense on finance leases”, “label”: “Finance Lease, Interest Expense”, “documentation”: “Amount of interest expense on finance lease liability.” } } , “auth ref”: “r465”, “r467”, “r719” } } , “us-gaap:FinanceLeaseLiabilityCurrent”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “FinanceLeaseLiabilityCurrent”, “crdr”: “credit”, “calculation”: “http://www.orsure.com/role/ConsolidatedBalanceSheets”, “parentTag”: “us-gaap:LiabilitiesCurrent”, “weight”: 1.0, “order”: 4.0 } } , “presentation”: “http://www.orsure.com/role/ConsolidatedBalanceSheets”, “lang”: “en-us”, “role”: “terseLabel”, “Finance lease liability”, “label”: “Finance Lease, Liability, Current”, “documentation”: “Present value of lessee’s discounted obligation for lease payments from finance lease, classified as current.” } } , “auth ref”: “r464” } } , “us-gaap:FinanceLeaseLiabilityNoncurrent”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “FinanceLeaseLiabilityNoncurrent”, “crdr”: “credit”, “calculation”: “http://www.orsure.com/role/ConsolidatedBalanceSheets”, “parentTag”: “us-gaap:LiabilitiesNoncurrent”, “weight”: 1.0, “order”: 1.0 } } , “presentation”: “http://www.orsure.com/role/ConsolidatedBalanceSheets”, “lang”: “en-us”, “role”: “terseLabel”, “Finance lease liability”, “label”: “Finance Lease, Liability, Noncurrent”, “documentation”: “Present value of lessee’s discounted obligation for lease payments from finance lease, classified as noncurrent.” } } , “auth ref”: “r464” } } , “us-gaap:FinanceLeasePrincipalPayments”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “FinanceLeasePrincipalPayments”, “crdr”: “credit”, “calculation”: “http://www.orsure.com/role/ConsolidatedStatementOfCashFlows”, “parentTag”: “us-gaap:NetCashProvidedByUsedInFinancingActivities”, “weight”: 1.0, “order”: 1.0 } } , “presentation”: “http://www.orsure.com/role/ConsolidatedStatementOfCashFlows”, “lang”: “en-us”, “role”: “negatedLabel”, “Cash payments for lease liabilities”, “label”: “Finance Lease, Principal Payments”, “documentation”: “Amount of cash outflow for principal payment on finance lease.” } } , “auth ref”: “r466”, “r468” } } , “us-gaap:FinanceLeaseRightOfUseAsset”: { “xbrltype”: “monetaryItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “FinanceLeaseRightOfUseAsset”, “crdr”: “debit”, “calculation”: “http://www.orsure.com/role/ConsolidatedBalanceSheets”, “parentTag”: “us-gaap:AssetsNoncurrent”, “weight”: 1.0, “order”: 3.0 } } , “presentation”: “http://www.orsure.com/role/ConsolidatedBalanceSheets”, “lang”: “en-us”, “role”: “terseLabel”, “Finance right-of-use assets, net”, “label”: “Finance Lease, Right-of-Use Asset, after Accumulated Amortization”, “documentation”: “Amount, after accumulated amortization, of right-of-use asset from finance lease.” } } , “auth ref”: “r463” } } , “us-gaap:FinancialInstrumentAxis”: { “xbrltype”: “stringItemType”, “nsuri”: “http://fasb.org/us-gaap/2024”, “localname”: “FinancialInstrumentAxis”, “presentation”: “http://www.orsure.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail”, “lang”: “en-us”, “role”: “terseLabel”, “Financial Instrument”, “label”: “Financial Instrument” } } }

"label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." }, "auth ref": "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r249", "r250", "r252", "r253", "r254", "r256", "r257", "r258", "r287", "r300", "r417", "r42", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r508", "r708", "r710", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r721", "r836", "r837", "r838", "r839", "r840", "r842", "r843", "r844", "r846", "r865", "r866", "r867", "r885", "r886", "r887", "r888", "r889", "r890" }, "us-gaap FintiteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FintiteLivedIntangibleAssetsAccumulatedAmortization", "crd": "credit", "presentation": "http://www.orsure.com/role/ConsolidatedBalanceSheetsParentDetail", "lang": "en-us", "role": "terseLabel", "documentation amortization of intangible assets", "label": "Fintite Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." }, "auth ref": "r122", "r262", "r264", "r690" }, "us-gaap FintiteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FintiteLivedIntangibleAssetsNet", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap AssetsNoncurrent", "weight": 1.0, "order": 4.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Intangible assets, net of accumulated amortization of \$33.714 and \$33.649", "label": "Fintite Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." }, "auth ref": "r509", "r871" }, "us-gaap ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crd": "credit", "presentation": "http://www.orsure.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Net foreign exchange gains (losses)", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." }, "auth ref": "r448", "r449", "r450", "r451", "r647" }, "us-gaap ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crd": "credit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 3.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "Unrealized foreign currency gain", "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." }, "auth ref": "r75", "r630", "r746", "r892", "r893", "r932" }, "us-gaap ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": "http://www.orsure.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "terseLabel", "Foreign Currency Transactions", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." }, "auth ref": "r447" }, "us-gaap ForeignIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations", "crd": "debit", "calculation": "http://www.orsure.com/role/IncomeTaxSummaryOfIncomeTaxExpenseDetails", "parentTag": "us-gaap IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 }, "presentation": "http://www.orsure.com/role/IncomeTaxSummaryOfIncomeTaxExpenseDetails", "lang": "en-us", "role": "terseLabel", "Foreign income tax expense (benefit)", "label": "Foreign Income Tax Expense (Benefit), Continuing Operations", "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations." }, "auth ref": "r152", "r364" }, "ecd ForgoreRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoreRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Forgore Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgore Recovery due to Disqualification of Tax Benefits, Amount", "documentation": "Amount of recovery due to disqualification of tax benefits." }, "auth ref": "r760", "r770", "r780", "r812" }, "ecd ForgoreRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoreRecoveryDueToExpenseOfEnforcementAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Forgore Recovery due to Expense of Enforcement, Amount", "label": "Forgore Recovery due to Expense of Enforcement, Amount", "documentation": "Amount of recovery due to expense of enforcement." }, "auth ref": "r760", "r770", "r780", "r812" }, "ecd ForgoreRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoreRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Forgore Recovery due to Violation of Home Country Law, Amount", "label": "Forgore Recovery due to Violation of Home Country Law, Amount", "documentation": "Amount of recovery due to violation of home country law." }, "auth ref": "r760", "r770", "r780", "r812" }, "ecd ForgoreRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoreRecoveryExplanationOfImpracticabilityTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Forgore Recovery, Explanation of Impracticability", "label": "Forgore Recovery, Explanation of Impracticability [Text Block]", "documentation": "Explanation of impracticability." }, "auth ref": "r760", "r770", "r780", "r812" }, "ecd ForgoreRecoveryEndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoreRecoveryEndName", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "Name", "label": "Forgore Recovery, Individual Name", "documentation": "Name of the reporting enterprise." }, "auth ref": "r760", "r770", "r780", "r812" }, "ecd ErValAsOPPrYrEndOfEqtyAwrdsGrntdInPrYrFldVstngCndsDrngCrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErValAsOPPrYrEndOfEqtyAwrdsGrntdInPrYrFldVstngCndsDrngCrdYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PrpDisclosure", "lang": "en-us", "role": "terseLabel", "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year That Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year That Fail to Meet Applicable Vesting Conditions During Covered Year", "documentation": "Prior year end fair value of equity awards granted in any prior year that fail to meet applicable vesting conditions during covered year." }, "auth ref": "r793" }, "osur FundingReceivedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.orsure.com/20240930", "localname": "FundingReceivedAmount", "crd": "credit", "calculation": "http://www.orsure.com/role/GovernmentCapitalContractsSummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowsDetail", "parentTag": "us-gaap PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 }, "presentation": "http://www.orsure.com/role/GovernmentCapitalContractsSummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowsDetail", "lang": "en-us", "role": "negatedLabel", "Reduction for funding received to date", "label": "Funding Received Amount", "documentation": "Funding received amount." }, "auth ref": "r1", "us-gaap FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": "http://www.orsure.com/role/PropertyPlantAndEquipmentNetScheduleOnPropertyPlantAndEquipmentDetail", "lang": "en-us", "role": "terseLabel", "Furniture and fixtures", "label": "Furniture and fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." }, "auth ref": "r1", "us-gaap GainLossOnDispositionOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnDispositionOfAssets", "crd": "credit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "Loss on sale of fixed assets", "label": "Gain (Loss) on Disposition of Assets", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." }, "auth ref": "r849" }, "us-gaap GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap OperatingExpenses", "weight": 1.0, "order": 3.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "terseLabel", "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of product or product line." }, "auth ref": "r69", "r633" }, "us-gaap GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": "http://www.orsure.com/role/TerminationBenefitsSummaryOfOneTimeTerminationBenefitsDetails", "lang": "en-us", "role": "terseLabel", "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." }, "auth ref": "r69", "us-gaap Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap AssetsNoncurrent", "weight": 1.0, "order": 5.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." }, "auth ref": "r121", "r263", "r543", "r687", "r689", "r709", "r720", "r869", "r870" }, "us-gaap GovernmentContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentContractMember", "presentation": "http://www.orsure.com/role/GovernmentCapitalContractsAdditionalInformationDetails", "parentTag": "us-gaap GovernmentContractReceivable", "weight": 1.0, "order": 1.0 }, "presentation": "http://www.orsure.com/role/GovernmentCapitalContractsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "Government Contract", "label": "Government Contract [Member]", "documentation": "Formal agreement with government or its agency." }, "auth ref": "r879", "us-gaap GovernmentContractReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentContractReceivable", "crd": "debit", "presentation": "http://www.orsure.com/role/GovernmentCapitalContractsAdditionalInformationDetails", "lang": "en-us", "role": "verboseLabel", "Government capital contracts funding amount", "label": "Government Contract Receivable", "documentation": "The amount of receivables that are derived from government contracts." }, "auth ref": "r506", "us-gaap GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crd": "credit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap OperatingIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "totalLabel", "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." }, "auth ref": "r63", "r67", "r97", "r151", "r237", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r446", "r685", "r686", "r687", "r688", "r689", "r690", "r691" }, "osur GuaranteedInvestmentCertificatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orsure.com/20240930", "localname": "GuaranteedInvestmentCertificatesMember", "presentation": "http://www.orsure.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "Guaranteed Investment Certificates", "label": "Guaranteed Investment Certificates [Member]", "documentation": "Guaranteed investment certificates." }, "auth ref": "r1", "osur HivMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orsure.com/20240930", "localname": "HivMember", "presentation": "http://www.orsure.com/role/RevenuesSummaryOfTotalNetRevenuesByProductLineDetail", "lang": "en-us", "role": "terseLabel", "HIV", "label": "HIV [Member]", "documentation": "HIV." }, "auth ref": "r1", "osur HivMember": { "xbrltype": "domainItemType", "nsuri": "http://www.orsure.com/20240930", "localname": "HivMember", "presentation": "http://www.orsure.com/role/RevenuesSummaryOfTotalNetRevenuesByProductLineDetail", "lang": "en-us", "role": "terseLabel", "HIV", "label": "HIV [Member]", "documentation": "HIV." }, "auth ref": "r1", "us-gaap ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": "http://www.orsure.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "terseLabel", "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." }, "auth ref": "r0", "r83" }, "us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "crd": "credit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "totalLabel", "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments." }, "auth ref": "r97", "r566", "r685", "r686", "r857", "r858", "r859", "r860", "r861", "us-gaap IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crd": "credit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "LOSS ON EQUITY INVESTMENT", "negatedTerseLabel": "Loss on equity investment", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "auth ref": "r10", "r64", "r93", "r184", "r190", "r194", "r235", "r558" }, "us-gaap IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": "en-us", "role": "terseLabel", "Income Statement [Abstract]", "label": "Income Statement [Abstract]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." }, "auth ref": "r267", "r268", "r436", "r437", "r440", "r575", "r576", "r634", "r674", "r711", "r902" }, "us-gaap IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": "http://www.orsure.com/role/GovernmentCapitalContractsAdditionalInformationDetails", "parentTag": "us-gaap IncomeStatementLocation", "weight": 1.0, "order": 1.0 }, "presentation": "http://www.orsure.com/role/RevenuesSummaryOfTotalNetRevenuesByProductLineDetail", "lang": "en-us", "role": "terseLabel", "Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." }, "auth ref": "r268", "r272", "r436", "r437", "r440", "r575", "r576", "r634", "r674", "r711", "r902" }, "us-gaap IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": "en-us", "role": "terseLabel", "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]", "documentation": "The entire disclosure for income tax." }, "auth ref": "r153", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r396", "r707" }, "us-gaap IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap NetIncomeLoss", "weight": -1.0, "order": 3.0 }, "presentation": "http://www.orsure.com/role/IncomeTaxSummaryOfIncomeTaxExpenseDetails", "parentTag": "us-gaap NetIncomeLoss", "weight": -1.0, "order": 14.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crd": "credit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crd": "debit", "calculation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 }, "presentation": "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "Increase (Decrease) in Contract with Customer Liability", "label": "Increase (Decrease) in Contract with Customer Liability", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." }, "auth ref": "r9", "us-gaap IncreaseDecreaseInContractWithCustomerLiability": {

```
"decrease": "Increase (Decrease) in Contract with Customer Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, {"auth_ref": "f7507", "r0480": "1", "us_gasp": "Increase Decrease Inventories", "xbrlyref": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInventories", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": "en-us", "role": "negatedLabel", "label": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, {"auth_ref": "f991", "us_gasp": "Increase Decrease Operating Capital Abstract", "xbrlyref": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": "en-us", "role": "terseLabel", "label": "Changes in assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, {"auth_ref": "f1", "osur": "Increase Decrease Other Non Cash Amortization", "xbrlyref": "monetaryItemType", "nsuri": "http://www.orsure.com/20240930", "localname": "IncreaseDecreaseOtherNonCashAmortization", "crdr": "debit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": "en-us", "role": "terseLabel", "label": "Other non-cash amortization", "label": "Increase Decrease In Other Non Cash Amortization", "documentation": "Increase decrease in other non-cash amortization." } } }, {"auth_ref": "f1", "us_gasp": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "xbrlyref": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": "en-us", "role": "negatedLabel", "label": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, {"auth_ref": "f991", "us_gasp": "Increase Decrease In Stockholders Equity Roll Forward", "xbrlyref": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": { "http://www.orsure.com/role/StockholdersEquitySummaryReconciliationChangesInStockholdersEquityDetail": { "lang": "en-us", "role": "terseLabel", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, {"auth_ref": "f1", "ecd IndividualAxis": "xbrlyref": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "xbrlyref": "xbrl.sec.gov/ecd/role/ErrCommDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": "en-us", "role": "terseLabel", "label": "Individual", "label": "Individual [Axis]" } } }, {"auth_ref": "f760", "r770", "r800", "r004", "r012", "r816", "r024": "1", "ecd InsiderTradingArrLineItems": "xbrlyref": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": "en-us", "role": "label", "label": "Insider Trading Arrangements [Line Items]" } } }, {"auth_ref": "f022", "ecd InsiderTradingPoliciesProcLineItems": "xbrlyref": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": "en-us", "role": "label", "label": "Insider Trading Policies and Procedures [Line Items]" } } }, {"auth_ref": "f752", "r028": "1", "ecd InsiderTradingPoliciesProcAdoptedFlag": "xbrlyref": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": "en-us", "role": "terseLabel", "label": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, {"auth_ref": "f752", "r028": "1", "ecd InsiderTradingPoliciesProcNotAdoptedTextBlock": "xbrlyref": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc": { "lang": "en-us", "role": "terseLabel", "label": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, {"auth_ref": "f752", "r028": "1", "us_gasp InventoryDisclosureAbstract": "xbrlyref": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": "en-us", "role": "terseLabel", "label": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, {"auth_ref": "f1", "us_gasp InventoryDisclosureTextBlock": "xbrlyref": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": { "http://www.orsure.com/role/inventories": { "lang": "en-us", "role": "terseLabel", "label": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, {"auth_ref": "f259", "us_gasp InventoryFinishedGoodsNetOfReserves": "xbrlyref": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.orsure.com/role/inventoriesScheduleofInventoriesDetail": { "parentTag": "us-gaap InventoryNet", "weight": -1.0, "order": 3.0 } }, presentation": { "http://www.orsure.com/role/inventoriesScheduleofInventoriesDetail": { "lang": "en-us", "role": "terseLabel", "label": "Finished goods", "label": "Inventory Finished Goods Net Of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, {"auth_ref": "f80", "r68": "1", "us_gasp InventoryNet": "xbrlyref": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap AssetsCurrent", "weight": -1.0, "order": 3.0 } }, presentation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "http://www.orsure.com/role/inventoriesScheduleofInventoriesDetail": { "lang": "en-us", "role": "terseLabel", "label": "Inventories", "totalLabel": "Inventories", "label": "Inventory Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, {"auth_ref": "f127", "r679", "r720": "1", "us_gasp InventoryRawMaterialsNetOfReserves": "xbrlyref": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.orsure.com/role/inventoriesScheduleofInventoriesDetail": { "parentTag": "us-gaap InventoryNet", "weight": -1.0, "order": 1.0 } }, presentation": { "http://www.orsure.com/role/inventoriesScheduleofInventoriesDetail": { "lang": "en-us", "role": "terseLabel", "label": "Raw materials", "label": "Inventory Raw Materials Net Of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, {"auth_ref": "f80", "r682": "1", "us_gasp InventoryWorkInProgress": "xbrlyref": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProgress", "crdr": "debit", "calculation": { "http://www.orsure.com/role/inventoriesScheduleofInventoriesDetail": { "parentTag": "us-gaap InventoryNet", "weight": -1.0, "order": 2.0 } }, presentation": { "http://www.orsure.com/role/inventoriesScheduleofInventoriesDetail": { "lang": "en-us", "role": "terseLabel", "label": "Work in process", "label": "Inventory Work In Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, {"auth_ref": "f804", "us_gasp InvestmentPolicyTextBlock": "xbrlyref": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": { "http://www.orsure.com/role/SummaryofSignificantAccountingPoliciesPolicies": { "lang": "en-us", "role": "terseLabel", "label": "Cash Equivalents & Short-Term Investments", "label": "Investment Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, {"auth_ref": "f565", "r591", "r592", "r593", "r594", "r656", "r657": "1", "us_gasp LandMember": "xbrlyref": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": { "http://www.orsure.com/role/PropertyPlantandEquipmentNetScheduleofPropertyPlantandEquipmentDetail": { "lang": "en-us", "role": "terseLabel", "label": "Land", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, {"auth_ref": "f879", "us_gasp Liabilities": "xbrlyref": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap LiabilitiesAndStockholdersEquity", "weight": -1.0, "order": 1.0 } }, presentation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "lang": "en-us", "role": "terseLabel", "label": "Total Liabilities", "label": "Liabilities", "label": "Liabilities Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, {"auth_ref": "f45", "r117", "r151", "r237", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r403", "r404", "r405", "r446", "r608", "r684", "r747", "r876", "r898", "r899": "1", "us_gasp LiabilitiesAndStockholdersEquity": "xbrlyref": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap LiabilitiesAndStockholdersEquity", "weight": -1.0, "order": 1.0 } }, presentation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "lang": "en-us", "role": "terseLabel", "label": "TOTAL LIABILITIES", "label": "Liabilities", "label": "Liabilities Current", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, {"auth_ref": "f127", "r43", "r44", "r45", "r46", "r47", "r48", "r49", "r151", "r237", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r403", "r404", "r405", "r446", "r608", "r684", "r747", "r876", "r898", "r899": "1", "us_gasp LiabilitiesAndStockholdersEquity": "xbrlyref": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "parentTag
```

"http://www.orasure.com/role/ConsolidatedStatementsOfCashFlows", "http://www.orasure.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "http://www.orasure.com/role/StockholdersEquitySummaryOfReconciliationOfChangesInStockholdersEquityDetail", "http://xbrli.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "role", "totalLabel": "NET (LOSS) INCOME", "terseLabel": "NET (LOSS) INCOME", "verboseLabel": "Net Loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "auth.ref": "r68", "r75", "r94", "r115", "r133", "r136", "r140", "r151", "r158", "r162", "r163", "r164", "r165", "r166", "r169", "r170", "r176", "r237", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r390", "r400", "r429", "r446", "r559", "r631", "r648", "r649", "r746", "r767", "us-gaap-NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "xbrliType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": "http://www.orasure.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": "en-us", "role": "role", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle Line Items", "label": "New Accounting Pronouncements or Change in Accounting Principle Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth.ref": "r109", "r110", "r111", "r112", "r113", "r114", "r157", "r158", "r159", "r160", "r161", "r164", "r171", "r183", "r199", "r200", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r265", "r266", "r269", "r373", "r374", "r375", "r376", "r377", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r443", "r444", "r458", "r459", "r460", "r470", "r471", "r472", "r473", "r474", "r475", "r510", "r511", "r512", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r590", "us-gaap-NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "xbrliType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": "http://www.orasure.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": "en-us", "role": "role", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle Table", "label": "Accounting Standards Update and Change in Accounting Principle Table", "documentation": "Disclosure of information about change in accounting principle or amendment to accounting standards or both. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards and other change in accounting principle.", "auth.ref": "r29", "r109", "r110", "r111", "r112", "r113", "r114", "r157", "r158", "r159", "r160", "r161", "r164", "r171", "r183", "r199", "r200", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r265", "r266", "r269", "r373", "r374", "r375", "r376", "r377", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r396", "r397", "r398", "r399", "r400", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r443", "r444", "r458", "r459", "r460", "r470", "r471", "r472", "r473", "r474", "r475", "r510", "r511", "r512", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r590", "us-gaap-NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "xbrliType": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": "http://www.orasure.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": "en-us", "role": "role", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle Table", "label": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "auth.ref": "r1", "osur-NonCommercialCustomerMember", "xbrliType": "domainItem", "nsuri": "http://www.orasure.com/20240930", "localname": "NonCommercialCustomerMember", "presentation": "http://www.orasure.com/role/RevenuesConcentrationRiskDetail", "lang": "en-us", "role": "role", "terseLabel": "Non-Commercial Customer", "label": "Non-Commercial Customer [Member]", "documentation": "Non-Commercial Customer", "auth.ref": "r1", "ecd-NonGaapMeasureDescriptionTextBlock", "xbrliType": "textBlockItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": "http://xbrli.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]", "auth.ref": "r796", "ecd-NonNeosMember", "xbrliType": "domainItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": "http://xbrli.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]", "auth.ref": "r760", "r778", "r780", "r804", "r812", "ecd-NonPeoNeoAvgCompActuallyPaidAmt", "xbrliType": "monetaryItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": "http://xbrli.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "auth.ref": "r78", "ecd-NonPeoNeoAvgTotalCompAmt", "xbrliType": "monetaryItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": "http://xbrli.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount", "auth.ref": "r786", "ecd-NonPeoNeoMember", "xbrliType": "domainItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": "http://xbrli.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]", "auth.ref": "r804", "ecd-NonRule10b51ArrAdoptedFlag", "xbrliType": "booleanItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": "http://xbrli.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "role", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "auth.ref": "r823", "ecd-NonRule10b51ArrTrmndFlag", "xbrliType": "booleanItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": "http://xbrli.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "role", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "auth.ref": "r823", "us-gaap-NoncashInvestingAndFinancingItemsAbstract", "xbrliType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "role", "terseLabel": "Non-cash investing and financing activities", "label": "Noncash Investing and Financing Items [Abstract]", "auth.ref": "r1", "us-gaap-NoncashOrPartNoncashAcquisitionFixedAssetsAcquired", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired", "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "role", "terseLabel": "Accrued property and equipment purchases", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. If part noncash refers to that portion of the transaction not resulting in cash receipts, cash payments in the period.", "auth.ref": "r267", "r272", "r281", "us-gaap-OneTimeTerminationBenefitsMember", "xbrliType": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OneTimeTerminationBenefitsMember", "presentation": "http://www.orasure.com/role/TerminationBenefitsSummaryOfOneTimeTerminationBenefitsDetails", "lang": "en-us", "role": "role", "terseLabel": "One-time Termination Benefits", "label": "One-time Termination Benefits [Member]", "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "auth.ref": "r691", "r692", "r693", "r694", "us-gaap-OperatingExpenses", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 2.0, "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "role", "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "auth.ref": "r1", "us-gaap-OperatingExpensesAbstract", "xbrliType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "role", "terseLabel": "OPERATING EXPENSES", "label": "Operating Expenses [Abstract]", "auth.ref": "r1", "us-gaap-OperatingIncomeLoss", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 1.0, "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "role", "totalLabel": "Operating (loss) income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "auth.ref": "r92", "r685", "r856", "r857", "r858", "r859", "r860", "us-gaap-OperatingLeaseImpairmentLoss", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": "http://www.orasure.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": "en-us", "role": "role", "terseLabel": "Operating lease, impairment loss", "label": "Operating Lease, Impairment Loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.", "auth.ref": "r897", "us-gaap-OperatingLeaseLiabilityCurrent", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 5.0, "presentation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "role", "terseLabel": "Operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "auth.ref": "r464", "us-gaap-OperatingLeaseLiabilityNoncurrent", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0, "presentation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "role", "terseLabel": "Operating lease liability", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "auth.ref": "r464", "us-gaap-OperatingLeaseRightOfUseAsset", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-AssetsNoncurrent", "weight": 1.0, "order": 2.0, "presentation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "role", "terseLabel": "Operating right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "auth.ref": "r463", "us-gaap-OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "xbrliType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": "en-us", "role": "role", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "auth.ref": "r1", "us-gaap-OtherAccruedLiabilitiesCurrent", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": "http://www.orasure.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "parentTag": "us-gaap-AccruedExpensesAndOtherCurrentLiabilities", "weight": 1.0, "order": 4.0, "presentation": "http://www.orasure.com/role/AccruedExpensesAndOtherCurrentLiabilitiesScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "lang": "en-us", "role": "role", "terseLabel": "Other", "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "auth.ref": "r44", "us-gaap-OtherAssetsCurrent", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 5.0, "presentation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "role", "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other.", "auth.ref": "r129", "r720", "us-gaap-OtherAssetsNoncurrent", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-AssetsNoncurrent", "weight": 1.0, "order": 7.0, "presentation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "role", "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other.", "auth.ref": "r123", "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0, "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "lang": "en-us", "role": "role", "terseLabel": "Currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature.", "auth.ref": "r3", "r560", "us-gaap-OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": "http://www.orasure.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfChangesInAccumulatedOtherComprehensiveLossComponentDetail", "lang": "en-us", "role": "role", "terseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after-tax of other comprehensive income (loss) attributable to parent entity.", "auth.ref": "r7", "r13", "r87", "r134", "r137", "r166", "us-gaap-OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "xbrliType": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "lang": "en-us", "role": "role", "terseLabel": "OTHER COMPREHENSIVE (LOSS) INCOME", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "auth.ref": "r1", "us-gaap-OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0, "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss", "lang": "en-us", "role": "role", "terseLabel": "Unrealized gain on marketable securities", "label": "OCI, Debt Securities, Available for Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "auth.ref": "r131", "r132", "r234", "osur-OtherForeignCountriesMember", "xbrliType": "domainItem", "nsuri": "http://www.orasure.com/20240930", "localname": "OtherForeignCountriesMember", "presentation": "http://www.orasure.com/role/RevenuesSummaryOfTotalNetRevenuesByGeographicAreaDetail", "lang": "en-us", "role": "role", "terseLabel": "Other regions", "label": "Other Foreign Countries [Member]", "documentation": "Other foreign countries.", "auth.ref": "r1", "us-gaap-OtherIncomeMember", "xbrliType": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeMember", "presentation": "http://www.orasure.com/role/GovernmentCapitalContractsAdditionalInformationDetails", "http://www.orasure.com/role/RevenuesSummaryOfTotalNetRevenuesByProductLineDetail", "lang": "en-us", "role": "role", "terseLabel": "Other", "label": "Other Income [Member]", "documentation": "Primary financial statement caption encompassing other revenue.", "auth.ref": "r68", "us-gaap-OtherLiabilitiesNoncurrent", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0, "presentation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "role", "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "auth.ref": "r47", "osur-OtherNonProductRevenuesMember", "xbrliType": "domainItem", "nsuri": "http://www.orasure.com/20240930", "localname": "OtherNonProductRevenuesMember", "presentation": "http://www.orasure.com/20240930", "localname": "OtherNon-product and services revenues", "label": "Other Non-Product Revenues [Member]", "documentation": "Other non-product revenues.", "auth.ref": "r1", "us-gaap-OtherNonoperatingIncomeExpense", "xbrliType": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0, "order": 2.0, "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "role", "terseLabel": "OTHER INCOME", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "auth.ref": "r70", "ecd-OtherPerfMeasureAmt", "xbrliType": "decimalItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": "http://xbrli.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount", "auth.ref": "r796", "osur-OtherProductAndServicesRevenuesMember", "xbrliType": "domainItem", "nsuri": "http://www.orasure.com/20240930", "localname": "OtherProductAndServicesRevenuesMember", "presentation": "http://www.orasure.com/role/RevenuesSummaryOfTotalNetRevenuesByProductLineDetail", "lang": "en-us", "role": "role", "terseLabel": "Other product and services revenues", "label": "Other Product And Services Revenues [Member]", "documentation": "Other Product And Services Revenues [Member]", "auth.ref": "r1", "osur-OtherRevenuesMember", "xbrliType": "domainItem", "nsuri": "http://www.orasure.com/20240930", "localname": "OtherRevenuesMember", "presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "role", "terseLabel": "Other", "label": "Other Revenues [Member]", "documentation": "Other revenues.", "auth.ref": "r1", "ecd-OutstandingAggtErrCompAmt", "xbrliType": "monetaryItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": "http://xbrli.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount", "auth.ref": "r758", "r768", "r778", "r810", "ecd-OutstandingRecoveryCompAmt", "xbrliType": "monetaryItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": "http://xbrli.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount", "auth.ref": "r761", "r771", "r781", "r813", "ecd-OutstandingRecoveryIndName", "xbrliType": "stringItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": "http://xbrli.sec.gov/ecd/role/ErrCompDisclosure", "lang": "en-us", "role": "role", "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name", "auth.ref": "r761", "r771", "r781", "r813", "ecd-PayVsPerformanceDisclosureLineItems", "xbrliType": "stringItem", "nsuri": "http://xbrli.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": "en-us", "role": "role", "label": "Pay vs Performance Disclosure [Line Items]", "auth.ref": "r785", "us-

gaap PayablesAndAccrualsAbstract: { "xbrlytrype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth ref": { "r1" } }, "us-gaap PaymentForContingentConsiderationLiabilityFinancingActivities": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Payment of acquisition-related contingent consideration", "label": "Payment for Contingent Consideration Liability Financing Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth ref": { "r5" } } }, "us-gaap PaymentForContingentConsiderationLiabilityOperatingActivities": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Payment of acquisition-related contingent consideration", "label": "Payment for Contingent Consideration Liability Operating Activities", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth ref": { "r6" } } }, "osur PaymentOfReductionInWorkforce": { "xbrlytrype": "monetaryItemType", "nsuri": "http://www.orsure.com/20240930", "localname": "PaymentOfReductionInWorkforce", "crdr": "debit", "presentation": { "http://www.orsure.com/role/TerminationBenefitsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Payment of reduction in workforce", "label": "Payment Of Reduction In Workforce", "documentation": "Payment of reduction in workforce." } } }, "auth ref": { "r1" } } }, "us-gaap PaymentsForRepurchaseOfCommonStock": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth ref": { "r72" } } }, "us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of short-term investments", "label": "Payments to Acquire Debt Securities, Available for Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth ref": { "r22", "r144", "r203" } } }, "us-gaap PaymentsToAcquireEquityMethodInvestments": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "http://www.orsure.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Investment in equity method investee", "terseLabel": "Payments to acquire equity method investments", "label": "Payments to Acquire Equity Method Investments", "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence." } } }, "auth ref": { "r23" } } }, "us-gaap PaymentsToAcquirePropertyPlantAndEquipment": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, includes cash outflows to pay for construction of self-constructed assets." } } }, "auth ref": { "r71" } } }, "ecd PeerGroupIssuersFnTxBlock": { "xbrlytrype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTxBlock", "presentation": { "http://xbrl.sec.gov/ecd/rp/PvDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [FnTxBlock]" } } }, "auth ref": { "r795" } } }, "ecd PeerGroupTotalShareholderRtnAmt": { "xbrlytrype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/rp/PvDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth ref": { "r795" } } }, "ecd PeerActuallyPaidCompAmt": { "xbrlytrype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/rp/PvDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth ref": { "r804" } } }, "ecd PEOName": { "xbrlytrype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PEOName", "presentation": { "http://xbrl.sec.gov/ecd/rp/PvDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Member", "label": "PEO Name" } } }, "auth ref": { "r797" } } }, "ecd PEOTotalCompAmt": { "xbrlytrype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PEOTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/2024", "localname": "PEOTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/rp/PvDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth ref": { "r786" } } }, "osur PercentageWithheldUnderGovernmentContractsSubjectToValidationTesting": { "xbrlytrype": "percentItemType", "nsuri": "http://www.orsure.com/20240930", "localname": "PercentageWithheldUnderGovernmentContractsSubjectToValidationTesting", "presentation": { "http://www.orsure.com/role/GovernmentCapitalContractsAdditionalInformationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage withheld under government contracts subject to validation testing", "label": "Percentage Withheld Under Government Contracts Subject to Validation Testing", "documentation": "Percentage of total capital costs incurred under government contract not reimbursed until completion of final validation testing." } } }, "auth ref": { "r1" } } }, "ecd PnsnAdjsPrvSvcStMmber": { "xbrlytrype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrvSvcStMmber", "presentation": { "http://xbrl.sec.gov/ecd/rp/PvDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost [Member]", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth ref": { "r780" } } }, "ecd PnsnAdjsPrvSvcStMmber": { "xbrlytrype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrvSvcStMmber", "presentation": { "http://xbrl.sec.gov/ecd/rp/PvDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth ref": { "r832" } } }, "ecd PnsnBnfsAdjFnTxBlock": { "xbrlytrype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnfsAdjFnTxBlock", "presentation": { "http://xbrl.sec.gov/ecd/rp/PvDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [FnTxBlock]" } } }, "auth ref": { "r787" } } }, "us-gaap PreferredStockParOrStatedValuePerShare": { "xbrlytrype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://www.orsure.com/role/ConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in USD per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth ref": { "r50", "r289" } } }, "us-gaap PreferredStockSharesAuthorized": { "xbrlytrype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://www.orsure.com/role/ConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth ref": { "r50", "r610" } } }, "us-gaap PreferredStockSharesIssued": { "xbrlytrype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { "http://www.orsure.com/role/ConsolidatedBalanceSheetsParentetical": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth ref": { "r50", "r289" } } }, "us-gaap PreferredStockValue": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value \$0.000001, 25,000 shares authorized, none issued", "label": "Preferred Stock Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth ref": { "r50", "r551", "r720" } } }, "us-gaap PrepaidExpenseCurrent": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth ref": { "r128", "r260", "r261", "r680" } } }, "osur ProceedsFromFundingUnderGovernmentContract": { "xbrlytrype": "monetaryItemType", "nsuri": "http://www.orsure.com/20240930", "localname": "ProceedsFromFundingUnderGovernmentContract", "crdr": "debit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from funding under government contract", "label": "Proceeds From Funding Under Government Contract", "documentation": "Proceeds from funding under government contract." } } }, "auth ref": { "r1" } } }, "us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities and redemptions of short-term investments", "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available for Sale", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth ref": { "r144", "r145", "r863" } } }, "us-gaap ProceedsFromStockOptionsExercised": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth ref": { "r4", "r15" } } }, "osur ProductAndServicesMember": { "xbrlytrype": "domainItemType", "nsuri": "http://www.orsure.com/20240930", "localname": "ProductAndServicesMember", "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "terseLabel": "Products and services", "label": "Product And Services [Member]", "documentation": "Products and services." } } }, "auth ref": { "r1" } } }, "srt ProductOrServiceAxis": { "xbrlytrype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfOperations": { "http://www.orsure.com/role/GovernmentCapitalContractsAdditionalInformationDetails": { "http://www.orsure.com/role/GovernmentCapitalContractsSummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowsDetail": { "http://www.orsure.com/role/RevenuesSummaryOfTotalNetRevenuesByProductLineDetail": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth ref": { "r195", "r508", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r676", "r697", "r730", "r732", "r733", "r736", "r737", "r874", "r875", "r878", "r901", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r914", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" } } }, "srt ProductsAndServicesDomain": { "xbrlytrype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": { "http://www.orsure.com/role/ConsolidatedStatementsOfOperations": { "http://www.orsure.com/role/GovernmentCapitalContractsAdditionalInformationDetails": { "http://www.orsure.com/role/GovernmentCapitalContractsSummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowsDetail": { "http://www.orsure.com/role/RevenuesSummaryOfTotalNetRevenuesByProductLineDetail": { "lang": { "en-us": { "role": { "terseLabel": "Product and Service (Domain)", "label": "Product and Service (Domain)" } } }, "auth ref": { "r195", "r508", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r676", "r697", "r730", "r732", "r733", "r736", "r737", "r874", "r875", "r878", "r901", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r914", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" } } }, "us-gaap PropertyPlantAndEquipmentAbstract": { "xbrlytrype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth ref": { "r1" } }, "us-gaap PropertyPlantAndEquipmentByTypeAxis": { "xbrlytrype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetAdditionalInformationDetail": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth ref": { "r11", "r469" } } }, "us-gaap PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrlytrype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNet": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment, Net", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth ref": { "r481", "r102", "r103", "r104" } } }, "us-gaap PropertyPlantAndEquipmentGross": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.orsure.com/role/GovernmentCapitalContractsSummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowsDetail": { "parentTag": "us-gaap PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "http://www.orsure.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail": { "parentTag": "us-gaap PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.orsure.com/role/GovernmentCapitalContractsSummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowsDetail": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Cost of assets, cumulative", "verboseLabel": "Property plant and equipment Gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth ref": { "r82", "r119", "r557" } } }, "us-gaap PropertyPlantAndEquipmentLineItems": { "xbrlytrype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetAdditionalInformationDetail": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": { "r469" } } }, "us-gaap PropertyPlantAndEquipmentMember": { "xbrlytrype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentMember", "presentation": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment [Member]", "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth ref": { "r1" } } }, "us-gaap PropertyPlantAndEquipmentNet": { "xbrlytrype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "http://www.orsure.com/role/GovernmentCapitalContractsSummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowsDetail": { "parentTag": "us-gaap PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "http://www.orsure.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail": { "parentTag": "us-gaap PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.orsure.com/role/ConsolidatedBalanceSheets": { "http://www.orsure.com/role/GovernmentCapitalContractsSummaryOfGovernmentContractsBalancesIncludedInConsolidatedStatementsOfCashFlowsDetail": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, net of accumulated depreciation of \$79,562 and \$85,143", "totalLabel": "Total Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth ref": { "r11", "r469", "r547", "r557", "r720" } } }, "us-gaap PropertyPlantAndEquipmentTextBlock": { "xbrlytrype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment [Table TextBlock]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth ref": { "r11" } } }, "us-gaap PropertyPlantAndEquipmentTypeDomain": { "xbrlytrype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetAdditionalInformationDetail": { "http://www.orsure.com/role/PropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetail": { "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived

```
"ogAssetID": "Domain", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." }, { "authRef": "r62", "r62": "r499"}, {"tag": "us-gaap ProvisionForDoubtfulAccounts", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ProvisionForDoubtfulAccounts", "crd": "debit", "calculation": "http://www.orasure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 }, {"presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "terseLabel", "label": "Provision for credit losses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." }, {"tag": "osur PurchaseOfPropertyAndEquipmentUnderGovernmentContracts", "xbrlType": "monetaryItemType", "nsuri": "http://www.orasure.com/20240930", "localName": "PurchaseOfPropertyAndEquipmentUnderGovernmentContracts", "crd": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedStatementsOfCashFlows", "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 }, {"presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "label": "Purchase of property and equipment under government contracts", "label": "Purchase Of Property And Equipment Under Government Contracts", "documentation": "Purchase of property and equipment under government contracts" }, {"tag": "http://xbrl.sec.gov/cdr/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "label": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "authRef": "r785"}, {"tag": "cd_PvPTableTextBlock", "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cdr/2024", "localName": "PvPTableTextBlock", "presentation": "http://xbrl.sec.gov/cdr/PvpDisclosure", "lang": "en-us", "role": "terseLabel", "label": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]", "authRef": "r785"}, {"tag": "osur Q12024ReductionInWorkforceMember", "xbrlType": "domainItemType", "nsuri": "http://www.orasure.com/20240930", "localName": "Q12024ReductionInWorkforceMember", "presentation": "http://www.orasure.com/role/TerminationBenefitsAdditionalInformationDetails", "parentTag": "osur TerminationBenefitsSummaryOneTimeTerminationBenefitsDetails", "lang": "en-us", "role": "terseLabel", "label": "Q1 2024 Reduction In Workforce", "label": "Q1 2024 Reduction In Workforce [Member]", "documentation": "Q1 2024 Reduction In Workforce", "authRef": "I"}, {"tag": "osur Q22024ReductionInWorkforceMember", "xbrlType": "domainItemType", "nsuri": "http://www.orasure.com/20240930", "localName": "Q22024ReductionInWorkforceMember", "presentation": "http://www.orasure.com/role/TerminationBenefitsAdditionalInformationDetails", "parentTag": "osur TerminationBenefitsSummaryOneTimeTerminationBenefitsDetails", "lang": "en-us", "role": "terseLabel", "label": "Q2 2024 Reduction In Workforce", "label": "Q2 2024 Reduction In Workforce [Member]", "documentation": "Q2 2024 Reduction In Workforce", "authRef": "I"}, {"tag": "osur Q32024ReductionInWorkforceMember", "xbrlType": "domainItemType", "nsuri": "http://www.orasure.com/20240930", "localName": "Q32024ReductionInWorkforceMember", "presentation": "http://www.orasure.com/role/TerminationBenefitsAdditionalInformationDetails", "parentTag": "osur TerminationBenefitsSummaryOneTimeTerminationBenefitsDetails", "lang": "en-us", "role": "terseLabel", "label": "Q3 2024 Reduction In Workforce", "label": "Q3 2024 Reduction In Workforce [Member]", "documentation": "Q3 2024 Reduction In Workforce", "authRef": "I"}, {"tag": "ecd RecoveryOfErrCompDisclosuresLineItems", "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/cdr/2024", "localName": "RecoveryOfErrCompDisclosuresLineItems", "lang": "en-us", "role": "label", "label": "Recovery Of Erroneously Awarded Compensation Disclosure [Line Items]", "authRef": "r753", "r763", "r773", "r805"}, {"tag": "osur ReimbursementOfEngineeringCost", "xbrlType": "monetaryItemType", "nsuri": "http://www.orasure.com/20240930", "localName": "ReimbursementOfEngineeringCost", "crd": "debit", "presentation": "http://www.orasure.com/role/GovernmentCapitalContractsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Reimbursement of engineering cost", "label": "Reimbursement Of Engineering Cost", "documentation": "Reimbursement of engineering cost", "authRef": "I"}, {"tag": "us-gaap ResearchAndDevelopmentExpense", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ResearchAndDevelopmentExpense", "crd": "debit", "calculation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap OperatingExpenses", "weight": 1.0, "order": 1.0 }, {"presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "terseLabel", "label": "Research and development", "label": "Research and Development Expense", "documentation": "Research and Development Expense", "authRef": "I"}, {"tag": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both used in research and development activity.", "authRef": "r359", "r674", "r686", "r900"}, {"tag": "us-gaap ResearchAndDevelopmentExpenseMember", "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "ResearchAndDevelopmentExpenseMember", "presentation": "http://www.orasure.com/role/TerminationBenefitsSummaryOneTimeTerminationBenefitsDetails", "lang": "en-us", "role": "terseLabel", "label": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "authRef": "I"}, {"tag": "osur ResearchAndDevelopmentExpensesAndOtherIncomeMember", "xbrlType": "domainItemType", "nsuri": "http://www.orasure.com/20240930", "localName": "ResearchAndDevelopmentExpensesAndOtherIncomeMember", "presentation": "http://www.orasure.com/role/GovernmentCapitalContractsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Research and Development Expenses and Other Income", "label": "Research and Development Expenses and Other Income [Member]", "documentation": "Research and development expenses and other income", "authRef": "I"}, {"tag": "ecd RestatementDateAxis", "xbrlType": "stringItemType", "nsuri": "http://xbrl.sec.gov/cdr/2024", "localName": "RestatementDateAxis", "presentation": "http://xbrl.sec.gov/cdr/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "label": "Restatement Determination Date", "label": "Restatement Determination Date [Axis]", "authRef": "r754", "r764", "r774", "r806"}, {"tag": "ecd RestatementDeterminationDate", "xbrlType": "dateItemType", "nsuri": "http://xbrl.sec.gov/cdr/2024", "localName": "RestatementDeterminationDate", "presentation": "http://xbrl.sec.gov/cdr/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "label": "Restatement Determination Date", "label": "Restatement Determination Date", "authRef": "r755", "r765", "r775", "r807"}, {"tag": "ecd RestatementDoesNotRequireRecoveryTextBlock", "xbrlType": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cdr/2024", "localName": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": "http://xbrl.sec.gov/cdr/ErrCompDisclosure", "lang": "en-us", "role": "terseLabel", "label": "Restatement does not require recovery", "label": "Restatement Does Not Require Recovery [Text Block]", "authRef": "r762", "r772", "r782", "r814"}, {"tag": "us-gaap RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": "http://www.orasure.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": "en-us", "role": "terseLabel", "label": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "authRef": "r118"}, {"tag": "us-gaap RestructuringCostAndReserveAxis", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "RestructuringCostAndReserveAxis", "presentation": "http://www.orasure.com/role/TerminationBenefitsSummaryOneTimeTerminationBenefitsDetails", "lang": "en-us", "role": "terseLabel", "label": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost", "authRef": "r270", "r271", "r273", "r274"}, {"tag": "us-gaap RestructuringPlanAxis", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "RestructuringPlanAxis", "presentation": "http://www.orasure.com/role/TerminationBenefitsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Information by individual restructuring plan", "authRef": "I"}, {"tag": "us-gaap RestructuringPlanDomain", "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "RestructuringPlanDomain", "presentation": "http://www.orasure.com/role/TerminationBenefitsAdditionalInformationDetails", "lang": "en-us", "role": "terseLabel", "label": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans", "authRef": "I"}, {"tag": "us-gaap RetainedEarningsAccumulatedDeficit", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "RetainedEarningsAccumulatedDeficit", "crd": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 5.0 }, {"presentation": "http://www.orasure.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "terseLabel", "label": "Retained Earnings (Accumulated Deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)", "authRef": "r53", "r86", "r554", "r583", "r595", "r611", "r720"}, {"tag": "us-gaap RetainedEarningsMember", "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "RetainedEarningsMember", "presentation": "http://www.orasure.com/role/StockholdersEquitySummaryOfReconciliationChangesInStockholdersEquityDetail", "lang": "en-us", "role": "terseLabel", "label": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)", "authRef": "r111", "r144", "r155", "r156", "r159", "r166", "r168", "r170", "r241", "r247", "r266", "r373", "r374", "r386", "r387", "r388", "r391", "r399", "r400", "r409", "r412", "r413", "r416", "r422", "r459", "r462", "r579", "r581", "r592", "r933"}, {"tag": "us-gaap RevenueFromContractWithCustomerAbstract", "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "RevenueFromContractWithCustomerAbstract", "lang": "en-us", "role": "terseLabel", "label": "Revenue from Contract With Customer [Abstract]", "label": "Revenue from Contract With Customer [Abstract]", "authRef": "I"}, {"tag": "us-gaap RevenueFromContractWithCustomerExcludingAssessedTax", "xbrlType": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localName": "RevenueFromContractWithCustomerExcludingAssessedTax", "crd": "credit", "calculation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "parentTag": "us-gaap GrossProfit", "weight": 1.0, "order": 1.0 }, {"presentation": "http://www.orasure.com/role/ConsolidatedStatementsOfOperations", "lang": "en-us", "role": "terseLabel", "label": "Revenue from contract with customer, excluding tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales-use tax, value added and excise", "authRef": "r95", "r96", "r184", "r187", "r188", "r192", "r194", "r195", "r196", "r198", "r321", "r322", "r50
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[The following text contains extremely dense, non-readable characters and symbols, likely representing corrupted or encrypted data.]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

gaap:FurnitureAndFixturesMember-2023-12-31-0001116463 us-gaap:ConstructionInProgressMember-2024-09-30-0001116463 us-gaap:ConstructionInProgressMember-2023-12-31-0001116463 us-gaap:PropertyPlantAndEquipmentMember-2024-01-01-2024-09-30-0001116463 us-gaap:MachineryAndEquipmentMember-2024-01-01-2024-09-30-0001116463 us-gaap:EquipmentAndLeaseholdImprovementsMember-2023-01-01-2023-09-30-0001116463 us-gaap:CostOfSalesMember-us-gaap:OneTimeTerminationBenefitsMembersosur:A2023ReductionInWorkforceMember-2023-01-01-2023-09-30-0001116463 us-gaap:ResearchAndDevelopmentExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:A2023ReductionInWorkforceMember-2023-01-01-2023-09-30-0001116463 us-gaap:SellingAndMarketingExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:A2023ReductionInWorkforceMember-2023-01-01-2023-09-30-0001116463 us-gaap:GeneralAndAdministrativeExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:A2023ReductionInWorkforceMember-2023-01-01-2023-09-30-0001116463 us-gaap:OneTimeTerminationBenefitsMembersosur:A2023ReductionInWorkforceMember-2023-01-01-2023-09-30-0001116463 us-gaap:A2023ReductionInWorkforceMember-2024-01-01-2024-09-30-0001116463 us-gaap:CostOfSalesMember-us-gaap:OneTimeTerminationBenefitsMembersosur:Q12024ReductionInWorkforceMember-2024-01-01-2024-09-30-0001116463 us-gaap:ResearchAndDevelopmentExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q12024ReductionInWorkforceMember-2024-01-01-2024-09-30-0001116463 us-gaap:SellingAndMarketingExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q12024ReductionInWorkforceMember-2024-01-01-2024-09-30-0001116463 us-gaap:GeneralAndAdministrativeExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q12024ReductionInWorkforceMember-2024-01-01-2024-09-30-0001116463 us-gaap:OneTimeTerminationBenefitsMembersosur:Q12024ReductionInWorkforceMember-2024-01-01-2024-09-30-0001116463 us-gaap:Q12024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:CostOfSalesMember-us-gaap:OneTimeTerminationBenefitsMembersosur:Q22024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:ResearchAndDevelopmentExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q22024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:SellingAndMarketingExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q22024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:GeneralAndAdministrativeExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q22024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:OneTimeTerminationBenefitsMembersosur:Q22024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:Q22024ReductionInWorkforceMember-2024-01-01-2024-09-30-0001116463 us-gaap:CostOfSalesMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q32024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:ResearchAndDevelopmentExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q32024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:SellingAndMarketingExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q32024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:GeneralAndAdministrativeExpenseMembersus-gaap:OneTimeTerminationBenefitsMembersosur:Q32024ReductionInWorkforceMember-2024-07-01-2024-09-30-0001116463 us-gaap:Q32024ReductionInWorkforceMember-2024-01-01-2024-09-30-0001116463 us-gaap:HivMembersus-gaap:SalesMember-2024-07-01-2024-09-30-0001116463 us-gaap:HivMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:COVID19Membersus-gaap:SalesMember-2024-07-01-2024-09-30-0001116463 us-gaap:COVID19Membersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:COVID19Membersus-gaap:SalesMember-2024-01-01-2024-09-30-0001116463 us-gaap:COVID19Membersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:MolecularSampleManagementSolutionsMembersus-gaap:SalesMember-2024-07-01-2024-09-30-0001116463 us-gaap:MolecularSampleManagementSolutionsMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:MolecularSampleManagementSolutionsMembersus-gaap:SalesMember-2024-01-01-2024-09-30-0001116463 us-gaap:MolecularSampleManagementSolutionsMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:HcvMembersus-gaap:SalesMember-2024-07-01-2024-09-30-0001116463 us-gaap:HcvMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:HcvMembersus-gaap:SalesMember-2024-01-01-2024-09-30-0001116463 us-gaap:HcvMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:RiskAssessmentTestingMembersus-gaap:SalesMember-2024-07-01-2024-09-30-0001116463 us-gaap:RiskAssessmentTestingMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:RiskAssessmentTestingMembersus-gaap:SalesMember-2024-01-01-2024-09-30-0001116463 us-gaap:RiskAssessmentTestingMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:OtherProductAndServicesRevenuesMembersus-gaap:SalesMember-2024-07-01-2024-09-30-0001116463 us-gaap:OtherProductAndServicesRevenuesMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:OtherProductAndServicesRevenuesMembersus-gaap:SalesMember-2024-01-01-2024-09-30-0001116463 us-gaap:OtherProductAndServicesRevenuesMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:MolecularServicesMembersus-gaap:SalesMember-2024-07-01-2024-09-30-0001116463 us-gaap:MolecularServicesMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:MolecularServicesMembersus-gaap:SalesMember-2024-01-01-2024-09-30-0001116463 us-gaap:MolecularServicesMembersus-gaap:SalesMember-2023-01-01-2023-09-30-0001116463 us-gaap:OtherNonProductRevenuesMembersus-gaap:OtherIncomeMember-2024-07-01-2024-09-30-0001116463 us-gaap:OtherNonProductRevenuesMembersus-gaap:OtherIncomeMember-2023-01-01-2023-09-30-0001116463 us-gaap:OtherNonProductRevenuesMembersus-gaap:OtherIncomeMember-2024-01-01-2024-09-30-0001116463 us-gaap:OtherNonProductRevenuesMembersus-gaap:OtherIncomeMember-2023-01-01-2023-09-30-0001116463 us-gaap:country:US-2024-07-01-2024-09-30-0001116463 country:US-2023-07-01-2023-09-30-0001116463 country:US-2024-01-01-2024-09-30-0001116463 country:US-2023-01-01-2023-09-30-0001116463 srt.EuropeMember-2024-07-01-2024-09-30-0001116463 srt.EuropeMember-2023-07-01-2023-09-30-0001116463 srt.EuropeMember-2024-01-01-2024-09-30-0001116463 srt.EuropeMember-2023-01-01-2023-09-30-0001116463 us-gaap:OtherForeignCountriesMember-2024-07-01-2024-09-30-0001116463 us-gaap:OtherForeignCountriesMember-2023-07-01-2023-09-30-0001116463 us-gaap:OtherForeignCountriesMember-2024-01-01-2024-09-30-0001116463 us-gaap:OtherForeignCountriesMember-2023-01-01-2023-09-30-0001116463 us-gaap:CommercialCustomerOneMembersus-gaap:SalesRevenueNetMembersus-gaap:CustomerConcentrationRiskMember-2024-07-01-2024-09-30-0001116463 us-gaap:CommercialCustomerTwoMembersus-gaap:SalesRevenueNetMembersus-gaap:CustomerConcentrationRiskMember-2023-07-01-2023-09-30-0001116463 us-gaap:NonCommercialCustomerMembersus-gaap:SalesRevenueNetMembersus-gaap:CustomerConcentrationRiskMember-2024-07-01-2024-09-30-0001116463 us-gaap:NonCommercialCustomerMembersus-gaap:SalesRevenueNetMembersus-gaap:CustomerConcentrationRiskMember-2023-07-01-2023-09-30-0001116463 us-gaap:NonCommercialCustomerMembersus-gaap:SalesRevenueNetMembersus-gaap:CustomerConcentrationRiskMember-2024-01-01-2024-09-30-0001116463 us-gaap:NonCommercialCustomerMembersus-gaap:AccountsReceivableMembersus-gaap:CustomerConcentrationRiskMember-2023-01-01-2023-09-30-0001116463 us-gaap:UpFrontPaymentMember-2024-09-30-0001116463 us-gaap:LongTermContractWithCustomerMember-2024-09-30-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

style="background-color:#ffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffff;padding:0 1pt"></td><td style="background-color:#ffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>735280000529543000-14941000-83931000430671000320002140002140005930001940001462000146200029680002968000-3584000-3584000-2556000-2556000739590000531263000-17497000-8751500042625100010330004240001984000198400033220003322000-615000-615000-1134000-1134000745680000532601000-18631000-881300004258400004400019000870008700028880002888000-4507000-450700014310001431000745930000535402000-17200000-92637000425565000727340000520446000-18435000-13758600036442500012000660006600073700022900012030001203000265500026550002721900027219000797000797000220000220000732540000521964000-17418000-11036700039417900024100008200046000046000023570002357000-4796000-479600028590002859000734130000523861000-14559000-115163000394139000200010000100009900031000200000200000259000025900001115900011159000-2813000-2813000734830000526261000-17372000-104004000404885000Commitments and Contingencies<div style="margin-top:6pt;text-align:justify">From time to time, the Company is involved in certain legal actions arising in the ordinary course of business. In management's opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on the Company's future financial position or results of operations.</div>In March 2021, the Company filed a complaint against Spectrum Solutions, LLC ("Spectrum") in the United States District Court for the Southern District of California alleging that certain saliva collection devices manufactured and sold by Spectrum infringe a patent held by DNAG. Spectrum filed an answer asserting that its device does not infringe the Company's patent and that the Company's patent is invalid. In August 2021, the Company amended its complaint to add a second patent to this litigation. Spectrum responded to the Company's amended complaint and asserted counterclaims for inequitable conduct and antitrust violations with respect to one of the patents in the litigation and subsequently filed a request for review of the second patent at the Patent and Trademark Office ("PTO"), which was granted by the PTO. The District Court issued multiple pretrial orders, resolving the infringement, antitrust, and inequitable conduct claims without trial. First, the District Court granted Spectrum's motion for summary judgment of noninfringement. The Company appealed the grant of summary judgment to the Court of Appeals on June 8, 2023. The Company is pursuing the appeal with respect to the first patent, with oral argument expected in the first quarter of 2025. Second, the Court denied Spectrum's motion to supplement its allegations of alleged antitrust violations, finding that if such an amendment were allowed, Spectrum's claims would not survive a motion for summary judgment. Spectrum thereafter withdrew its antitrust and inequitable conduct counterclaims. Spectrum did not appeal the District Court's denial of its motion to amend. On February 7, 2024, the PTO issued a Final Written Decision regarding the second patent in the litigation, holding that claims 1, 3-8, 11 and 12 of U.S. Patent No. 11,002,646 B2 are unpatentable. On March 8, 2024, the Company filed a Request for Rehearing by the Director of the PTO of the Final Written Decision. On March 27, 2024, the Company's Request for Rehearing was denied. On September 15, 2023, Spectrum filed a separate petition forinter partes review of a third patent, which DNAG did not assert in the District Court. On March 26, 2024, the PTO issued a Decision Granting Institution ofInter Partes Review and scheduled oral argument for January 13, 2025. On July 2, 2024, the Company filed a Motion to Amend the claims of the third patent, which remains pending.falsefalsefalsefalse"